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Abstract 
Natural products had been indispensably used by many cultures and traditions in folklore 
medicines for thousands of years. These traditional medicines cater to about 85% of the 
world population for their primary health care needs. Natural products have been 
intensively explored also for their bioactive pharmacophores by modern pharmaceutical 
companies. In fact they are the skeletal framework of about 60% of the modern drugs that 
are available today. Of these, about 80% of antibacterial drugs and 90% of antimalarial 
drugs are natural derivatives. One of the interesting secondary metabolite groups which 
provides these potent drug leads are the alkaloids. Owing to their broad range of 
bioactivities, bioprospecting for these natural products are undertaken in many countries. In 
this study, on the molecular basis of traditional medicine of Bhutan, particularly those with 
potential antimicrobial components, four alkaloid positive medicinal plants, i.e. Aconitum 
orochryseum Stapf, Corydalis gerdae Fedde, Rununculus brotherusi Freyn and an 
Australian naturalized plant Tribulus terrestris Linn, but also used in Bhutan, were selected 
for phytochemical analysis.  
Bhutanese traditional medicines use Aconitum orochryseum (whole parts) for the treatment 
of bilious fever or high fever related to bile disorders including cold and flu, fever of bile 
(liver), fever caused by malaria, snake bites and for treating blood infections. Corydalis 
gerdae (whole parts) is used for the treatment of malaria and infections.  Ranunculus 
brotherusi (aerial parts) is used for treating wounds, pus, infections and as antipyretics. 
Tribulus terrestris (fruit) is used for the treatment of arthritis, kidney diseases and as a 
diuretic. Though Tribulus terrestris and Ranunculus brotherusi failed to give any alkaloids, 
a number of new as well as known alkaloids were isolated from Aconitum orochryseum and 
Corydalis gerdae.  
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Three new hetisane type diterpenoid alkaloids named orochrine, 2-O-acetylorochrine, and 
lingshinaline, together with two known alkaloids atisinium chloride and virescenine and six 
other unidentified alkaloids, were isolated from Aconitum orochryseum.  The structures of 
the new alkaloids were elucidated by 1H-NMR, gCOSY, gNOESY, TOCSY, 13C-NMR, 
DEPT, gHSQC and gHMBC spectral data analysis. Atisinium chloride, a major alkaloid of 
the plant, was identified by single crystal X-ray crystallography.  
Four known protopine type and protoberberine type isoquinoline alkaloids (protopine, 
scoulerine, cheilanthifoline, and stylopine) along with one unidentified alkaloid were 
isolated from Corydalis gerdae. The protopine was the major alkaloid of this plant. The 
alkaloids were identified by MS and 1H-NMR spectral data comparison. 
The antibacterial testing of crude methanol extracts, crude alkaloids and the major alkaloids 
(atisinium chloride, orochrine and protopine) of these two plants were found inactive 
against the bacterium Staphylococcus aureus (MIC = >125 µg/ml) and Vancomycin 
resistant Enterococcus faecium (MIC =  >125 µg/ml).  But the in vitro antimalarial assay of 
crude methanol extracts, crude alkaloids, atisinium chloride, protopine, and cheilanthifoline 
gave very significant activity against Plasmodium falciparum, TM4 and K1 strains. Crude 
methanol extract (AO-ME) of Aconitum orochryseum was not that active (IC50 of >10 
µg/ml for both the strains). Increased activity was observed for its crude alkaloid (AO-
CEA) with IC50 values of 20.40 µg/ml against TM4 and 19.20 µg/ml against K1 strains. 
The activity was further increased for atisinium chloride with IC50 values of 4.02 µM 
against TM4/8.2 and 3.59 µM against K1CB1 strains.  
The antimalarial activity was better for the extracts and alkaloids of Corydalis gerdae. Its 
crude methanol extract (CG-ME) had the IC50 values of 1.00 µg/ml against TM4 strain and 
 ix
2.56 µg/ml against K1 strain. The activity of crude alkaloid of this plant was far better with 
IC50 values of 0.33 µg/ml against TM4 strain and 0.63 µg/ml against K1 strain. Protopine 
had IC50 values of 4.25 µM against TM4/8.2 and 4.29 µM against K1CB1 strains. 
Cheilanthifoline had the IC50 values of 3.76 µM against K1 and 2.78 µM against TM4 
strains.  
These alkaloids have the potential to become candidates for antimalarial leads. Similar 
activities may be expected from other alkaloids including new ones isolated from these two 
plants. Therefore, the combination of these two plant extracts would make the best 
antimalarial herbal mixture for Bhutanese traditional medicines. The results proved that 
ethno-directed biorational approach, combined with an alkaloid focus, is an efficient 
strategy for drug lead discovery. The results also proved for the first time at the molecular 
level that Bhutanese traditional medicines have clinical efficacy. The medicinal plants of 
Bhutan thus have potential to provide important new drug leads. Bioprospecting them 
would benefit local people, pharmaceutical industries and the patients at large.  
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Chapter 1 
Natural Product-Based Drug Discovery and Recent Developments 
1.1 General Introduction 
With the advancement in science and technology, remarkable progress has been made 
in the field of medicine including diagnosis, treatments and pharmaceutics. Recent drug 
discovery techniques based on Structure-Activity Relationships, Computer Modelling, 
Combinatorial Chemistry, High Throughput Screening and Spectroscopy (MS, NMR, 
and IR) have triggered and spearheaded the discoveries of many natural and synthetic 
drugs. In 1999, world sales of pharmaceuticals (excluding veterinary medicines) were 
valued at ca US$ 325 billion1.  
Despite these developments, of the known 30,000 human diseases or disorders, only 
one-third can be treated symptomatically with drugs (either in part or fully) and that too 
at a great economic and social cost. This is because of the fact that the drugs available 
today are still not very effective particularly with respect to the fight against drug 
resistant pathogens and newly emerging infections. This includes infectious diseases 
such as AIDS, influenza, tuberculosis and malaria as well as other chronic disorders 
like cancer, autoimmune disorders and central nervous system disabilities (e.g. 
Alzheimer’s disease). The lead cause of death is HIV-AIDS, followed by tuberculosis 
and malaria.  In 1996, the HIV virus had infected at least 21,000,000 people 
worldwide2 and in 2001, UNAIDS estimated that over 14,000 new infections occurred 
daily, nearly half of them in women3 and strikingly affecting Africa4. While malaria 
continues to affect 1-3 million lives each year5, ca. 2 billion people (including at least 
15 million Americans) are affected by tuberculosis6,7. These infectious diseases 
(microbial) will continue to be the leading causes of premature death in human beings 
of both developed and developing nations as their resistance to many conventional 
drugs is increasing. Therefore, microbial resistance especially by bacteria and protozoa 
to drugs is of special concern to communities worldwide and to researchers.  
 
1.2      Development of Antibacterial Resistance     
The discovery of bacteria in 1683 by van Leuwenhoek helped mankind to understand 
the infectious pathogens and appropriately develop antiseptic and antibiotic protocol in 
the following years. By the beginning of 20th century, Paul Ehrlich proposed the 
principle of chemotherapy and his work including Structure-Activity Relationships 
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significantly contributed to shaping synthetic protocols and helped in the later 
discoveries of antibacterial drugs2. Antibiotics were designed either to kill bacteria 
(bactericidal) or to nullify growth (bacteriostatic)8 and three groups of antibacterial 
agents, which included bacterial cell wall inhibitors, protein synthesis inhibitors9 and 
DNA inhibitors, were developed to fight the bacterial infections. The sulphonamides 
were the first group of effective antibacterials to be developed following a chance 
discovery in 1932 by Domagk of antibacterial activity in the synthetic azo dye, 
prontosil.  
Many antibacterial drugs were developed in the late 1940s following the first report of 
resistance in Staphylococcus aureus (1941) and in Mycobacterium tuberculosis 
(1940s)2, a mycobacterium which also developed resistance later to the drugs isoniazid 
and rifamycin in the 1950s and 1960s. However, by the 1980s most major infectious 
diseases in the developed world were almost eradicated and half the major 
pharmaceutical companies in Japan and the USA stopped their antibacterial drug 
development programs10. As a result drug-resistant pathogens were on the rise 
worldwide11. Streptococci that causes nosocomial infections showed innate resistance 
to drugs including cephalosporins, clindamycin and aminoglycoside2,10. The bacterium 
(Staphylococcus aureus) has now developed multi-drug resistant strains and threatens 
to put an end to successful chemotherapy12. Vancomycin resistance among enterococci 
became noticeable in 1987 resulting in a true ‘super bug’. A summary of bacterial 
resistance to chemotherapy is shown in Table 1. 
 
Table 1.   Bacteria that have acquired resistance to some drug therapy2. 
Resistant type Bacteria Disorder Date (approx.) 
Penicillin 
resistant 
Pneumococci 
Legionella 
Borrelia burgdorferi 
Salmonella 
Staphylococci 
E.coli 
Pneumonia, meningitis 
Legionnaire’s disease 
Lyme disease 
Gastrointestinal disorders 
Toxic shock syndrome 
Gastrointestinal disorders 
Mid 1970s-present 
Mid 1970s-present 
1980s-present 
1980s-present 
1980s 
Mid 1980s-present 
Multi-drug 
resistant 
M.tuberculosis Tuberculosis Late 1980s-present 
Vancomycin 
resistant 
Enterococci 
V.cholerae 
Wound, blood, enteric infections 
Cholera 
Late 1980s-present 
Multi-drug 
resistant  
“super bugs”  2002 
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1.2.1  Mechanism of Bacterial Resistance 
The mode of bacterial resistance is either intrinsic (maintained on the bacterial 
chromosome) or acquired through chromosomal mutations and plasmid transformation, 
transposition, transductions and conjugation from other species2,13. The fundamental 
mechanisms of resistance generally observable in bacteria include inactivation or 
degradation of the antibacterial drug by enzymatic action, decreasing or changing of 
membrane permeability of the bacterial cell wall to antibiotics, the alteration of the 
bacterial proteins that are antimicrobial targets, and less often, auxotrophic or metabolic 
by-pass2. For example, the resistance to the penicillins and cephalosporins occurs 
through antibiotic hydrolysis mediated by the bacterial enzyme beta-lactamase while 
the resistance to trimethoprim, the sulphonamides, the aminoglycosides, 
chloramphenicol and the quinoline drugs occurs by the productions of antibiotic-
modifying enzymes and the synthesis of antibiotic-insensitive bacterial targets14.  
It was found that the degree of resistance may vary based on the level and the capacity 
of the pathogenic micro-organisms to manipulate, alter and combine all of these 
biochemical and genetic processes. Several factors, such as inappropriate prescription 
of drugs (use of doses that are too low), over prescription in trying to meet patients’ 
demand, extravagant prescription due to excessive choices of available drugs, poor 
infection control practices, the length of therapy (incomplete course taken by patients) 
and the duration of bacterial exposure to long-acting agents compared to drugs with 
short half-lives have been found to influence the rate of selection of resistance and play 
a role in the  worsening situation of global resistance15. Other determinants such as the 
state of immunity and the phenotypes of bacterial pathogens also influence the mode of 
resistance. 
 
1.3    Development of Antimalarial Resistance 
Malaria is another pandemic disease endemic to 102 countries16. It is an infectious 
disease caused by four types of parasitic protozoan in the genus Plasmodium: 
Plasmodium Falciparum, Plasmodium malariae, Plasmodium ovale and Plasmodium 
vivax. Falciparum malaria is the most severe form of malaria and it has already 
developed resistance to many of the currently available drugs. The parasites are 
transmitted by the bite of female anopheles mosquitoes. Insecticides such as DDT 
(dichlorodiphenyltrichloroethane) were used in many countries to control the mosquito 
vector. Though it has partially helped to bring malaria under control, it has also 
generated many long-term detrimental effects.  
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The search for agents to combat malaria became particularly intense in the 1800s as 
British soldiers in India were infected with malaria and as outbreaks of malarial 
epidemics took heavy tolls in tropical, subtropical and temperate regions of the world 2.  
Population growth, urbanization, refugees, conflicts and global warming17 have 
contributed significantly to the outbreak of further epidemics. Quinine 1 was the first 
antimalarial drug discovered in 1820 by Caventou and Pelletier from the bark of 
Cinchona officinalis18. By the early and mid 20th century, its synthetic derivatives such 
as quinacrine, mefloquine and chloroquine became available. In continuation of 
searches for antimalarial drugs, the first major research on plant extracts was started in 
1947 by the screening of 600 species of plants belonging to 126 families but it was only 
in the mid 1980s that the testing of these plant extracts were completed19. The research 
found several plants, particularly in two families, the Simaroubaceae and 
Amaryllidaceae, active against avian malarias18.  
With the discovery of many cheap antimalarial drugs, malaria was eliminated from 
Europe, North America, Australia, South America and Asia and the search for new 
antimalarial agents became secondary for these countries. The limited armoury of drugs 
is now greatly compromised by the spread of drug resistant parasite strains20. The 
chloroquine resistant strains of Plasmodium falciparum have now developed resistance 
to mefloquine, halofantrine and quinine21,22. Malaria is again claiming millions of lives, 
mainly affecting children under the age of five in Sub-Saharan Africa4 (Figure 1). 
Currently, a combination of synthetic drugs like sulfadoxine and pyrimethamine 
(Fansidar) is used in treating these resistant parasites. Other combination therapy like 
pyrimethamine with dapsone, quinine/tetracyclines, and atovaquone/proguanil are also 
used. Nevertheless, resistance to such combined drug therapy has also been reported in 
Africa, Thailand, Burma, Laos, Vietnam, Cambodia and China.  
Artemisinin 2, which was discovered in 1972 from the Chinese medicinal plant, 
Artemisia annua22, is the main hope  for saving millions of lives from the multi-drug 
resistant parasite, Plasmodium falciparum. Artemisinin and its derivatives such as 
artemether, arteether, dihydroartemisinin, artelinic acid and artesunic acid (intravenous 
and intramuscular administration)22 are currently used worldwide. Recently, the potent 
antimalarial agents, raphidecurperoxin 3 and polysyphorin 4, were isolated from the 
Vietnamese medicinal plants, Rhaphidophora decursiva23. These natural products 
showed strong activity against Plasmodium falciparum in vitro without any toxicity and 
may become potential candidates for antimalarial drugs. 
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Figure 1. World map showing the occurrence of malaria and chloroquine resistant areas4. 
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Voacamine (a bisindole alkaloid), isolated from Voacanga species (Apocynaceae) has 
also been found to give promising in vitro activity against chloroquine-sensitive and 
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resistant strains, Plasmodium falciparum24. Termilignan, thannilignan, 7-hydroxy-3′,4′-
(methylenedioxy) flavan, and anolignan B, all isolated from Terminilla bellerica, have 
also shown anti-HIV, antimalarial and antifungal activity in vitro25.  
 
1.3.1   Mechanism of Parasite Resistance 
Malarial infections are increasing due to the development of resistance by the parasites 
to traditional drugs as well as acquisition of resistance to DDT by the vector Anopheles 
mosquitoes. It was suggested that resistance to the inhibitors of dihydro-folate 
reductase and dihydro-pteroate synthetase enzymes, and the novel antimalarial 
atovaquone, occurs through genetic point mutations26. The mechanism of resistance to 
quinoline drugs like chloroquine has been attributed to mutations in two genes; pfmdrl 
and pfCRT 27. These mechanisms of drug resistance in parasite are yet to be defined but 
certainly the mechanism of resistance do seem to vary according to the use and type of 
drugs, each of which having distinct modes of action on parasites.  
 
1.4 Strategy for Control of Bacterial and Malarial Infections  
As the microbial infections continue to plague the nations worldwide due to very few 
effective drugs that are available today (antibacterial agents make up only 12-15% of 
the total pharmaceutical business2), there is an urgent need to find concrete solutions 
for combating such epidemics. Prevention of famines, droughts, poverty, floods, wars, 
political upheaval, economic failures, environmental depletion and pollution would be 
good solutions to help reduce infections and microbial resistance.  
Another measure to prevent microbial resistance (bacterial and malarial) is to use the 
currently available antimicrobial drugs more judiciously and optimally. In general, 
resistance is observed higher in areas of high consumption of antibiotics and lower in 
areas of low consumption28. A study conducted on controlling resistance in 
community-acquired pathogens in Finland in the 1990s, revealed that there was a 50% 
reduction in the macrolide resistant group-A Streptococci when the use of macrolides 
such as erythromycin were reduced for treating the diseases29. Therefore, choosing the 
correct drug, dose, dose interval and duration of therapy may more efficiently provide 
clinical benefits while contributing less to resistance than choosing the drug with the 
narrowest spectrum30.  
Above all, the most important strategy to control, cure and to prevent reinfection is to 
develop more appropriate treatment regimens including the super drugs. Super drugs 
could be developed synthetically, but as experience has taught us, natural products are 
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rich in structurally diverse bioactive molecules like alkaloids, which quite often 
become potential candidates for the development of drugs.  
  
1.5      Development of Drugs from Bioactive Natural Products 
Bioactive natural products are mainly secondary metabolites which are used by the host 
as defensive and protective mechanisms against their enemies and predators31. 
Generally, screening of these secondary metabolites and development of drugs is a very 
hard task requiring much effort starting from botanical identification, collection, 
extraction, isolation, purification and compound identification to pharmacological and 
clinical testing. However, the enormous chemical diversity and highly unusual 
structures provided by natural products is greater than that provided by most available 
combinatorial approaches based on heterocyclic compounds32,33.  
When screening for natural products, three main types of search strategies, namely 
biorational, chemo-rational and random approaches34 are followed. The bio-rational 
approach includes ethno-medically directed screening (as discussed above) and random 
screening. Random high throughput screening is based on field observation such as 
pest-plant analysis and plant characteristics. Drugs such as artemisinin, morphine, 
quinine, and ephedrine were discovered using the ethno-directed bio-biorational 
approach35. Conocurvone36, an anti-HIV agent was discovered as a result of random 
high throughput screening. The chemo-rational approach is based on chemo-
taxonomical considerations such as alkaloid surveys, and investigation of specific 
families which are known to contain potential drug leads37. Employing these three 
search strategies as many as 88,000 natural product compounds have been isolated 
from different sources such as plants, animals, marine organisms, insects and micro-
organisms.  
It is estimated that ca. 250,00038 to 500,000 species of plants grow on earth39,40 and 
70% of all the world’s biodiversity of vertebrates, higher plants and butterflies are 
harboured by 12 countries; Mexico, Colombia, Ecuador, Peru, Brazil, Zaire, 
Madagascar, China, India, Malaysia, Indonesia and Australia41. The 18 global 
biodiversity hotspots support nearly 50,000 endemic plant species41. A high rate of 
endemism is predicted in mountainous areas like Bhutan, oceanic islands like Australia, 
mutuallistic special pollinators as present in Madagascar and plant symbionts like 
orchids42. These endemic species were found to contain varieties of distinctly new 
chemical structures. It is reported that only 10-15% of terrestrial biodiversity especially 
higher plants were explored phytochemically for medicinal applications40, and the main 
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categories of plant-derived drugs are terpenes (34%), glycosides (32%), alkaloids 
(16%) and others (18%)43. Around 85% to 90 % of terrestrial resources are still intact 
and await exploration. 
Amongst the animal kingdom, lower groups of animals especially those secreting 
venoms and toxins such as insects, amphibians, reptiles, wasps, and spiders, produce 
interesting and novel bioactive compounds. There are 30 million species of insects and 
very few have been studied for bioactive secondary metabolites34. Out of ca 100, 000 
species of spiders, only ca 30 have been studied until date44. The marine world 
represents 70% of earth’s surface, but only 5% of the marine organisms have been 
explored chemically and a huge diversity of marine fauna and flora are yet to be 
investigated31. Marine secondary metabolites are often observed to have anticancer 
activity. Approximately 300 patents on marine natural products were issued between 
1969 and 199945 and a number of compounds have progressed to clinical trials. 
Micro-organisms have been a frequent source of antibiotics, ever since the discovery of 
penicillin from the filamentous fungus Penicillium notatum by Alexander Fleming in 
1928. Cyclosporins and rapamycin (an immunosuppressive agent), ivermectin (an 
anthelmintics and antiparasitic drugs), streptomycin, chloramphenicol, tetracyclines 
and cephalosporin (antibiotics) were isolated from Streptomyces or Penicillium species. 
Only an estimated 1% of bacterial and 5% of fungal species have been examined to 
date38. Extremophiles such as alkalophiles, halophiles, barophiles, thermophiles and 
psychrophiles also offer a potentially diverse source of novel bioactive agents38.  
 
1.5.1     Application of Alkaloids in Medicine 
Hesse defined alkaloids as “nitrogen containing organic substances of natural origin 
with lesser or greater degree of basic character” and include both alkaloids with 
nitrogen as part of a heterocyclic system as well as the extra cyclic bound nitrogen44. 
However, Roberts and Wink have suggested that a basic character is no longer a pre-
requisite for alkaloids46.  
Many workers in the field of alkaloids have attempted classifying alkaloids based on 
their biogenesis from amino acid derivatives, structural relationships, biological origin, 
and spectroscopic properties44. Since many alkaloids are derived from more than one of 
the major precursors, there is extreme heterogeneity in alkaloid structures, which makes 
their orderly classification very difficult. The classification is, thus to some extent, 
arbitrary and not well established. 
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Nevertheless, biogenetic groupings of alkaloids are most commonly followed. 
According to this system47, four main types of alkaloid groups are distinguishable: 
i) Alkaloids of amino acid derivatives, like ornithine, histidine, tryptophan, 
tyrosine, lysine, anthranilic and nicotinic acids. 
ii) Alkaloids of purines like zanthine and caffeine. 
iii) Alkaloids of aminated terpenes, like the diterpenoid alkaloid, aconitine and 
the triterpenoid alkaloid solanine. 
iv) Alkaloids of polyketides like coniine and the coccinellines46.  
Alkaloids derived from ornithine are categorized into: simple alkaloids, tropane 
alkaloids, pyrrolizidine alkaloids, phenanthroindolizidine alkaloids, spermine, 
spermidine and related alkaloids and the miscellaneous alkaloids. Alkaloids derived 
from lysine are grouped into: simple piperidines, lobelia alkaloids, lycopodium 
alkaloids, lythraceae alkaloids and complex and miscellaneous alkaloids. Alkaloids 
derived from anthranilic acid include the quinoline, furanoquinoline, acridine and 
quinazoline groups.  
Alkaloids derived from tyrosine consist of simple β-phenylethylamine derivatives, 
Amaryllidaceae alkaloids, and the isoquinoline alkaloids, which are further sub-
categorized into many sub-types. Alkaloids derived from tryptophan constitute the 
largest alkaloid group and include tryptamine derivatives, carbazoles, ergot alkaloids, 
borreria alkaloids, monoterpenoid and indole alkaloids. Alkaloids derived from 
aminated terpenes include, monoterpenoid pyridine alkaloids, nuphar alkaloids, 
celastraceae alkaloids, erythrophleum alkaloids, diterpenoid alkaloids, steroidal 
alkaloids, and the daphniphyllum alkaloids. Diterpenoid alkaloids are a major and 
fascinating sub group in this category and they have been the source of many bioactive 
compounds in the past. It has been found that species in a given genus or related genera 
yield the same or structurally related alkaloids; for example seven different genera of 
plants in the Solanaceae contain hyoscyamine48, while 164 genera of 47 families 
produce both isoquinoline and indole alkaloids49. 
With alkaloid nomenclature, trivial naming is commonly observed, however about four 
different types of naming are followed based on44: 
i) A systematic plant name, e.g Papaverine is derived from Papaver species. 
ii) The plant discoverer, for example spegazzinine from Aspidosperma 
chakensi SPEGAZZI.  
iii) Geographical settings for example tasmanine after Tasmania.  
iv) A person’s name, for example macrosalhine after the lady Salhiha.   
 
 
10 
But such naming of alkaloids falls short when several new alkaloids are isolated from a 
single plant. Judicious naming can be followed based on the chemist’s imagination, 
assigning sufixes like ‘-ine’, ‘-idine’, ‘- anine’,  ‘-aline’, and ‘-inine’44, since IUPAC 
naming becomes complex as most of the natural products are very large molecules.  
In 1988, the NAPRALERT database listed ca.16000 alkaloids with varying types of 
nomenclature as described above40,46. It is estimated that 10-15% of all vascular plants 
contain alkaloids, but they are observed particularly in the families: Apocyanaceae, 
Papaveraceae, Papilionaceae, Ranunculaceae, Rutaceae and Solanaceae48. The 
alkaloids serve plants as a feeding deterrent to protect them from predators and they are 
also believed to act allelopathically in some plants44.  
Alkaloid distribution in the plant can vary. In many cases higher concentrations are 
observed in areas where herbivores usually attack, i.e. in the inflorescence, young 
growing tips and peripheral cell layers of stems and roots46. An analysis of 3,589 
varieties of plants of various origin in different growth phases and parts of the plant 
revealed the fact that the maximum amount of total alkaloids is produced by young 
plants and by green parts of the plant50. The alkaloid content and the types of alkaloids 
also vary from species to species, season to season and region to region. The 
biosynthesis and the formation of alkaloids in plants involve elaborate chemical 
reactions that are performed sequentially in a way unique to each species and quite 
often different from laboratory synthesis51.  
Lipinski and his co-workers49,52 suggested alkaloids as suitable candidates for orally 
bio-available drugs. Such drugs should have:  
a) Less than five hydrogen bond donor groups (such as –OH and -NH). 
b)  Less than ten H-bond acceptors in the molecule (such as oxygen and nitrogen 
atoms). 
c) A molecular weight less than 500 Dalton. 
d) A Log P value less than five units. 
At present, approximately 600 alkaloids have been analysed for their bio-medicinal 
properties and many of them have become important drug leads or actual drugs in the 
pharmaceutical industry46. For example, the taxol, isolated from Taxus brevifolia and 
the vincristine and vinblastine isolated from Catharanthus roseus (Madagascar) are the 
important anti-cancer drugs derived from plant alkaloids. Very recently, provir, an oral 
product for the treatment of respiratory viral infections, and virend, a topical antiviral 
product for the treatment of herpes (both in clinical trials) were developed from plant 
alkaloids53. Hadi et al54 isolated the antimicrobial alkaloids: lombine, cononaridine, and 
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mataranine A and B from the plant Vocanga foetida Rolfe. These alkaloids were 
reported to have strong activity against Staphylococcus aureus. A mixture of 
mataranine-A and B was found active in vitro against Plasmodium falciparum. While 
25 to 50% of the current pharmaceuticals, including antimalarial drugs, were derived 
from plants, no ideal antibacterial drugs (antibiotics) have yet been developed from 
plants55. 
Captopril, an antihypertensive agent31 was derived from an alkaloid, teprotide (isolated 
from Snake venom). Epibatidine, which was isolated from the frog Epipedobates 
tricolor56 was shown to be a novel non-opioid analgesic agent with two hundred times 
the analgesic potency of morphine. In the mid 1980s, bryostatin-1 was isolated from 
Bugula neritina, a marine bryozoan, and was found to be effective against ovarian 
carcinoma and non-Hodgkin’s’ lymphoma38. Halobacilin, bisucaberin and 
homocereulide await clinical applications57. Studies on the egg masses of Dicathais 
orbita (a marine mollusc) by Benkendorf et al. using an ecologically-directed approach 
resulted in the isolation of the broad spectrum antibacterial alkaloid derivative, 
tyriverdin58. 
 
1.6     Natural Products in Traditional Medicines 
Because Homo sapiens are herbivores to some degree, they first encountered bioactive 
agents in vegetal food items59. Having lived harmoniously in close association with the 
environment, they learned to utilise the toxic and medicinal properties of plants and 
other natural products. Some of those toxic plants were used as poisons for causing 
death and as arrow poisons for hunting food, warfare, depredating wild animals and for 
gaining mastery over a hostile environment46,60. The most remarkable of all the ancient 
inventions was the art of utilising these toxic and medicinal natural products for 
treating various ailments but the ethno-medical knowledge was restricted to a few elites 
such as priests, medicine men, shamans, magicians and witch doctors59. Although some 
cultures used individual herbs or plants as medicines, many traditions propounded 
powerful combinations with different ingredients known as poultices, tinctures and 
mixtures.  
It was the Mesopotamians who first used the herbs like oils of cypress, cedar, liquorice 
and poppy juice for treating different ailments in  2600 B.C38 followed by the Indian 
Buddhist system of medicine that dates to 2500 BC61. Then came the Egyptian’s Ebers 
Papyrus (1500 BC) that documented some of the 700 drugs including formulas such as 
gargles, snuffs, poultices, infusions, pills and ointments38, the Chinese materia medica 
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Wu-Shi Er-Bing Fang which contains 52 prescriptions dating to 1100 BC38,62 and the 
Indian Ayurvedic Medicine that dates to 1000 BC (Susruta and Charaka) documenting 
the medicinal use of plants like Datura, Aconitum, Canabis and Sarcostemma59.    
From these ancient cultures, some of the knowledge reached Mediterranean countries 
through traders and migrations and it was in Hippocrates’s (460-377 BC) time that 
pharmacognosy reached a summit in Greece59. Theophrastus (ca 300 to 322 BC), who 
was a philosopher and naturalist, was the first to deal with the history of plants, which 
later on helped in the classification of plants including herbs. Pedanius Dioscorides, a 
Greek physician (ca 40-90 AD) produced De materia medica in 78 AD, which 
described more than 500 medicinal plants and their uses in detail.  
Galen (ca 129-199 AD) founded “Galenics” and taught pharmacy and medicine in 
Rome63. Avicenna (980-1037 AD), a Persian pharmacist, physician, philosopher and a 
poet described 1400 drugs and medicinal plants which greatly contributed to the 
formation of a codified Graeco-Roman Medicine in the 5th century38,59. Paracelsus 
(1493-1541) administered dosage formulations separating “Arkanum” from non-active 
ingredients of drugs. Western medicine and pharmacy originated from this medical 
system.  
Tibetan medicine, also called gSo-ba Rig-pa, took shape in the 7th-8th century with the 
advent of Mahayana Buddhism in the country61,64. Bhutanese traditional medicine 
known as gSo-ba Rig-pa was conceived subsequent to Tibetan medicines in the 8th 
century and contain more than three hundred herbal formularies and recipes65,66. In the 
USA, homeopathy, that includes hydrotherapy, nutritional therapy, herbal therapy, 
manual manipulation and midwifery, was founded by German physician Hahnemann 
(1755-1843) became popular in 1830s.  
The discovery of antibiotics and vaccines in the 20th century dramatically changed 
medical practice worldwide and as a result a separate field of ethno-medicine emerged 
as an academic specialization focusing on traditional healing systems67. The 
investigation of the principles of drug action of Japanese traditional Sino-medicine at 
the molecular level have resulted in obtaining many novel compounds and the 
uncovering of new mechanisms of drug action68. Clinical trials of Tibetan medicine, the 
PADMA Products, also proved successful in the treatment of irritable bowel 
syndrome69 and fibrinolysis with stable intermittent claudication70,71. This products also 
furnished new anti-oxidative mechanisms at the molecular level72.  
Thus, traditional medicines were found to be effectively addressing the health needs of 
millions of people including developed nations by completely different strategies and 
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well defined approaches, and generally with minimal side effects67. Current WHO 
estimates show that 75% of the French population, 30% of the Vietnamese population, 
and 40% of Indonesia’s population uses traditional medicines73. In Germany, 77% of 
pain clinics provide acupuncture, in Japan 72% of registered western style doctors uses 
kampo medicine73 and in Bhutan, traditional medicine caters to 80% of the population. 
Overall, traditional medicines provide primary health care needs to almost 65-85% of 
the world’s population including developed nations39,40. In terms of economic value, 
traditional therapies contribute to US $ 60 billion a year and the USA alone spends US 
$ 2.7 billion per year followed by China with US $ 1.8 billion and Australia with Aus $ 
1 billion a year73.  
Since almost every traditional medicine regimen uses medicinal plants as the bulk 
ingredients, they also play significant roles in natural product based drug discoveries. 
More than 13,000 species of plants are used in traditional medicines and herbal 
cosmetics43. About 8000 of these medicinal plant species are known in South Asia 
alone74. Many pharmaceutical companies have successfully explored these medicinal 
plants by applying an ethno-directed biorational approach75. In fact, among the search 
strategies, the ethno-directed bio-rational approach has proved to be the shortest and the 
most effective search strategy for discovering drugs from Nature. For example, the 
National Cancer Institute, USA, has noted that extracts from medicinal plants in in vitro 
bioassays gave greater rates of bioactivity than those from other plants75. In another 
survey, out of 800 medicinal plant extracts collected from Vietnam and Laos, at least 
25 biologically active compounds were isolated; of these 13 were new anti-HIV agents 
and 3 were antimalarial agents76. Similarly, in the USA, out of 119 plant drugs 
available from 1959 to 1980, 74% of these were discovered as a result of chemical 
studies directed at isolating the active substances from the plants used in traditional 
medicines38.   
However, in using this ethno directed search strategy, it is crucial to have intimate 
understanding of the disease concepts of the culture whose pharmacopeia is under 
examination. The products used as medicines by local people are usually not those that 
are tested in the laboratory. Most of the effective brews or formularies are multi-
ingredient compounds. Chemical reactions occur within these mixtures or poultices and 
are most often associated with synergism making them more effective than the single 
isolated lead compound. When the medicinal plants are subjected to phytochemical 
screening, researchers often target only one compound, or a few limited compounds, 
which quite often turn out to be biologically inactive owing to the loss of other active 
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components during this screening process. Therefore, the ethno-medical indication may 
not necessarily be productive when screening is directed towards only specific 
phytochemical isolations. 
 
1.7 Natural Products and Bhutanese Traditional Medicine 
Bhutanese Traditional Medicine is locally known as gSo-ba Rig-pa, which means “The 
Art of Healing Sciences”65. It is one of the world’s oldest surviving medical traditions, 
preserved intact, and practised in Bhutan in conjunction with western medicine.  
Currently it provides primary health care to 80% of the country’s population. The 
history of gSo-ba Rig-pa dates back to the era of Buddha Kashyapa, the predecessor of 
the historical Sakyamuni Buddha. It was Buddha Kashyapa who transmitted the 
medical teachings to Brahma and then ultimately propagated them to the human realm 
as a weapon to fight suffering66,77. Buddha Sakyamuni, also sometimes called the 
Supreme Physician, was then said to have taught a healing system ‘Vimalagotra’ 
(Immaculate Lineage) simultaneously with the first turning of the Wheel of Dharma at 
Sarnath on Four Noble Truths in India, followed by the text gSo-dPyad hBum-pa (One 
Hundred Thousands Verses of Healing) at Jagoe Phungpoi Ri (Vulture’s Peak) and 
gSer-′od Dampai mdo (Supreme Golden Rays Sutra) that contained a separate chapter 
on “Nad-thams Cad Zhi-bar bYed-pai rGyud” (The Ways of Completely Curing 
Diseases) during the third turning of the wheel78. Dul-ba rLung (Vinaya Sastra) 
teaching on moral discipline also contained medical teachings.  
He taught his disciples and followers, mostly using disease and healing as metaphors to 
illustrate his philosophy of the human condition79. Though Buddha’s teachings spread 
to many Asian countries, gSo-ba Rig-pa became prominent only in Tibet and Bhutan. It 
was in 718-785 A.D. that Tibet saw the peak development of astrology, medicine and 
astronomical science80. During that time, Tibet hosted several medical conferences at 
Samye inviting the great healers from Tibet, China, India, Persia, Byzantium and 
Himalayan countries like Bhutan and Nepal79. It was reported that all the different 
medical systems were analysed at this conference and the best practices were 
incorporated into gSo-ba Rig-pa. Pre-Buddhist Shamanistic views and the Bon tradition 
also influenced the way Tibetan Medicine evolved81,82.  
With the advent of Mahayana (Tantric) Buddhism from Tibet in the 8th century, the 
gSo-ba Rig-pa (Art of Healing) also took shape in Bhutan as well65. The Buddhist 
philosophy remained as the mainstream of this medical tradition. However, Tibetan 
Medicine, Indian Ayurvedic Medicine, Unani Medicine, Chinese Traditional Medicine, 
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Shaman Medicine, Local Ethno-Medicine, Exorcism and the Bon Tradition had a 
definite influence on the way Bhutanese Traditional Medicine evolved.  
Philosophically, gSo-ba Rig-pa is based on the fact that all suffering is caused by 
ignorance of the nature of reality and the craving, attachment, and grasping that arise 
from such ignorance and that the path to overcome such suffering is to follow the 
Noble Eightfold Path of Lord Buddha, which consists of right views, right intention, 
right speech, right action, right livelihood, right effort, right-mindedness, and right 
contemplation. Fundamentally, gSo-ba Rigpa states that human beings are composed of 
three main elements called “Three Humours”; rLung inadequately translates as air, 
mKhris-pa translates as bile and Bae-dkan, translates as phlegm64-66. They are 
interrelated in all the vital systems and functions of the body such as the nervous 
system, circulatory system, digestive system, excretory system, reproductive system, 
respiratory system and musculo-skeletal system. Each of the three humours has 
different functions in the body (Table 2).  
 
Table 2.     The Three Humours and Body Function 65,78,79. 
Three Humours Characteristics Function 
RLung (air) Has the nature of air, 
rough, light, cold, 
subtle, hard and mobile 
 
Controls movement and bodily functions such as 
respiration, excretion, circulation, speech, intellect, 
impulses, gives clarity to sense organs and sustains 
life by means of acting as a medium between mind 
and body. 
mKhris-pa (bile) It has the nature of fire, 
oily, fluidity, hot, 
sharp, light, fetid and 
purgative  
Controls digestion, assimilation, and basic 
metabolism generating heat and energy. Stimulate 
feelings of hunger and thirst, gives lustre to body 
complexion and provides courage and determination 
Bae-dKan 
(Phlegm) 
Cold in nature, oily, 
cool, heavy, blunt, 
smooth, firm,  sticky 
Firmness of body, stability of mind, induces sleep, 
connects body joints, generates tolerance, lubricates 
the body and regulates the balance of energies. 
 
Based on this, body meridians are drawn to help diagnose diseases related to the energy 
system of the body. Explicit knowledge of body meridians is important in acupressure 
therapy of gSo-ba Rig-pa, so the Buddhist medical system is more than a study of 
anatomy, physiopathology and the pharmacopoeia. Physiopathology, as per gSo-ba 
Rig-pa, is based on the close relationship between the human microcosm and the 
universal macrocosm65. Each of the three humours of the human body is considered a 
combination of the five basic constituents (proto-elements) of the Universe: Sa (earth), 
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Chu (water), Mei (fire), rLung (wind/air) and Nam-mKha (space)78. They are essential 
elements for the existence of all life on earth and they coexist in equilibrium. As long 
as these proto-elements are in their natural state and maintain a proper balance, 
suffering does not erupt from the environment nor do they affect the three humours. 
When these three humours are well balanced in an individual, then the person is said to 
be healthy65.  
Any sign of imbalance or modifications in the three humours are clearly apparent in the 
pulse, urine and on the surface of the body. Based on this theory, physicians perform 
pulse readings, physical urinalyses and observe the eyes, tongue and earlobes (in 
babies) to detect disorders. In modern allopathic medicine, pulse reading is only used to 
detect anomalies of the heart and the circulatory system, but in gSo-ba Rig-pa, the 
pulse reading links the network of body meridians and can detect any diseases affecting 
different parts, organs and systems of the body66.  
The treatment regimen in gSo-ba Rig-pa is holistic in nature and it mainly includes five 
kinds of healing methods like behavioural modification, herbal physiotherapy, minor 
surgery and prescription of herbal medicine. Bhutanese traditional medicine texts report 
the use of as many as 2200 traditional prescription drugs and each of these drugs are 
multi-ingredient drugs77,81. However, in 1969, only 167 formulations, which used 300 
different types of ingredients, were selected for the essential drugs list83. The essential 
drugs list was further streamlined based on disease patterns and prevalence in Bhutan 
and was reduced to 103 after thorough examination and standardization processes84.  
The manufacturing unit in Bhutan produces 8-9 tonnes of traditional medicines 
annually and these are formulated into different dosage forms which includes pills 
(39.81%), tablets (30.10%), ointments (3.88%), syrups (1.94%), capsules (12.62%), 
powders (3.88%), crude extracts (0.97%) and unestablished dosage forms (6.80%)85. 
Some pills like Rinchen Rilbu also uses precious metals such as gold, silver, turquoise, 
pearls, gems and other rare minerals as ingredients.  
There are 46 alkaloid-containing drugs on the Bhutanese essential drugs list. Toxic raw 
materials are pre-processed and detoxified before formulation following traditional 
methods. Since 1998, the standardization of traditional drugs has been done using the 
Total Quality Profiling Method86,87. These standardized drugs have the potential to go 
forward for regulatory approval. Bioprospecting the medicinal plants used in gSo-ba 
Rig-pa medicine also has an international market value and should play an important 
role in any new drug discovery programme.  
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1.8      Research Aims and Objectives 
As discussed earlier, microbial (bacteria, fungi, viruses) and parasite (protozoan) 
resistance to traditional antimicrobial and antimalarial drugs has emerged continuously 
and has become a great health concern for the communities worldwide. A new arsenal 
of antiinfective drugs is required for combating these resistant pathogens. Bhutan is 
rich in its ethno-medical heritage including treatments for infectious diseases (bacterial, 
fungal and viral infections and also for malaria) and uses more than 300 medicinal 
plants in different preparations. However, till date, active components of herbal 
mixtures have not been identified at the molecular level. Based on this ethno-botanical 
knowledge, analysing Bhutanese medicinal plants for anti-infective agents, with a focus 
on alkaloidal compounds, were the twin themes of the research described in this thesis.  
Therefore, the main objectives of this research project were: 
a) To investigate the alkaloidal components of selected medicinal plants of Bhutan 
where their use suggested antibacterial and antimalarial activities.  
b) To determine structures of the new alkaloids isolated from the selected 
medicinal plants. 
c) To assess their antibacterial and antimalarial properties and identify potential 
new lead compounds. 
d) To provide validation for gSo-ba Rig-pa, in an effort to help preserve the gSo-
ba Rigpa and to help to develop it as a sustainable traditional medicine.  
The medicinal plants of Bhutan selected for the study are discussed in Chapter 2. 
Chapter 3 presents the isolation of alkaloids from the medicinal plant, Aconitum 
orochryseum Stapf. In Chapter 4, the isolation of alkaloids from the plant Corydalis 
gerdae Fedde is discussed. Chapter 5 and Chapter 6 present an investigation of the 
alkaloids from Tribulus terrestris Linn and Ranunculus brotherusi Freyn respectively. 
Chapter 7 discusses the antimicrobial testing conducted on some isolated pure 
compounds and the crude extracts of the plants. Conclusions and future directions are 
presented in Chapter 8, while Chapter 9 covers the experimental section of the study.  
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Chapter 2 
Selection and Collection of Bhutanese Medicinal Plants 
2.1    General Introduction 
Bhutan is known to the outside world for its youthful inaccessible mountains, rich 
biodiversity and unique culture and tradition. It is sandwiched between the two 
historically, culturally, and politically contrasting giant nations of the world, India and 
China88 (Figure 2).  It has an area of 47000 square kilometres and a population of 
600,000.    
Geographically, Bhutan is laterally divisible into four zones with a continuous South-
North gradation of vegetation. The foothills region ranging from 95 to 2000 metres 
above sea level receive the heat of the Sahara desert and an annual rainfall of 80-90 
inches per annum, and thus supports tropical vegetation such as riverine species, sal 
evergreen forests and dense savannah grasses.  
The interior valleys (ranging from 2000 to 3000 meters) have cool pleasant winters and 
mild hot summers, which supports temperate vegetation. The annual rainfall ranges 
between 30-35 inches per annum and most of the flowering plants grow in this region. 
The alpine zone (starting from 3000 to 6000 metres) experiences intense cold winters 
and cool summers with scanty rainfall. This region has Tundra vegetation and supports 
meadows, scrub and shrubs. Most of the rare herbs grow in this zone. The 
mountaintops are permanently snow clad and don’t support any form of vegetation but 
they are a permanent source of rivers and spring waters in Bhutan.  The highest point 
measures 7800 meters above sea level on the peaks of the major inaccessible 
mountains88.  
Due to this unique topographical and climatic position89, the country is blessed with 
great biological diversity. About 5603 to 7000 species of plants including 60 species of 
Rhododendron and 600 species of orchids are reported to grow in Bhutan90,91. Out of 
50,000 endemic plant species reported to thrive in global hotspots of the world92, about 
82 endemic plant species have been discovered in Bhutan90. Bhutan has also abundant 
fungal and parasitic flora. As a result, Bhutan is often described as a “Botanist’s 
Paradise”93 and, recently, Bhutan was identified as one of the ten global hotspots of 
biodiversity in the world94,95. The conservation and preservation of this rich 
biodiversity (environment) including the medicinal plants is one of the country’s top 
development strategic priorities. Bhutanese view the environment as an essential 
component not only for material life but also for medical and spiritual life and thus 
about 72.5% of the forest is still preserved in its original form89.  
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Figure 2.  Map showing the strategic location of Bhutan. 
 
The rich Bhutanese biodiversity supports many medicinal plants. In fact, owing to the 
plentiful medicinal plants thriving in the country, Bhutan was known as “sMan-jong”, 
the land of medicinal plants77. Taking advantage of the availability of such rich 
medicinal plants and other bioactive natural products applications, the Bhutanese 
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developed their own medical tradition called gSo-ba Rig-pa. Around 600 species of 
medicinal plants have been identified to date and 300 of them are in routine use in the 
day-to-day formulation of gSo-ba Rig-pa medicines. 
 
2.2 Medicinal plants of Bhutan  
According to gSo-ba Rig-pa, there are seven categories of medicinal sources: three are 
of vegetable origin, which comprising of Sgo-sman (High Altitude Medicinal Plants 
and Herbs above 3000 metres), Khrog-sman (Low Altitude Medicinal Plants below 
3000 metres) and Rtsi-sman (resins and extracts); two are of mineral origin comprising 
of Rin-po-che-sman (precious stones/gems), rdo-sman (base minerals/stone) and Sa-
sman (medicinal soils) while one is of animal origin or srog-chags-sman (includes 
marine organisms). About 2990 species of medicinal plants73, 35 types of animal 
parts96, 18 types of minerals including precious stones and precious metals such as 
gold, silver, copper and iron are used in traditional medicine in Bhutan97. Marine 
products like crabs, pearls, seashells and other marine products are also used.  
Almost 70% of these raw materials, almost all of which are collected in the wild, are 
available within the country73. Only 30% are imported from India. Some rare and 
expensive animal parts such as rhino’s horn, tiger bone, elephant tusk and musk or 
gLar-tsee (used in 30% of the formulations) are banned from use in the herbal 
formulations96. Low Altitude Medicinal Plants (Khrog-sman) are collected from the 
temperate and tropical zone (Figure 3, Collection site-II) and the High Altitude 
Medicinal Plants (Ngo-sman) are collected from the alpine region (Figure 3, Collection 
site-I). About 60% of the species are harvested from high altitudes-between 3000 to 
6000 metres above sea level and only 40% are collected from low altitudes. The herbs 
are harvested and collected by the Pharmaceutical and Research Unit in Bhutan once a 
year employing good harvesting practices and with strict quality control monitoring.  
The time of collection is based on gSo-ba Rig-pa guidelines. According to these 
guidelines, therapeutic properties of the plants are directly affected by the collection 
season, picking time (morning, afternoon and evening) and the nature of drying 
conditions that has to be carefully monitored. For example, some medicinal plants need 
to be picked only in the presence of moonlight. If such plants are picked at other times, 
it is believed that they lose their efficacy. Plants are collected as whole plants (40 
species), fruits (26 species), seeds (20), roots/bulbs (31 species), stems (12), flowers (9 
species), leaves (7 species), extracts/resins (7 species) and bark/cambium (3 species)97.  
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Figure 3. Map of Bhutan showing the collection sites of medicinal plants. 
 
Some medicinal plants that are not used by the Institute have recently been explored by 
the Aromatic and Phytochemical Section of the Tashi Commercial Corporation of 
Bhutan and the Japan Himalayan Company which was established in 199098. 
 
2.2.1  Sustainability of Medicinal Plants  
Bhutanese Traditional Medicine is gaining popularity among people within the country 
as well as internationally. Many medicinal plants such as Aquilaria agallocha, 
Rauwolfia serpentine, Ephedra gerardina, Taxus bacccata, Rheum nobile, Rheum 
accuminata, Picrorhiza kurroa, Nardostachys jatamansi, Aconitum species, Artemisia 
species, Panax pseudo-ginseng sub species himalaicus and Cordyceps sinensis are in 
high demand for pharmaceuticals and have potential international market value99. As a 
result, the pressures on the alpine medicinal plants have increased undermining their 
sustainability. In fact, because of the legalisation of the regional trade of highly prized 
perennial herbs like Picrorhiza kurrooa, Nardostachys grandiflora and Cordyceps 
sinensis in Asia100 and  highly executed operational networks of illegal traders in the 
region, these medicinal plants are already at high risk of overexploitation 100,101.  
Since Bhutan is an agricultural country, removal of forests for farming has had an 
adverse impact on the environment, particularly resulting in the loss of the medicinal 
plant species.  Cattle, yak and sheep rearing is another significant economic activity of 
Bhutan. Overgrazing of the forest by such animals has a detrimental effect on the 
survival of the grazed plant species. For example, intense browsing by yaks checks the 
growth of seedlings of the Himalayan yew, Taxus baccata102.  Some plant species like 
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Senecio and the Ligularia, which contain pyrrolizidine alkaloids, were found to be 
toxic to yaks and cattle44,103. Such poisonous plants are cleared by cattle herders in 
order to protect the cattle.  This act significantly contributes to the extinction of many 
alkaloid-containing plant species.  
The threats to medicinal plants also stem from logging activity carried out in Bhutan.  
This has led to deforestation and the loss of a number of medicinal plants. The natural 
phenomenon of decaying and dying of Himalayan mountains also contributes to the 
loss of some plant species104. Industrialization poses another significant threat to the 
medicinal plants of Bhutan. 
Although, some medicinal plants may be cultivated, the content of phytochemicals in 
these plants may not be same as that in the wild species but cultivation is the only 
proper solution to meet this ever increasing demand. Before all wild plants become 
extinct or fully domesticated, it is essential to assess them for their chemical content in 
their original state. In this context, the author has selected some potential medicinal 
plants used in the traditional medicine of Bhutan for thousands of years and has 
analysed them for potential antimicrobial and antimalarial lead drug molecules. 
 
2.3 Selection of Medicinal Plants   
Based on an ethno-directed biorational approach, the databases of Traditional Medicine 
of Bhutan97,105 as well as the inventory carried out by the ethno-botanist77 and the 
Forestry Department99 were analysed and a list of medicinal plants was generated 
consisting of 156 plant species (Table 3). Every effort has been made to assign 
individual therapeutic uses based on the text, “Medicinal Flora of Bhutan”105. The 
medicinal plants list was then further analysed and those plants which met all the 
selection criteria were short listed for collection and phytochemical analysis. 
 
2.3.1  Criteria for Selecting the Medicinal Plants 
Because of the large number of possible species for analysis, criteria were established 
for plant selection as follows:  
a) Only those medicinal plants that were used for treating malaria or infectious 
diseases were to be selected. 
b) Further selection of medicinal plants was then based on those that were 
endemic to Bhutan and the Himalayas (high altitude plants, above 3500 
metres above sea level). 
c) Finally, only alkaloid-containing medicinal plants were to be selected. 
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Many plants listed in Table 3 have been used for treating fever arising from different 
disorders including malaria but only Corydalis gerdae was specifically used against 
malaria. Aconitum orochryseum was used for treating infections, snake bite, and bilous 
fever or fever arising from bile disorders. There were also many medicinal plants used 
for treating infections including blood infections, skin infections, and infections of 
internal organs. About fifty five medicinal plants were selected based on the first 
criterion. The selection was then streamlined by focusing on endemic species growing 
at high altitudes (ca 4000m), since these species were the least studied phytochemically 
and could contain new molecules that would potentially be new drug leads. About 26 
medicinal plants were short listed based on this criterion. Introduced medicinal plant 
species were not considered here except for Tribulus terrestris.  
Only those medicinal plants that contained alkaloids were then selected from these 26 
species. This is because alkaloids have interesting structural types with a wide range of 
biological activities and have quite often become potential drug leads. An effort was 
also made to select medicinal plants representing different families since different 
families usually contain different classes of alkaloids. So preliminary tests for the 
presence of alkaloids were conducted on the selected medicinal plants of Bhutan 
(Table 4) at the Pharmaceutical and Research Unit Laboratory in Bhutan using the 
Culvenor and Fitzgerald106 test procedure. Only fifteen plants were found to contain 
alkaloids. The result was reported only as alkaloid positive or alkaloid negative and the 
degree of alkaloid content was not estimated. Finally, only five alkaloid-containing 
medicinal plants were selected for chemical analysis (Table 5) based on their 
availability for larger scale collection. The selection methodology is summarised in 
Scheme 1.  
 
Free listing of medicinal plants (160 species) 
 
Medicinal plants used for treating malaria and infectious diseases ( 55 species) 
 
Medicinal plants that are endemic to the Himalayas and Bhutan (26 species) 
 
Alkaloid-containing medicinal plants (15 species) 
 
Final selection (5 species) 
 
Scheme 1. Flow chart for the selection of the medicinal plants based on the four selection criteria. 
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Table 3.     Medicinal plants considered with ethno-medical information. 
Botanical name Family gSo-ba rigpa 
name 
Alti-
tude 
Distribution Part 
used 
Ethno-medical use 
Aconitum lacinatum Ranunculaceae Bong-nga-nag-
po 
HA Himalaya R/L Tinging of muscles, meat 
poisoning and bones 
Aconitum orochryseum Ranunculaceae Bong-nga-dkar-
po 
HA Endemic A  Flu-fever, infections and 
antidote for snake bite 
Aconitum violaceum Ranunculaceae Bong-nga-
dmar-po 
HA Himalaya R   
Aconogonon tortuosum Polygonaceae Sna-lo HA Himalaya R  
Acorus calamus Araceae  Shu-dag-nag-po LA Cosmopolitan R   
Aletris pauciflora Liliaceae Dam-bu-ka-ra LA Himalaya W Lung and liver disorders, 
pneumonia, cuts and wounds 
Allium sativum  Liliaceae Sgog-skya LA Cosmopolitan B   
Allium wallichi Liliaceae Re-sgog HA Himalaya W Gastritis, tuberculosis, 
inflammation, and rlung 
disorders 
Amomum subulatum Zingiberaceae  Ka-ko-la  LA Himalaya F   
Androsace strigillosa Primulaceae  Sga-tig-nag-po HA Himalaya  W  Oedema, fever and infections 
Anemone rivularis Ranunculaceae  Srub-ka HA Himalaya S Antipyretics, blisters, 
antiseptics, antidote, and to 
increase body temperature 
Aquilaria agallocha Thymelaceae A-ga-ru LA Bhutan, India 
and  Indonesia  
W  
Areca catechu  Palmae Go-yu LA Asia S  
Arenaria kansuensis Caryophyllaceae  Rtsva-a-krong HA Tibet and  
Bhutan  
Fl Lund disorders and abscess 
above chest including head  
Aristolochia griffithii Aristolochiaceae  Ba-le-ka LA Himalaya St  
Asparagus racemosus Asparagaceae  Nye-shing LA Cosmopolitan R   
 
Aster flaccidus Conpositae Lug-mig HA Himalaya  F  Bronchitis, cramps, common 
cold and to relieves pain 
Aster stracheyi Compositae  Chu-de-ba HA Himalaya A  
Astragalus floridus Leguminosae  Srad-ser HA Himalaya    
Beaumontia grandiflora Apocynaceae  Dug-mo-nyung  LA Bhutan and 
Nepal 
S  
Berberis aristata Berberidaceae  Skyer-pa-dkar-
po 
HA Himalaya. Bk  
Bistorta macrophylla Polygonaceae  Spang-ram HA Himalaya.  R Diarrhoea and blood dysentery 
Bombax ceiba Bombacaceae  Pad-ma-ge-ser LA Tropics  Fl  
Brassica juncea Brassicaceae  Spong-thogs-pa HA Cosmopolitan  A Meat-poisoning, spasmolytic, 
lung, heart and blood disorders 
Butea buteiformis  Leguminosae  Ma-ru-rtse  LA Bhutan  and 
India  
S  
Capsella bursapastoris  Cruciferae  So-ka-pa HA Cosmopolitan A  
Caragana jubata Leguminosae  Mdzo-mo-shing HA Bhutan and 
India 
St.  
Carum carvi  Umbelliferae  Go-snyod  HA Cosmopolitan S/A Detoxifiers, headache, migraine, 
nausea and eyes disorders 
Cassia fistula  Leguminosae  Dong-ga LA Himalaya and 
Burma 
  
Cassia tora Leguminosae Thal-ka-rdor-rje LA South America  
and Bhutan 
S  
Cavea  tanguensis Compositae Ming-chen-nag-
po 
HA Himalaya A  
Cedrilla toona Meliaceae Snying-sho-sha LA America and 
Bhutan 
F  
Choenomeles lagenaria Rosaceae Bse-yab LA Bhutan F  
Chrysosplenium 
forrestii 
Saxifragaceae  gYaa-kyi-ma HA Himalaya A Bile diseases 
Cinnamomum tamala Lauraceae Shing-tsa LA Himalaya R 
Bk 
 
Clematis connata Ranunculaceae Bbyi-mong-
dkar-po 
HA Himalaya. St. Sexually transmitted diseases  
and digestion 
Codonopsis bhutanica Campanulaceae Klu-bdud-rdor-
rje 
HA Endemic W  Evil affliction, tinging, 
nephrosis, numbness, gout, 
leprosy and blood regulator 
Codonopsis 
convulvulaceae 
Campanulaceae Snyi-ba HA Himalaya B  Cough and cold, sore throat, 
chest pain and decongestant 
Cordyceps sinensis Fungus Dbyar-rtsva-
dgun-bu 
HA Himalaya W  
Coriandrum sativum Umbelliferae hu-su HA/
LA 
Cosmopolitan S Bay-kan disorders including 
digestive system disorders 
Corydalis flabellata Fumariaceae Re-rdzun HA Himalaya A Anti-hypertension, blood 
purifier and  nerve pain  
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Corydalis gerdae Fumariaceae Stong-ri-zil-pa HA Bhutan and 
Chumbi valley 
W Antimalarial  and infections 
Corydalis stracheyi Fumariaceae Bya-rgod-sug-
pa 
HA Himalaya A Blood  disorders, liver disorders 
and analgesic  
Cotoneaster 
microphyllus 
Rosaceae Bya-pho-tsi-tsi Ha Himalaya. F  
Curcuma longa Zingiberaceae  Yung-ba LA Bhutan and 
India 
Rh  
Cynoglossum 
glochidiatum 
Boraginaceae  Nad-ma-gyu-lo HA Afghanistan to 
Bhutan 
  
Dactylorhiza hatagirea Orchidaceae  Dbang-lag HA  Himalaya R Suppleness of the body tonics 
and builds body 
Delphinium 
brunonianum 
Ranunculaceae Bya-rgod-spos HA  Himalaya A Fevers, trembling,  bile 
malfunctioning  and as 
detoxifiers  
Delphinium 
drepanocentrum 
Ranunculaceae Bya-rkang HA  Endemic to 
Nepal and 
Sikkim 
A Dermatitis and dysentery, 
wounds and abscess 
Diospyros spp. Ebenaceae Rgun-bdrum-
nag-po 
LA Himalaya F  
Dracocephalum 
tanguiticum 
Labiatae  Pri-yang-ku HA Tibet A Stomach, lung and the liver 
disorders and heals wound 
Dryopteris fragrans Polypodiaceae  Re-rel LA Cosmopolitan Rh.  
Elettaria cardamomum  Zingiberaceae  Sug-smel LA Sub-tropics F  
Ephedra gerardiana  Ephedraceae Mtshe-ldum HA Afghanistan to 
Bhutan 
A Fever, wounds, injuries, 
bleeding and heals every fever 
including malaria 
Elshoutia eriostachya Labiatae Bje-rug HA  A Boils, wounds and tuberculosis  
Eriophyton  wallichiana Labiatae Spang-mtshan-
spu-ru 
HA W.Nepal to 
S.W China  
W  
Erythrina arborescens Leguminosae  Mkhal-ma-sho-
sha 
LA India, Bhutan, 
China and 
Burma 
F  
Eugenia fruticosa Myrtaceae Sa-bras LA Himalaya F  
Euphorbia griffithi Euphorbiaceae Dur-byid HA Tropics R  
Euphorbia spp.  Euphorbiaceae Thar-nu HA Tropics R  
Euphrasia himalaica Scrophulariaceae  Zhim-thig-le-
dkar-po 
HA Afghanistan to 
Bhutan 
A  
Fragaria indica.  Saxifragaceae  Bri-rta-sa-dzin  HA Worldwide W Anthelmintics, neurological 
infection, chest infections, and 
lung inflammation 
Fritillaria delavayi Liliaceae Dkar-po-chig-
thub 
HA Himalaya  B Detoxifier, blood purifier and as 
antipyretic 
Fritillaria gardneri Liliaceae A-bhi-kha HA Himalaya A Detoxicant and joining bone 
Galium aparine Rubiaceae  Zings-rtsi-dkar-
po 
HA  Himalaya W Bile disorders like jaundice, 
migraine, and sinusitis 
Gentiana algida Gentianaceae  Spang-rgyan-
sngon-po 
HA Kashmir and 
S.W China 
Fl Anti-dote, inflammation of 
throat and lung, and pain reliever 
Gentiana spp. Gentianaceae Spang-rgyan-
dkar-po 
HA Himalaya Fl Bile  related disorders, leprosy 
and blood disorders 
Gentiana urnula Gentianaceae Gang-ga-chung HA Himalaya A Diarrhoea  and as 
Detoxicant 
Geranium spp. Geraniaceae Gla-sgang HA Himalaya A Sore throat and bronchitis, 
intestinal disorders, fevers, 
tuberculosis and diarrhoea 
Geranium tuberaria Geraniaceae li-ga-dur HA Pakistan, India 
and  Central 
Asia 
R Common cough and cold and 
swelling of limbs 
Glycyrrhiza glabra  Leguminosae  Shing-mgar LA Cultivated R  
Hemiphragma 
heterophylla Wall 
 A-bi-ra  HA Himalaya W Body tonic, for roper blood and 
menstruation regulation, UTI 
infection and backache  
Heracleum candicans Umbelliferae Spru-nag HA Himalaya R Leprosy, bleeding, headache and 
neurology 
Herpetospermum 
caudigerum 
Cucurbitaceae Gser-gyi-me-
tog 
HA Semi-cultivated S Bile disorders and intestinal 
disorders 
Hippophae rhamnoides Elaegnaceae Star-bu HA Central Asia, 
India and  
Pakistan 
F Tuberculosis, anticoagulant and 
Liver diseases 
Hypecoum leptocarpum Fumariaceae Par-pa-ta HA  Himalaya A Common cold and  detoxifier 
Impatiens laxiflora Balsaminaceae  Byiu-star-ga HA Tibet  W  
Inula grandiflora Compositae Ming-can-ser-
po 
HA  Pakistan and 
Central Nepal  
Fl Abscess/boils, numbness and 
fever,  evil affliction 
Inula racemosa Compositae Manu HA Cultivated R  
Iris kemaonensis Iridaceae Dres-ma HA  India and 
Pakistan 
F Anthelmintic and antipyretic 
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Jaeschkea oligosperma Gentianaceae  Lcags-tig HA Kashmir A  
Juniperus squamata Cupressaceae  Shug-pa-tsher-
can 
HA Afghanistan, 
and S.W.China 
L/F  
Lancea  tibetaca Scrophulariaceae  Pa-yag HA Himalaya  W Wounds, lung and heart 
disorders 
Lepisorus spp. Polypodaceae  Brag-spos-pa HA Himalaya W Bone fracture, burns, wounds 
and kidney disorders 
Luffa aegyptiaca Cucurbitaceae  Ka-bed LA Tropics S  
Malva sylvestris  Malvaceae Lcam-pa HA Himalaya A Revitalising kidney, diuretic, 
wounds and diarrhoea 
Malva verticillate Malvaceae  So-ma-ra-dza LA Pakistan, India, 
Euro-Asia and  
Africa 
S  
Meconopsis horridula Papaveraceae Tsher-ngon HA Himalaya A Broken bones (skull) and make 
joints strong  
Meconopsis paniculate Papaveraceae Ud-pal-ser-po HA Utter Pradesh to 
S.E. Tibet 
Fl  
Meconopsis primulina Papaveraceae Yi-mo-mdeu-
byin 
HA  Himalaya A  
Meconopsis 
simplicifolia 
Papaveraceae Ud-pel-sngon-
po 
HA C. Nepal to S.E 
Tibet 
A Antipyretics, antimalarial, lungs 
disorders, liver cirrhosis and 
blood disorders. 
Morina nepalensis Dipsacaceae Spyang-tsher-
lo-ma-phra-ba 
HA W. Nepal to 
S.W. China 
A  
Myricarea rosea Tamaricaceae Chu-shing-om-
bu 
HA C.Nepal to  
S.W China 
A  
Myristica fragrans Myristicaceae  Dza-ti LA South East Asia S  
Nardostachys 
grandiflora  
Valerianaceae  Spang-spos HA Utter Pradesh to 
S.W China 
R Chronic fever, detoxicant, and 
heart disorders 
Onosma hookeri  Boraginaceae Bri-mog HA Himalaya R Asthma, hypertension  and 
pneumonia  
Oreosolen wattii Scrophulariaceae Khron-bu HA West Nepal to 
Bhutan 
R  
Oxytropis lapponica Leguminosae Srad-dkar HA Pakistan and  
India  
Fl  
Oxytropis reniformis Leguminosae Sngo--stag-sha HA Himalaya W Antiseptic, wounds and antidote 
Parnassia ovata Saxifragaceae  Dngul-tig HA Himalaya A Bile disorders and ganglion 
blockage. 
Pedicularis flagellaris Scrophulariaceae  Glang-sna HA Himalaya A Anti-diuretic and wounds 
Pedicularis longiflora Scrophulariaceae Lug-ro-ser-po HA Pakistan to S.W 
China 
A Dehydration of mouth and 
tongue 
Pedicularis megalantha Scrophulariaceae Lug-ru-smug-
po  
HA Utter Pradesh to 
S.E Tibet 
A Antidote, meat poisoning and 
intestinal disorders 
Pedicularis siphonantha Scrophulariaceae Lug-ru-dmar-po HA  Utter Pradesh to 
S.E Tibet 
A  
Phlomis rotate Labiatae  Rta-lpags HA W. Nepal to 
S.W China 
A  
Pholidota recurva Orchidaceae  Pu-shel-rtse LA Himalaya St.  
Phyllanthus emblica Euphorbiaceae  Skyu-ru LA India and  
Nepal 
F  
Phytolacca  esculanta Phytolaccaceae Dpah-bo-dkar-
po 
HA Cultivated  R  
Picrorhiza kurroa Scrophulariaceae Hong-len HA Pakistan to 
Utter Pradesh  
R Blood purifiers 
Piper nepalense  Piperaceae  Pi-pi-ling  LA Himalaya F  
Plantago erosa Plantaginaceae Tha-ram HA Cosmopolitan S Diarrhoea 
Pleurospermum amabile  Umbelliferae Rtsad  HA Himalaya  W Antidote, fever and indigestion 
Pleurospermum hookeri  Umbelliferae Tang-kun-dkar-
po 
HA Pakistan to S.W 
China 
R Heart disorders 
Podophyllum 
hexandrum(emodi) 
Podophyllaceae  Hol-mo-se HA  Afghanistan to 
S.W China 
F Female gynaecological 
problems, paralysis, blood 
disorders and kidney disorders  
Polygonatum 
singalilense  
Liliaceae  Lug-mnye HA  Himalaya Rh.  
Polygonatum 
verticillatum 
Liliaceae Ra-mnye HA Pakistan to 
S.E.Tibet 
Rh. Fluid accumulation in joints, 
anthelmintics, tranquilliser, 
appetiser and longevity 
Potentilla peduncularis  Rosaceae  Gro-ma  HA Nepal R Dysentery 
Pterocephalus hookeri Dipsacaceae  Spang-rtsi-do-
bo 
HA  W.Nepal to 
S.W.China 
W Gout, dysentery, fever and  
hypertension  
Punica granatum  Punicaceae  Se-bru LA Tropics  F  
Rununculus  
brotherusi (nuichillus) 
Ranunculaceae  lChe-tsha HA  Himalaya A Antiseptic, wounds and pus and 
as antipyretic 
 
Ranunculus tricuspis  Ranunculaceae  Chu-rug-pa  HA Kashmir to 
S.E.Tibet 
W Relieves nerve pain, hbam-grum 
and fevers 
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Rheum australe  Polygonaceae Chu-rtsa HA India and Nepal R  
Rhodiola himalenses Crassulaceae  Sro-lo-dmar-pa HA Kashmir  R  
Rhododendron 
anthopogon  
Ericaceae  Dvali-dkar-po HA  Pakistan to S.E 
Tibet 
Fl  
Rhododendron 
lepidotum 
Ericaceae  Dva-li-nag-po  HA  Pakistan to S.W 
China 
L  
Rhus semi-alata Anacardiaceae  Da-trig LA Kashmir, S.W 
China, Japan, 
and Burma 
F  
Ricinus communis Euphorbiaceae  Dan-rog  LA Tropics S  
Rosa macrophylla  Rosaceae  Se-rgod  HA  Himalaya F Constipation, liver and bile 
disorders, cough and cold, 
antidote and abscess 
Rosa sericea Rosaceae  Se-bai-me-tog HA Himalaya  Fl.  
Roscoea capitata Zingeberaceae  Sga-skya  LA Nepal Rh.  
Rubia cordifolia  Rubiaceae  Brtsod  LA Pakistan to 
S.E.Tibet 
St.  
Salvia castanea  Labiatae  Jib-rtsi-chen-po HA Himalaya  R  
Sambacus adnata Caprifoliaceae  Yu-gu-shing HA W. Nepal to 
S.W. China 
A  
Saussurea gossypiphora Compositae  Bya-rgod-sug-
pa 
HA Kashmir to S.W 
China 
A  
Saussurea spp.  Compositae Ru=rta HA Himalaya  R  
Saxifraga 
moorcroftiana 
Saxifragaceae  Zang-tig HA Pakistan to S.W 
China 
W Antipyretic and bile disorders 
Saxifraga parnassiflora  Saxifragaceae  Gser-tig HA Utter .Pradesh 
to Bhutan 
W Wounds, cough cold, and bile 
disorders including jaundice 
Saxifraga umbellulata Saxifragaceae Tig-ta HA Himalaya A Liver and bile disorders, 
wounds, and fever 
Scopolia lurida Solanaceae  Thang-phrom-
nag-po 
HA Cosmopolitan S  
Selaginella pulvinate  Selaginellaceae  Chu-srin-sder-
mo 
LA Himalaya  A  
Shorea robusta  Dipterocarpaceae  Spos-kar  LA Himalaya  Re.  
Silene satisperma  Caryophyllaceae  Ra-sug  HA Pakistan to E. 
Nepal 
W  
Soroseris  hookeri  Compositae  Srol-gong-ser-
po  
HA India to S.E 
Nepal 
W  
Swertia chirata Gentianaceae  Rgya-tig LA Himalaya  W   
Swertia wolfangiana  Gentianaceae Rgu-drue HA Himalaya A Wounds and  joins nerves 
Swertia kingii Gentianaceae Kyi-lce-dkar-po HA Himalaya  Fl.  
Symplocos ramosissima Symplocaceae  Byi-tang-ka  LA  India to S.W 
China 
F  
Tanacetum nubigenum  Compositae  Khan-pa-dkar-
po 
HA India to Bhutan W Abscess, kidney disorders and 
haemorrhage  
Taraxacum officinalis Compositae Khur-mong  HA  Europe, Asia 
and North 
America 
W Stomach disorders, all fevers 
and detoxifiers 
Terminalia bellerica Combretaceae  Ba-ru  LA  Tropics  F  
Terminalia chebula  Combretaceae A-ru LA  Tropics  F  
Tribulus terrestris Zygophyllaceae Gze-ma-ra-go-
ma 
LA Tropics F Arthritis, diuretics and kidney 
disorders 
Thalictrum reniforme Ranunculaceae  Sngo-sprin  HA  Nepal to 
Bhutan  
A  Antidote, anti-bacterial, anti-
malarial and painkiller 
Thermopsis barbata  Leguminosae  Gla-ba-sran-ma  HA  Kashmir to S.W 
China  
  
Thlaspi arvense  Cruciferae  Bre-ga  HA  Cosmopolitan  W  Pneumonia and kidney disorders 
Tinospora cordifolia  Menispermaceae  Sle-tres  LA    Himalaya.  C  
Verbascum thapsus Scrophulariaceae  Shing-gi-gser-
bye 
HA  Euroasia  S  
Veronica himalensis Scrophulariaceae Ldom-nag-
ldom-mkhri 
HA Himalaya  Ulcers, heals wounds, and 
haemorrhage 
Unidentified  Liliaceae  Byiu-lp-hug HA Himalaya W  
Unidentified   Stab-seng  LA  Himalaya  C   
Unidentified  Moraceae  Seng-ldeng  LA  Himalaya Wd  
  
Note: A: aerial, Bk: bark, B: Bulb, C: Cambium, Fl: flower, F: fruit, R: root, Rh: Rhizome, S: seed, St: 
stem, W: Whole, Wd: Wood, LA: Low altitude, HA: High altitude. 
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Table 4. Medicinal plants investigated for alkaloids at ITMS using the Culvenor and Fitzgerald 
procedure106. 
Botanical name Gso-ba Rig-pa name Alkaloid Test 
Aconitum lacinatum Btsan-dug Positive  
Aconitum orochryseum Bong-dkar Positive  
Aletris pauciflora Dam-bu-kara Positive 
Bistorta macrophylla Spang-ram Negative  
Chrysosplenium forrestii gYa-kyi-ma Positive  
Codonopsis bhutanica Klu-bdud-dorji Positive  
Corydalis flabellata Re-skon Positive 
Corydalis gerdae Tong-ri-zil-pa Positive  
Corydalis megacalyx sTong-zil Positive 
Corydalis stracheyi Bya-rgod-sug-pa Positive 
Delphinium brunonianum Bya-rgod-spos Positive  
Fritillaria devalayi Dkar-po-chig-thub Negative  
Parnassia ovata Dngul-tig Positive  
Pleurospermum amabile  Rtsad Positive 
Polygonatum verticillatum Ra-mne Negative 
Ranunculus brotherusi Che-rtsa Positive  
Rhododendron anthopogon Da-li  Positive 
Rosa macrophylla Se-rgod Negative 
Thalictrum reniforme Sgno-sprin Positive  
Thlapsi arvense Bre-ga Negative 
 
Table 5.     Selected medicinal plants with their indications. 
Botanical name Family Distribution Ethno -medical  use 
Aletris pauciflora Liliaceae Himalayas  
4100 metres 
Pneumonia, liver and lung  diseases 
Ranunculus brotherusi Ranunculaceae Himalayas  
4100 metres 
Antipyretic, wounds & pus 
Codonopsis bhutanica Campanulaceae Endemic  
4500 metres 
Gout, leprosy and infections 
Corydalis gerdae Fumariaceae Bhutan and 
Chumbi  
4100 metres 
Malaria and infections 
Aconitum Orochryseum Ranunculaceae Endemic 
4720 metres 
Fever, antidote (snake bite) and 
infections 
Tribulus terrestris Zygophyllaceae Australia and 
Coastal areas 
Arthritis, diuretics and kidney 
diseases 
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Extracts of two of the selected medicinal plants, Aletris pauciflora and Codonopsis 
bhutanica, were damaged on transportation to Wollongong, so as an alternative, the 
locally available plant, Tribulus terrestris L107 was selected for the study. This plant 
was known to have caused hepatopathy108, staggers109 and locomotor effects110 in 
Australian sheep but the specific compound (suspected to be an alkaloid) responsible 
for neurotoxicity whose symptoms are related to the symptoms of Parkinson’s disease 
in humans, was not known. The plant is also used in the traditional medicine of Bhutan. 
It should be noted that the medicinal plants used in Bhutanese traditional medicine 
were never used as single plant components, but rather as a mixture of two or more 
active ingredients.  
The theory behind using multi-ingredient compounds is that those mixtures of 
ingredients are believed to act synergistically by neutralising the toxicity of individual 
ingredient and enhancing the therapeutic values of the mixture. So, quite often the 
individual therapeutic indication is lost when it is formulated as multi-ingredient 
products. For example, Tribulus terrestris is used for formulating four different multi-
ingredient products in combination with other ingredients (Table 6). Although the 
therapeutic properties of Tribulus terrestris are retained while formulated, the 
individual therapeutic properties of other ingredients used in the formulation of 4 
products (Table 6) could have lost. 
 
Table 6.  Traditional medicine products which use Tribulus terrestris in their formulation. 
Sl. No. Name of Product Traditional use 
1 Go-yu-28 Diuretic & kidney disorders 
2 Seng-lden-25 Paralysis, arthritis, *CNS disorders 
3 Ba-sam-lha-rlung Kidney and renal  disorders 
4 Bdud-rtsi-nga-lum Paralysis, gout and arthritis 
*CNS: Central Nervous System 
 
Similarly, Aconitum orochryseum is used for formulating eighteen different multi-
ingredient products (Table 7). Only three of these products (Products 8, 9 and 10) have 
similar therapeutic indications as those of the individual plant and Products 8 and 9 
could be possibly good antimalarial compounds since they are used against high fever.  
The other products (Products 1, 2, 3, 4, 5, 6, 7, 11, 12, 13, 14, 15, 16, 17 and 18) have 
entirely different therapeutic indications to that of the individual therapeutic properties. 
Two products (Products 5 and 12) are used against poisoning and infections, and to 
treat liver diseases. 
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Table 7.  Aconitum orochryseum Stapf. used in formulating 18 types of multi-ingredient drugs. 
Sl. No. Name of Product Traditional use 
1 Tig-ta-8 Jaundice and Headache 
2 Tig-ta-16 Jaundice and yellowing of eyes 
3 Gser-mdog-11 Gallstone  
4 Hong-len-9 Hypertension and joint pain 
5 Thang-chen-25 Poisoning and Infections 
6 Gyu-rgyal Rheumatism 
7 Bol-sman-7 Stomach upset  
8 Rta-ze-dmar-po High fever related to cold and flu 
9 Spang-rtsi-12 High fever  
10 Gtso-bo-8 Cough and Cold 
11 Dbang-po-kuen-sel Sinusitis  
12 Gur-gum-13 Liver diseases 
13 Man-sil Poisoning and Bile disorders 
14 Ko-la-19 Spleen diseases 
15 Dvag-sman-15 Indigestion 
16 Brag-zhun-9 Stomach ulcer 
17 Mkhris-phyi-7 Dysentery  
18 Ded-pon-10 Constipation 
 
Corydalis gerdae and Codonopsis bhutanica are used for the formulation of a product 
called kLu-bdd-8 which is used for treating dermatitis and leprosy. 
 
2.4   Collection of medicinal plants 
The collection was done from July to August 2002 by the medicinal plant collection 
team from the Pharmaceutical and Research Unit of the Institute for Traditional 
Medicine Services. Corydalis gerdae Fedde is endemic to Bhutan and the Chumbi 
valley in Tibet111 and was collected from the upper Mochu (Yha-le-La near Lingshi), 
Chomolhari (4400-4900 m) bases and from nearby mountain screes77 (Figure-3, 
Collection site-I). Codonopsis bhutanica, Ranunculus brotherusi, Aletris pauciflora 
were also collected from the Lingshi region (Figure 3, Collection site-I). Aconitum 
orochryseum Stapf. has been collected from alpine regions (3950-4720 m)111 including 
Thampe la, Zaradingthang and Tolegang77 in Bhutan. However, for this study, 
Aconitum orochryseum was collected from Chukhalung, Lingshi (Figure 3, Collection 
site-I). Herbarium specimens for each of the plants collected for this study are housed 
at the Pharmaceutical and Research Unit of the Institute for Traditional Medicine 
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Services, Thimphu, Bhutan. The herbarium voucher number and the collection codes 
are noted in Table 8. 
Tribulus terrestris was collected from near Wellington (Central West, NSW) in 
February 2002 by Dr. Chris Bourke, Orange Agriculture Institute, Orange, NSW. The 
air-dried (room temperature) plant material (stems, leaves, flowers and fruits, approx. 8 
kg) has been coarse chopped using a petrol driven plant-mulching machine.  
 
Table 8.   Site of collection of the selected medicinal plants.  
 
Medicinal Plants 
Collection season Collection sites 
(Bhutan)  
Parts 
collected 
Herbarium  
No. 
Aletris pauciflora July/August Zangpothang Whole 47 
Codonopsis bhutanica July/August Chewla Whole  71 
Ranunculus brotherusi July/August Zangpothang Whole  18 
Corydalis gerdae July/September  Chukhalung Whole  07 
Tribulus terrestris February  Wellington, 
NSW,  Australia 
Aerial  NA  
Aconitum orochryseum July/August Jaradingthang Aerial 83 
 
Except for Aletris pauciflora and Codonopsis bhutanica, all the plants collected here 
are rare species77, and care was taken with respect to the environmental impact. The 
collected plants were then analysed for their alkaloidal components and the results of 
the investigations are discussed in the ensuing chapters. 
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Chapter 3 
Alkaloids from Aconitum orochryseum Stapf. 
 
 
 
 
 
 
 
3.1     Botanical Description and Ethno-medical Use 
Aconitum orochryseum is a herbaceous perennial plant and is a close relative of 
Delphinium species77. The plant grows to a height of 40-100 cm with pubescent slender 
stems77, palmately divided or cleft leaves (3-9 cm diameter) and hairy petalled, 2-10 
racemes flowers. There are more than 100 species of Aconitum and they are native to 
temperate regions of the northern hemisphere.  
Aconitum and Delphinium species both contain biologically active diterpenoid 
alkaloids. Crude preparations from plants in these two genera have long had a broad 
range of applications in Asia, Alaska, and Europe59, ranging from covert human 
poisons (e.g. Aconitum napellus is used in arrowhead dips and reputedly as an agent for 
euthanasia) to traditional medical uses in neuralgia, gout, hypertension and rheumatism 
and they have also been included as ingredients in intoxicating liquors112. The 
powdered root of Aconitum heterophyllum Wall has been used by Indians (Asia) as a 
febrifuge and bitter tonic, especially in combating debility after malaria and other 
fevers113. It is also considered efficacious in the treatment of diarrhoea, dysentery, 
cough, dyspepsia and chronic enteritis114.  
Aconitum leucostomum Vorosch is used in China for the treatment of traumatic 
injury115, while Aconitum hemsleyanum Pritz has been used as a folk remedy for the 
treatment of arthritic pain116. In Bhutan, three species of aconites: Aconitum lacinatum, 
Aconitum violatum and Aconitum orochryseum are used in the formulation of more 
than 25 traditional medicines85. Aconitum orochryseum, which is endemic to Bhutan 
and her bordering areas, has been used for bilious fever, as an antidote against snake 
bite and also for the treatment of malaria105.  
 
 
Family:    Ranunculaceae 
Genus:   Aconitum 
Species:   orochryseum 
Common name:   Aconites 
gSo-ba Rig-pa name:  Bong-nga-dkar-karpo 
Distribution:  Endemic to Himalayas 
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3.2     Diterpenoid Alkaloids: Biosynthesis and Classification 
Diterpenoid alkaloids occur mainly in the families Ranunculaceae (Aconitum, 
Delphinium, Thalictrum and Consolida genera), Cornaceae (Garrya species), Rosaceae 
(Spirea japonica) and Compositae (Inula royleana) and possess widely recognised 
pharmacological and biological activities 117-122. The majority of the phytochemical 
studies of these three genera have been carried out with species from Asia, Europe, and 
North America123,124. A series of new and known alkaloids have been isolated and 
identified from them.  
Over two hundred diterpenoid alkaloids are reported to date from 92 different species 
of Aconitum alone47. These diterpenoid alkaloids occur commonly either as amino 
alcohols or as esters of amino alcohols and these permutations and combinations thus 
give rise to many interesting bases121. A number of common biosynthetic pathways 
have been proposed for the diterpenoid alkaloids which are skeletally closely related. 
Some authors have suggested, based on the structural similarities, that the diterpenoid 
alkaloids are derivatives of mevalonate 5. 
 
     O
OH CH3
O      
 5 Mevalonate 
 
However, the classification of these alkaloids by some authors in this field indicated 
that the alkaloids arise from cyclization and rearrangement processes. Pelletier and 
Keith125, Dalton121, and Southon and Buckingham47 have classified these alkaloids 
mainly into two major structural types, the C19 and C20 diterpenoid alkaloids. The C19 
diterpenoid alkaloids have three types of basic skeletal ring systems: the aconitum-type 
6, the lycoctonine-type 7, and the lactone-type or heteratisane-type 8.  
The aconitane group accounts for the majority of the alkaloids of this diterpenoid class 
and they differ only in the substitution by hydroxy, methoxy, acetyloxy, benzoyloxy 
and acyloxy47 groups. Recently, tuberaconitine and tubermesaconitine, along with the 
known alkaloids flaconitine, mesconitine, tuberanine and aconitine that belong to the 
aconitane group have been isolated126. Hemsleyatine 9 was the first aconitane-type C19 
diterpenoid alkaloid bearing an amino group at the C-8 position and it was isolated 
from the plant Aconitum hemsleyanum Pritz127.  
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The un-substituted C-14 aconitane ring system with C-7 substitution occurs in the 
lycoctonine-type alkaloids. Its sub-type, the pyrodelphinine-type 10 of the C19 
diterpenoid alkaloids, originates as a result of C-8-C-15 double bond formation in the 
aconitane ring system. The oxidative fission of the C-13-C-14 bond of the aconitane 
framework forms lactone or heteratisane-type alkaloids as represented by heteratisine47. 
Two new C19 diterpenoid alkaloids, jiufengdine and jiufengtine, were also isolated 
recently from Delphinium potainii W.T.Wang varieties jiufengshanense W.J.Zhang et 
G.H.Chen128.  
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The second major group are the C20 diterpenoid alkaloids based on the atidane ring 
system 11. Atidine was first isolated from the Himalayan plant Aconitum 
heterophyllum Wall along with the known alkaloids atisine, hetisine, heteratisine, and 
benzoylheteratisine129. The atisane-type alkaloid 12 represents a smaller group with 
interesting chemical features and complex structures which has been the subject of 
extensive chemical study130. Atisine, the first representative of this type,  was isolated 
as the major alkaloid from the Himalayan plant Aconitum heterophylloides Stapf., but it 
has also been reported from Aconitum gigas, Aconitum anthara and Aconitum 
heterophyllum131. It was suggested132 that the aconitanes were derived from compounds 
with the atisine skeleton, through the rearrangement of the C-8-C-9 bond to the C-8-C-
15 position and the loss of the C-17 substituent133. Hetisane and delnudine together 
represent the biggest sub-types of atidane-based C20 diterpenoid alkaloids and they are 
discussed separately in section 3.2.1.  
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The third major group is represented by the veatchine skeletal type 13 of the C20 
diterpenoid alkaloids. Delphinium species (Ranunculaceae) generally contain veatchine 
or atisine-type diterpenoid alkaloids134-136. A striking similarity is present in the 
chemistry of atisine 14 isolated from Aconitum heterophyllum Wall (Ranunculaceae) 
and veatchine 15 isolated from Garrya veatchii Kellogg (Garryaceae)137,138 although 
they belong to different families139.  A study of the NMR spectra of 44 alkaloids from 
these two plants confirmed that atisine-type alkaloids which contain an oxazolidine 
ring, have a boat conformation in ring E 14138.  
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Varieties of bases, that don’t fit into any of the above structural types, could also be 
formed by either modifications of these skeletal rings or by introduction of a new ring 
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system (as a result of bond formation) into the main structural skeleton as is the case 
with the icacine 16 and they are grouped under miscellaneous diterpenoid alkaloids140. 
A new C20 diterpenoid alkaloid, arcutinine 17, that has a C-5-C-20 bond instead of the 
normal C-11-C-17 and C-10-C-20 bridging bonds, was isolated recently from Aconitum 
arcutum Maxim and is still the only one of its kind141. Secokaraconitine 18, another 
new diterpenoid alkaloid that has no C-7-C-17 bond, was isolated from the Kyrgystan 
plant Aconitum karacolicum Rapaics142. 
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3.2.1  Hetisane-type Diterpenoid Alkaloids 
The strong interest in hetisane-type alkaloids is due to their complicated structures, 
unique chemistry, valuable pharmacological properties and the widespread popularity 
of plants containing these compounds in folk medicine122. The first representatives of 
this type, paniculatine, hetisine and kobusine, were isolated in the 1930s and 1940’s122. 
As of 1998, more than 100 hetisane-type representatives were known122. 
While some sources have suggested that the introduction of additional rings into the 
atidane ring system by formation of C-14-C-20 and N-C-6 bonds forms the hetisane-
type 19 C20 diterpenoid alkaloids, a recent review more accurately pointed out that the 
formation of the bridge bonds C-14-C-20 and N-C-6 bridges in atisine produces the 
hetisane carbon framework122,143. The contraction of ring C in the hetisane forms 
complex derivatives belonging to the delnudine type of alkaloid as exemplified by 
delnudine 20. The 13-O-acetyl derivative of hetisine was isolated from a related plant, 
Delphinium nutallianum Pritz144. 
It was proposed that the formation of the N-C-6 bond is based on the structures of the 
natural alkaloids miyaconitine and miyaconitinone, an analogue of the intermediate 21 
122,143. Other alternatives for forming the N-C-6 were also studied, proposed and 
reviewed recently.118  
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As illustrated in structure 19, the skeletal system of the hetisane-type alkaloids is made 
up of six membered (chair shaped ring-A and ring-B, and a boat shaped ring-C, ring-D, 
ring-E and ring-F) and five membered  (ring-G with a twist-form, ring-H with an 
envelope form and the ring-I with an equal mixture of the twist and an envelope 
conformations) rings145. For all the hetisane alkaloids the fusion of rings A, B and C is 
identical. This structural framework and ring conformations of the hetisane type 
alkaloids significantly helped the author in structural elucidation and the 
conformational analysis of the compounds isolated from Aconitum orochryseum Stapf..   
 
3.3 Pharmacological Investigation of the Diterpenoid Alkaloids from Aconitum 
species. 
Aconitum alkaloids have been the subject of extensive chemical and pharmacological 
investigation owing to their toxicity as well as their potential medicinal values. An 
aconitane-type diterpenoid alkaloid, such as aconitine, which was isolated as the major 
component from the poisonous plant, Aconitum napellus, was probably the first 
diterpenoid alkaloid to have been studied pharmacologically146. Aconitine-containing 
liniments like AconitysatTM, BrinpaxTM, EtermolTM and PectovoxTM have been used in 
modern medicine for the treatment of rheumatism, neuralgia and sciatica146. Another 
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derivative, deacetylranaconitine, which was isolated from the roots of Aconitum 
finetianum, showed good analgesic activity47. 
Hetisane and atisane type alkaloids are closely related and have been reported to have 
the lowest cytotoxicity among the different categories of aconitum-diterpenoid 
alkaloids114. About 12 diterpenoid alkaloids were isolated from Aconitum coreanum 
Rapaics collected from the Korean Peninsula and China and have been assessed for 
structure-biological activity relationships147. This study found that atisine chloride, 
isoatisine and coryphine had the highest toxicity as well as the highest myorelaxant 
activity among the 12 alkaloids, and hetisine-type alkaloids were found to be less toxic 
with less myorelaxant activity. This indicated that the therapeutic value is proportional 
to the toxicological index.  
The veatchine-type diterpenoid alkaloids, napelline and its acyl derivatives (isolated 
from the most toxic plants Aconitum napellus, Aconitum karakolicum and Aconitum 
yesoense), were studied for their antiarrhythmic activity148 and it was found that one of 
the derivatives, 1-O-benzoylnapelline, had maximum activity, even markedly 
exceeding that of napelline itself and the reference Class I antiarrhythmic drugs 
novocainamide, quinidine and lidocaine.  
Although studies on diterpenoid alkaloids from Aconitum species have been extensive 
and they are still vigorously continued in pursuit of potential new alkaloids, little has 
been reported on the antimicrobial activity of these diterpenoid alkaloids. In this 
context, a Bhutanese medicinal plant, Aconitum orochryseum Stapf. was analysed for 
alkaloids and antimicrobial activity of the alkaloids. 
 
3.4     Isolation, Structural Elucidation and Identification of Diterpenoid Alkaloids 
from Aconitum orochryseum Stapf. 
The methanol extract of whole parts of air-dried plant material was subjected to a series 
of extraction, fractionation, separation, purification and crystallization processes 
(Chapter 9). This resulted in the isolation of eleven alkaloids from Aconitum 
orochryseum Stapf.. Comparative literature analysis of data revealed that two of the 
alkaloids were the known compounds virescenine and atisinium chloride. The structure 
of virescenine was established by NMR spectral analysis and that of atisinium chloride 
was confirmed by single crystal X-ray crystallography. Three other alkaloids were 
identified as new alkaloids and they were named as orochrine, 2-O-acetylorochrine and 
lingshinaline. Orochrine was named after the species orochryseum, 2-O-
acetylorochrine was based on the acetate substituent at the C2 position of orochrine, 
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while lingshinaline was named after the place of collection called Lingshi in Bhutan. In 
the presence of base Na2CO3, some of the alkaloids existed in an amino keto form 
(apply to all the three new alkaloids that were isolated as salts), which would be soluble 
in chloroform. However, there may have been some left in the aqueous phase.  
Among the compounds isolated, atisinium chloride was found to be the major alkaloid 
from the plant followed by lesser amounts of lingshinaline, orochrine, virescenine, and 
2-O-acetylorochrine. To identify and establish their structures, physico-chemical and 
spectral analysis were conducted for each of these three alkaloids and the results are 
discussed sequentially in the following section. Six other alkaloids were isolated as 
minor components. 
 
3.4.1   Orochrine   
a.   Physico-chemical properties 
The alkaloid named orochrine 22 was obtained as needle-like crystals (14.9 mg/1 kg 
dried plant weight) on recrystallization from acetone/diethyl ether. This alkaloid 
formed a translucent solid in the presence of chloroform. The alkaloid was optically 
active and had a high melting point.  
 
b.  Spectral Analysis of Orochrine. 
Low Resolution Chemical Ionisation Mass Spectrometry (LRCIMS) indicated a 
molecular ion peak at m/z 342 (MH+), which was 18 amu less than that of the alkaloid 
vakhmadine. High Resolution Chemical Ionisation Mass Spectrometry (HRCIMS) and 
High Resolution Electron Impact Mass Spectrometry (HREIMS) supported the 
molecular formula C21H27NO3 for this alkaloid, and hence an index of hydrogen 
deficiency of 15. In the LREIMS (Appendix 1), the molecular ion fragments were 
observed at m/z 341 (M+), together with major fragment ions at m/z 326, 313, 282, 254, 
192, 136, 122, 84, 55, and 44 (100%). The number of protons (from integration in the 
1H-NMR spectrum) and carbons (from the 13C-NMR) matched with the number of 
protons and carbons presented by the molecular formula (HRCIMS).  
The structure of orochrine 22 was established by the analysis of 1H-NMR (Appendix 
2), 13C-NMR (Appendix 3), DEPT (Appendix 4), gCOSY (Appendix 5), TOCSY 
(Appendix 6), gNOESY (Appendix 7), gHSQC (Appendix 8) and gHMBC 
(Appendix 9) spectral data. No signals for aromatic protons were evident in the 1H-
NMR spectrum so the index of hydrogen deficiency was structurally indicative of 
saturated rings or double bonds. Two broad singlets (5.04 ppm, 1H and 4.94 ppm, 1H) 
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indicated the presence of the H-17 exocyclic methylene group. A strong singlet 
resonating at 1.48 ppm (3H) was ascribed to the H-18 methyl group. Signals ascribed to 
the H-20 and H-12 (1H each, bs) protons were observed at 4.27 ppm and 2.98 ppm 
respectively. The H-19 protons resonated at 3.35 ppm (d, 1H, J=11.5 Hz) and 4.30 ppm 
(d, 1H, J=11.5 Hz). Since almost all hetisane type alkaloids contain these four 
characteristic proton signals122, it was concluded that the alkaloid (orochrine) belonged 
to the hetisane type diterpenoid alkaloids (Section 4.2.1).  
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Figure 4.  3D-Model of orochrine (N-blue, O-red, C-black, H-white). 
 
From the gCOSY spectrum, a distinct geminal coupling was observed between the 
proton signals at 2.69 ppm (d, 1H, J = 17 Hz, H-15) and 2.52 ppm (d, 1H, J=17.5 Hz, 
H-15). These geminal protons (2.69 ppm, d, 1H, J=17 Hz and  2.52 ppm, d, 1H, 
J=17.5Hz) were coupled to the H-17 exocyclic methylene protons (5.04 ppm, bs,1H 
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and 4.94 ppm, bs, 1H), clearly indicating that they were close to each other. The 
gCOSY spectrum also showed strong coupling between the H-19 protons at 4.30 ppm 
(d, 1H, J = 11.5 Hz), and 3.35 ppm (d, J = 11.5 Hz).  
From the 13C-NMR spectrum, the peaks at 142.3 ppm and 112.3 ppm indicated the 
presence of an alkene group in the structure. A ketone carbonyl group was assigned to 
the resonance signal at 208.7 ppm. Generally, for the hetisane type C20 diterpenoid 
alkaloids, a doublet for C-2 with chemical shifts of 66.1-67.2 ppm, and its respective 
protons resonating between 4.02-4.31 ppm a broad singlet, has been assigned to the C-2 
α-hydroxyl moiety149,150.  In the 13C-NMR spectrum of the alkaloid isolated here, the 
chemical shift ascribed to the C-2 carbon resonated at 65.5 ppm and its associated 
proton resonated at 4.14 ppm (H-2β) as a broad singlet in the 1H-NMR spectrum. Thus, 
based on this evidence, a hydroxyl group (C-2αOH) was assigned to the C-2 position of 
orochrine.  
The DEPT spectral analysis showed that there were fifteen protonated carbons. Seven 
of them were methylene carbon atoms (-CH2 × 7 including the exocyclic methylene 
group), six were methine carbon atoms (-CH × 6) and two were methyl carbon atoms (-
CH3 × 2). Based on DEPT, gHSQC, gCOSY and TOCSY spectral analysis, complete 
carbon-proton connectivity, proton-proton correlations and group assignments were 
achieved (Table 9). The gHSQC correlations found that C-17 had a chemical shift of 
112.3 ppm and that of C-18 (methyl carbon) corresponded to the signal resonating at 
30.3 ppm. 
The structure was then drawn by cross peak analysis of the gHMBC (proton-carbon 
correlations. of a maximum of 4 bonds away) and gNOESY spectra (Table 10). Using 
the scaffold of the hetisane-type diterpenoid alkaloid 19, the appropriate carbon peaks 
of the ring were assigned and a complete structure for orochrine was established as 22. 
From the gHMBC correlation (Table 10), C-4, C-6, C-8, C-10, C-13 and C-16 were 
found to be the quaternary carbons. The chemical shifts of C-4 (36.6 ppm) and C-10 
(47.4 ppm) matched the range of chemical shifts reported in the literature on hetisane 
type alkaloids122. 
The gNOESY correlation is also represented diagrammatically in Figure 5. Based on 
this gNOESY correlation, the stereochemistry of orochrine was established. The 
gNOESY correlation was also consistent with the spatial arrangements of protons and 
functional groups observed in a computer generated 3D model (Figure 4) of orochrine 
(enantiomeric form, exept at C-2), using the Spartan program. The long range 
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correlation existing between the N-Me and the C-14 was clearly seen in this 3D 
computer model because orochrine has a rigid spatial conformation. 
 
Table 9.  The gHSQC,  gCOSY and TOCSY NMR data (500 MHz, CD3OD) of orochrine 22. 
 
Carbon                                                    
                                    g HSQC (δC to δH) 
δC (ppm)    Assignment    δH (ppm)    Multiplicity    Integration        J(Hz)                
gCOSY 
Correlation 
TOCSY 
Correlation    
C-1 34.5 -CH2 1.59 
1.75 
d 
d 
1H 
1H 
15 
15 
H-2β  
C-2 65.5 -CH 4.14 bs 1H  H-1, H-3 H-1, H-3 
C-3 41.4 -CH2 1.60 
1.93 
d 
t 
1H 
1H 
15 
15 
H-1 H-1 
C-4 36.6 Q       
C-5 59.1 -CH 2.15 s 1H   H-9 
C-6 106.2 Q-OH       
C-7 38.2 -CH2 2.23 
2.31 
d 
d 
1H 
1H 
12.5 
12.5 
  
C-8 43.9 Q       
C-9 49.4 -CH 2.20 s 1H  H-11 H-11 
C-10 47.4 Q       
C-11 23.3 -CH2 1.86 
2.03 
d 
d 
1H 
1H 
14 
14.5 
 H-9 
C-12 53.5 -CH 2.97 bs 1H  H-9, C-11 H-11 
C-13 208.7 Q,C=O       
C-14 56.3 -CH 2.98 bs 1H    
C-15 32.6 -CH2 2.52 
2.69 
d 
d 
1H 
1H 
17.5 
17 
H-17  
C-16 142.6 Q       
C-17 112.3 -CH2 5.04 
4.94 
bs 
bs 
1H 
1H 
 H-15 H-15 
C-18 30.3 -CH3 1.48 s 3H    
C-19 70.5 -CH2 3.35 
4.30 
d 
d 
1H 
1H 
11.5 
11.5 
  
C-20 75.1 -CH 4.27 s 1H    
C-21 (N-Me) 37.3 -CH3 2.90 s 3H   H-3, H-7 
Note: Q = Quaternary carbon 
 
CH3
CH2
OH
N
CH3
O
OH
-+ OH
 
                                            Figure 5. gNOESY Correlation of orochrine. 
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Table 10.  gHMBC and gNOESY NMR correlation (500 MHz, CD3OD) of orochrine 22. 
 
Carbon                 δC (ppm)   δH (ppm)            
                                gHMBC Correlation  
δC  to δH                                                    δH  to   δC                       
gNOESY 
Correlation 
C-1 34.5 1.59, 
1.75 
H-20 C-2, C-3, C-4, C-5, C-10,  
C-20  
H-3  
C-2 65.5 4.14 H-1, H-3  C-20 H-1, H-3 
C-3 41.4 1.60, 
1.93 
H-1, H-18, H-19 C-1, C-2, C-4, C-5, C-10,  
C-18 
H-1, H-18  
C-4 36.6  H-3, H-18, H-19   
C-5 59.1 2.15 H-1, H-3, H-7, H-15, H-20 C-9, C-18, C-19, C-20 H-1, H-18 
C-6 106.2  H-7, H-9, H-19, H-20,  
H-21 
  
C-7 38.2 2.23, 
2.31 
 C-5,  C-6, C-8, C-9, C-11,  
C-14, C-15, C-20 
H-5, H-9 
C-8 43.9  H-7, H-11, H-15, H-20   
C-9 49.4 2.20 H-5, H-7, H-15, H-20 C-5, C-6, C-8, C-10, C-11,  
C-12, C-14, C-20 
H-1, H-5, H-11 
C-10 47.4  H-11, H-12, H-14, H-20 
H-1, H-3 
  
C-11 23.3 1.86, 
2.03 
 C-8, C-9, C-10, C-12, C-13, C-16 H-1 
C-12 53.5 2.97 H-9, H-11, H-15, H-17 C-13, C-14, C-15, C-16,  
C-17  
H-11 
C-13 208.7  H-11, H-12, H-14, H-20   
C-14 56.3 2.98 H-7, H-12, H-15 (w),  
H-19, H-20 
C-9, C-13, C-15, C-16, C-20  H-7, H-15,  
H-21 (N-CH3)  
C-15 32.6 2.52, 
2.69 
H-12, H-14, H-17 C-7, C-8, C-9, C-12, C-14, C-16, 
C-17 
H-7, H-9 
C-16 142.6  H-11, H-12, H-14, H-15   
C-17 112.3 5.04, 
4.94 
H-12, H-15 C-12, C-15, C-16 (w) H-12, H-15 
C-18 30.3 1.48 H-3, H-5, H-19 C-3, C-4, C-5, C-19  
C-19 70.5 3.35, 
4.30 
H-3, H-5, H-18, H-20,  
H-21 
C-3, C-4 (w), C-5 (w), C-6, 
C-14, C-18, C-20, C-21 
H-3, H-18,  
H-21 (N-Me)  
C-20 75.1 4.27 H-1, H-2, H-5, H-9, H-12, 
H-14, H-19, H-21 
C-1, C-4 (w), C-6, C-8, C-9, C-10 
(w), C-13, C-14, C-19  
H-1, H-14,  
H-19, H-21 
C-21 (N-Me) 37.3 2.90 H-19 C-6, C-19, C-20  H-7, H-15 
 
From the gHMBC and gNOESY cross peak assignments, orochrine was assigned to 
have N-C-6 and C-14-C-20 bonds. The presence of a quaternary nitrogen (attached to 
C-19, C-20, C-6 and C-18 methyl group) and the quaternary carbon at C-6 (attached to 
C-5, C-7, N-Me and hydroxyl group) indicated its relation to vakhmadine 23 which was 
isolated as a quaternary base (i.e. nitrogen bonded to CH3, C-19, C-20 and C-6) from 
Aconitum palmatum151.  
In order to check consistency in the chemical shift assignments of functional groups, 
the NMR data for orochrine was compared with those for vakhmadine and also with the 
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range of chemical shifts reported in the literature on C20 hetisane type diterpenoid 
alkaloids122 (Table 11). 
 
Table 11.  Comparison of NMR data (500 MHz, CD3OD) of the orochrine with vakhmadine (300 MHz,  D2O)151 and the 
range of chemical shift generally observed  for hetisane type alkaloids. 
 
 
Carbon 
 
Compounds 
General range of δ C (ppm) and δH 
(ppm) for hetisane-type alkaloids* 
Vakhmadine 
δC                δH (J=Hz) 
Orochrine 
  δC                 δH (J=Hz) 
 
    δC                                      δH (J=Hz) 
C-1 30.0  34.5 1.59, 1.75 26.4-39.3   
C-2 69.3 3.97 (bs, 1H, H-2β,) 65.5 4.14 (bs, 1H , H-2β) 66.1-67.2 (d,) with OH 4.02-4.31 (bs) 
C-3 73.5 3.33  (d, 1H, J= 4.3) 41.4 1.60 (d, 1H, 
1.93 (t, 1H) 
36.5-43.3 (-OH attached 
in C-2) 
  
C-4 40.6  36.6  35.9-38.7 1.29-1.68  
(-OH in C-6) 
C-5 58.9  59.1 2.15 58.0-62.3   
C-6 105.0  106.2  96.8-107.2   
C-7 40.1  38.2 2.23 
2.31 
42.5-46.7 (β-effect of   
-OH at C-6) 
  
C-8 41.5  43.9  40.5-44.2 (s)   
C-9 45.3  49.4 2.20 48.6-48.9 (due to C=O 
group on C-13) 
  
C-10 45.2  47.4  46.0-52.0   
C-11 21.4  23.3 1.86 
2.03 
22.7-23.4 (with C=O on 
C-13) 
  
C-12 41.5  53.5 2.97 53.2-54.0 (with C=O 
group on C-13) 
2.14-2.94  
( bs) 
C-13 67.8 3.93 (d, 1H,13β, 
J=11.0) 
208.7 Ketone group    
C-14 48.1  56.3 2.98 58.8-61.9 (d, with C=O on 
C-13) 
  
C-15 31.8  32.6 2.52 (d, 1H, J=17.5 ) 
2.69 (d, 1H, J=17) 
32.3-36.1 (t)   
C-16 148.1  142.6  138.0-147.0 (s)   
C-17 107.2 4.59 (s, 1H) 
4.73 (s, 1H) 
112.3 4.94 (s, 1H) 
5.04 (s, 1H) 
104.3-114.4 (t) 4.8-5.52 
(bs, 1H each) 
C-18 25.3 1.40 (s, 3H) 30.3 1.48 (s, 3H) 28.5-32.0 (q)   
C-19 66.7 4.05 (d, 1H, J=11.7) 70.5 3.35 (d, 1H, J = 11.5) 
4.30 (d, 1H, J =11.5)  
62.7-65.0 
 
2.21-3.02  
2.61-3.85 
(J =11.5-14) 
C-20 73.2 4.22 (s, 1H) 75.1 4.27 (bs, 1H) 65.0-75.0 (d) 2.04-4.30 
(1H, bs) 
C-21 
(N-Me) 
36.3 2.58 (s, 3H) 37.3 2.90 (s, 3H)    
Note: The range of chemical shifts were adapted from the literature review by Bessonova et al122. 
 
From this comparative analysis, the chemical shifts of the carbon and proton signals of 
orochrine were found to be consistent with those reported for vakhmadine122,151. In both 
cases, the presence of a quaternary nitrogen atom caused a weak deshielding effect on 
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nearby protons of N-Me (2.90 ppm), H-19 (3.35 ppm, d, 1H, J= 11.5 Hz and 4.30 ppm, 
d, 1H, J=11.5 Hz) and H-20 (4.27 ppm, bs). Similarly, the hydroxyl group at C-6 
caused the protons of C-18 to shift slightly downfield to 1.48 ppm and the N-methyl 
carbon and protons to shift upfield to 37.3 ppm (γ effect)122 and 2.907 ppm152 
respectively. This C-6 hydroxyl group also affected the chemical shift of C-5 (1H) 
which resonated at 59.1 ppm. 
However, unlike vakhmadine, which has a hydroxyl group at C-13 and an extra 
hydroxyl group attached at C-3, orochrine 22 does not have a C-3 hydroxyl either. 
Because of the C-13 carbonyl group, the chemical shifts of C-9 (49.4 ppm), C-11 (23.3 
ppm) and C-12 (53.5 ppm) were shifted downfield compared to the same carbon 
position assignments in vakhmadine 23.  
When orochrine was compared with the structure of panicudine 24 that has a C-13 
carbonyl group and no C-3 hydroxyl group, the chemical shifts of C-13 and its 
neighbouring carbons (C-9, C-12, and C-11) in orochrine were found to be consistent 
with the corresponding chemical shifts for the carbon and proton signals of panicudine. 
Panicudine was isolated from Aconitum paniculatum Lam122. Therefore, the above 
analysis supported 22 as the structure of orochrine. 
The counter ion for the structure of orochrine 22, 2-O-acetylorochrine 25 and 
lingshinaline 26 was assigned as a hydroxide ion (OH-) because only methanol and 
water had been used for the extraction, separation and purification.  Vakhmadine 23 
was also isolated as its hydroxide salt. 
 
3.4.2  2-O-acetylorochrine  
a.   Physico-chemical properties 
The optically active alkaloid named 2-O-acetylorochrine 25 was obtained as a creamy 
white solid. It dissolved readily in chloroform and methanol.  
b.  Spectral Analysis of 2-acetylorochrine 
LRCIMS gave a peak at m/z 384 (MH+) which was 42 amu more than that of orochrine. 
HRCIMS and HREIMS supported the molecular formula C23H29NO4 for this alkaloid, 
and thus an index of hydrogen deficiency of 10. The LREIMS spectra (Appendix 10) 
showed a molecular ion at m/z 383 (M+), plus fragment ions at m/z 368, 355, 340, 324, 
296, 282, 254, 226, 176, 174, 134, 122, 105, 91, 84, 70, 58, 55, and 43.  
Its structure was established by 1H-NMR (Appendix 11), 13C-NMR (Appendix 12), 
DEPT (Appendix 13), gCOSY (Appendix 14), gNOESY (Appendix 15), TOCSY 
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(Appendix 16), gHSQC (Appendix 17) and gHMBC (Appendix 18) spectral data 
obtained in deuterated methanol (CD3OD). The structure of this compound differed 
from orochrine only in the C-2 functional group. This compound had an acetate group 
rather than a hydroxyl at C-2 position. Such biosynthetically reasonable acetylations 
are not unusual in these types of alkaloids.  
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Figure 6.  3D-Model of 2-O-acetylorochrine (N-Blue, O-Red, C-Black, H-White). 
 
Like orochrine, no signals for aromatic protons were evident in the 1H-NMR spectrum 
of 25 and so the index of hydrogen deficiency was structurally indicative of saturated 
rings or double bonds. However, the presence of an exocyclic methylene group was 
indicated by two broad singlets (1H each) observed at 4.86 ppm and 4.95 ppm. These 
protons were attached to the carbon signal resonating at 112.4 ppm in the 13C-NMR 
spectrum from the gHSQC correlation. The proton signals in this case shifted upfield  
(+ 0.087 ppm) but the signal for the carbon shifted downfield (+ 0.15 ppm) in 
comparison to the equivalent signals in orochrine. The signal at 30.1 ppm in the 13C-
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NMR was assigned to C-18, while the associated methyl protons resonated at 1.43 ppm 
(s, 3H).  
The N-CH3 carbon was assigned to the signal at 37.3 ppm, with the methyl protons 
resonating at 2.90 ppm (s). In addition, another singlet for the acetyl protons was 
present at 2.06 ppm (s, 3H), which in turn correlated with a carbon signal at 23.3 ppm.  
A new carbon peak at 171.3 ppm was assigned to the ester carbonyl group. The C-13 
carbonyl group resonated at 208.7 ppm. The signal at 106.6 ppm was ascribed to C-6 
which was substituted by a hydroxyl group, the assignment being based on the gHMBC 
spectrum.   
From the 1H-NMR and gCOSY spectra, the H-15 geminal protons (2.47 ppm, d, 1H, J 
= 17 Hz, and 2.62 ppm, d, 1H, J=17.5 Hz) were coupled to each other and to the H-17 
exomethylene protons. The H-19 geminal methylene protons at 3.37 ppm (d, 1H, J = 12 
Hz), and 3.79 ppm (d, J = 12 Hz) were also coupled. Like all hetisane type alkaloids122, 
the singlet (1H) at 3.37 ppm for H-20 and the doublet at 2.98 ppm (1H, J = 3.5Hz) for 
H-12 were present. The signals for H-5 (1H) and H-9 (1H) appeared as a partially 
resolved broad singlet. Unlike orochrine, the signal for H-11 (2H) was a multiplet (half 
width = 3.5 Hz) and the signal for H-14 was a doublet at 2.97 ppm (1H, J = 2Hz). A 
doublet signal for H-2β was observed slightly downfield at 5.11 ppm (1H, J = 3Hz) due 
to the presence of the adjacent α-acetate group122. The chemical shift for the carbon (C-
2) to which they were attached was observed at 69.0 ppm.  
The DEPT spectra revealed sixteen protonated carbons; seven methylene (-CH2 × 7 
including the exomethylene group), six methine (-CH × 6), and three methyl groups (-
CH3 × 3). The complete carbon-proton correlations for these protons and carbons were 
established by analysing the gHSQC, gCOSY and TOCSY spectra as presented in 
Table 12. The gHMBC and gNOESY correlations (Table 13) provided complete 
information on the carbon-proton connectivities and their arrangements. The structure 
was derived by both carbon-proton correlations cross peak analysis and assignments. 
The gHMBC data analysis generated a structure 25 and the gNOESY spectrum 
confirmed the relative stereochemistry of this alkaloid. The gNOESY correlation is 
diagrammatically represented in Figure 7. 
The gHMBC correlation indicated C-4, C-6, C-8, C-10, C-13 and C-16 were quaternary 
carbons. The peaks at 36.5 ppm, 47.4 ppm and 58.5 ppm were assigned to C-4, C-10 
and C-5 respectively as the chemical shifts were within the normal range noted for 
these carbon signals in the related alkaloids122. A 3D model (Figure 6) was generated 
for 2-O-acetylorochrine (enantiomer shown, apart from C-2) using the Spartan 
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computer program and the spatial arrangements of atoms and functional groups in the 
structure were analysed. The gNOESY correlations were found to be consistent with 
the orientations of protons and functional groups in the 3D model of the structure 
giving added weight to stereochemical assignments. 
 
Table 12.  gHSQC,  gCOSY and TOCSY NMR data (500 MHz, CD3OD) of  2-O-acetylorochrine 25.   
 
Carbon                                                    
                                     gHSQC (δC to δH) 
δC (ppm)  Assignment  δH (ppm) Multiplicity Integration  J (Hz)                 
gCOSY 
Correlation 
     TOCSY 
Correlation    
C-1 31.6 -CH2 1.65 d 2H 17.5   
C-2 69.0 -CH 5.11 d 1H 3 H-1, H-3 H-1, H-3  
C-3 38.5 -CH2 1.66 
1.92 
d 
d 
1H 
1H 
15.5 
16 
H-1  
C-4 36.5 Q       
C-5 58.5 -CH 2.17 s 1H    
C-6 106.6 Q, -OH       
C-7 38.0 -CH2 2.23 
2.27 
d 
d 
1H 
1H 
14.5 
14.5 
  
C-8 44.2 Q       
C-9 49.3 -CH 2.17 s 1H  H-11 H-11 
C-10 47.4 Q       
C-11 23.3 -CH2 1.84 m 2H 3.5   
C-12 53.3 -CH 2.89 d 1H 3.5 C-11 H-11 
C-13 208.7 Q, C=O       
C-14 56.2 -CH 2.97 d 1H 2  H1, H-7 
C-15 32.4 -CH2 2.47 
2.62 
d 
d 
1H 
1H 
17 
17.5 
  
C-16 142.3 Q       
C-17 112.4 -CH2 4.86 
4.95 
bs 
bs 
1H 
1H 
43.5 H-15 H-15 
C-18 30.1 -CH3 1.43 s 3H    
C-19 70.5 -CH2 3.37 
3.79 
d 
d 
1H 
1H 
12 
12 
  
C-20 75.1 -CH 3.76 s 1H  H-14  
C-21 (N-Me) 37.3 -CH3 2.90 s 3H   H-3, H-7 
C-22 (CH3*COO) 
C-23 (*CH3COO) 
171.3        
21.3 -CH3 2.06 s 3H    
Note: Q = Quaternary carbon, *carbon represented in numbering 
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CH2
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Figure 7.  gNOESY correlation of 2-O-acetylorochrine 25. 
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Table 13.   gHMBC and gNOESY NMR data (500 MHz, CD3OD)  of  2-O-acetylorochrine 25. 
 
Carbon                        δC              δH 
                                     (ppm)      (ppm)             
                                gHMBC Correlation  
   δC  to δH                                        δH  to   δC                       
gNOESY 
Correlation 
C-1 31.6 1.65 H-3, H-11 (w),  H-20 C-2, C-3 (w), C-4, C-5, C-10,  
C-20 
 
C-2 69.0 5.11 H-1, H-3, H-18 (w) C-22 H-1, H-3 
C-3 38.5 1.66 
1.92 
H-1, H-19 C-1, C-2, C-4, C-5, C-10, C-18 
(w), C-19 
H-1, H-18 
C-4 36.5  H-1, H-3, H-18, H-19   
C-5 58.5 2.17 H-1, H-3, H-7, H-9, H-18  C-7 (w), C-9 (w), C-14, C-18,  
C-19, C-20 
H-18 
C-6 106.6  H-5, H-7, H-19, H-20, H-21   
C-7 38.0 2.23 
2.27 
H-9 (w), H-15 C-5, C-6, C-8, C-9 (w), C-14,  
C-15 (w) 
 
C-8 44.2  H-7, H-9, H-11, H-15   
C-9 49.3 2.17 H-5, H-7, H-11,  H-12, H-14,  
H-15, H-20 
C-5 (w), C-7 (w), C-12, C-14,  
C-20 
H-1, H-11  
C-10 47.4  H-1, H-3, H-9 (w), H-11, H-14   
C-11 23.3 1.84  C-1 (w), C-8 (w), C-9, C-10,  
C-12, C-13, C-16 
H-1 
C-12 53.3 2.89 H-9, H-11, H-15, H-17 C-9, C-13, C-14, C-15 H-11 
C-13 208.7  H-11, H-12, H-14, H-20   
C-14 56.2 2.97 H-7, H-9, H-15, H-19 (w),  
H-20, H-21 (w) 
C-9,C-10, C-13, C-20 H-7,  H-15 
C-15 32.4 2.47 
2.62 
H-7, H-12, H-17 C-7 (w), C-8, C-9,  C-12,  C-14,  
C-16, C-17  
H-7 
C-16 142.3  H-11,  H-15   
C-17 112.4 4.86 
4.95 
H-12 (w), H-15 C-12, C-15 H-12,  H-15 
C-18 30.1 1.43 H-1,  H-3, H-5, H-19 C-3, C-4, C-5, C-19  
C-19 70.5 3.37 
3.79 
H-3, H-5, H-18, H-20, H-21 C-4, C-5,  C-14 (w), C-18, C-20 H-18,   
H-21 (N-Me) 
C-20 75.1 3.76 H-1,  H-5, H-14, H-19, H-21 C-1, C-6, C-8, C-9 (w), C-13,  
C-14 (w),  C-19 
H-1, H-14,  
H-20,  H-23 
C-21 (N-Me) 37.3 2.90  C-6, C-19, C-20 H-7 
C-22 (COOCH3) 
C-23 (CH3COO) 
171.3  H-2, H-23   
21.3 2.06  C-22  
 
The chemical shifts of protons and carbons of the structure of 2-O-acetylorochrine were 
then compared with the chemical shifts of protons and carbons of orochrine and also 
with the general range of chemical shifts for the respective carbons and protons 
reported in the literature for hetisane-type diterpenoid alkaloids. Except for the C-2 
acetyl group, all the chemical shifts of protons and carbons in the respective NMR 
spectra of 2-O-acetylorochrine were found to be consistent with those of orochrine and 
the relevant chemical shifts reported in the literature. Thus, the structure was confirmed 
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as drawn in 25. The NMR spectroscopic comparison of 2-O-acetylorochrine with the 
orochrine is tabulated in Table 14.  
 
Table  14.  Comparison of NMR data of the 2-O-acetylorochrine (500 Mhz, CD3OD) with orochrine (500 Mhz, CD3OD). 
 
Carbon 
Compounds 
2-O-acetylorochrine 
  δC (ppm)           δH (ppm, J=Hz) 
Orochrine 
  δC (ppm)              δH (ppm, J=Hz) 
C-1 31.6 1.65 (d, 2H, J=17.5) 34.5 1.59 (d, 1H, J =15) 
1.75 (d, 1H, J =15 
C-2 69.0 5.11 (d, 1H-2β, J=3) 65.5 4.14 (bs, 1H-2β) 
C-3 38.5 1.66 (d, 1H, J=15.5) 
1.92 (d,1H, J=16 
41.4 1.60 (d, 1H, J=15) 
1.93 (t, 1H, J=15 
C-4 36.5  36.6  
C-5 58.5 2.17 (s, 1H) 59.1 2.15, (s, 1H) 
C-6 106.6  106.2  
C-7 38.0 2.23 (d, 1H, J=14.5) 
2.27 (d, 1H, J=14.5) 
38.2 2.23, (d, 1H, J=12.5) 
2.31, (d, 1H, J=15 
C-8 44.2  43.9  
C-9 49.3 2.17 (s, 1H) 49.4 2.20  (s, 1H) 
C-10 47.4  47.4  
C-11 23.3 1.84 (m, 2H, Half width =3.5) 23.3 1.86 (d, 1H, J=14) 
2.03 (d, 1H, J=14.5 
C-12 53.3 2.89 (d, 1H, J=3.5) 53.5 2.97 (bs, 1H) 
C-13 208.7 ketone group 208.7 ketone group 
C-14 56.2 2.97 (d, 1H, J=2) 56.3 2.98 (bs, 1H) 
C-15 32.4 2.47 (d, 1H, J=17) 
2.62 (d, 1H, J=17.5) 
32.6 2.52, (d, 1H, J =17.5) 
2.69 (d, 1H, J=17) 
C-16 142.3  142.6  
C-17 112.4 4.86, (bs, 1H) 
4.95  (bs, 1H) 
112.3 4.94 (bs, 1H) 
5.04 (bs, 1H) 
C-18 30.1 1.43 (s, 3H) 30.3 1.48 (s, 3H) 
C-19 70.5 3.37 (d, 1H, J=12) 
3.79, (d, 1H, J =12) 
70.5 3.35 (d, 1H, J=11.5) 
4.30 (d, 1H, J=11.5) 
C-20 75.1 3.76 (s, 1H) 75.1 4.27 (s, 1H) 
C-21 (N-Me) 37.3 2.90 (s, 3H) 37.3 2.90 (s, 3H) 
C-22 (COOCH3) 
C-23 (CH3COO) 
171.3   
Not present 21.3 2.06 (s, 3H) 
 
3.4.3 Lingshinaline 
a.  Physico-chemical properties 
Lingshinaline 26, was isolated as a pale green solid. The alkaloid was optically active 
but the [α]D was smaller than for orochrine or 2-O-acetylorochrine. Its melting point 
was also lower than orochrine or 2-O-acetylorochrine.  
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Figure 8.  3D-computer model of lingshinaline (N-blue, O-red, C-black, H-white). 
b.   Spectral Analysis  
HRCIMS indicated the MH+ peak at m/z 400 (calc. 400.2124) and the LREIMS gave 
the M+ peak at m/z 399 that is 16 amu more than that of 2-O-acetylorochrine. HRCIMS 
and HREIMS supported the molecular formula C23H29NO5 for this alkaloid, and hence 
an index of hydrogen deficiency of 10. This suggested that lingshinaline had one extra 
hydroxyl group compared with 2-O-acetylorochrine. The LREIMS spectrum 
(Appendix 19) showed ions at m/z 399 (M+), 382, 370, 356, 340, 315, 312, 270, 176, 
174, 173, 148, 134, 122, 105, 91, 84, 55, and 43.  
The structure of lingshinaline was established by 1H-NMR (Appendix 20), 13C-NMR 
(Appendix 21), DEPT (Appendix 22), gCOSY (Appendix 23), gNOESY (Appendix 
24), TOCSY (Appendix 25), gHSQC (Appendix 26) and gHMBC (Appendix 27) 
spectral data analysis obtained in deuterated chloroform (CDCl3).  
Like orochrine and 2-O-acetylorochrine, the 1H-NMR spectrum of lingshinaline had no 
signals for aromatic protons and so the index of hydrogen deficiency was structurally 
indicative of saturated rings or double bonds. However, the exomethylene peaks were 
clearly present at 4.92 ppm (bs, 1H) and 5.00 ppm (bs, 1H). These protons were 
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connected to the C-17 carbon, resonating at 112.4 ppm (t) in the 13C-NMR. The C-18 
carbon had a chemical shift of 29.7 ppm, and its protons resonated at 1.52 ppm (s, 3H). 
The N-methyl carbon had a chemical shift of 40.4 ppm and its protons resonated at 3.12 
ppm (s). A singlet ascribed to acetate ester protons (s, 3H) was present at 2.10 ppm and 
corresponded to a carbon signal at 21.4 ppm. A carbon peak assigned to the ester 
carbonyl was present at 169.1 ppm. The C-13 carbonyl group resonated at 206.7 ppm. 
The signal ascribed to the carbinolamine C-6 substituted by a hydroxyl group resonated 
at 105.7 ppm. The N-C-6 bond was established using the HMBC spectrum (see Table 
16).   
The 1H-NMR and gCOSY spectra revealed that the H-15 geminal protons (2.48 ppm, d, 
1H, J = 17.5 Hz, and 2.96 ppm, d, 1H, J=17.5 Hz) were coupled to the H-17 
exomethylene protons. The H-19 geminal methylene protons at 3.42 ppm (d, 1H, J = 
11.5 Hz), and 3.61 ppm (d, J = 11.5 Hz) were also coupled. Like all hetisane 
alkaloids122, the H-20 (3.63 ppm, s, 1H) and H-12 (2.95 ppm, s, 1H) proton signals 
were also present. The signal for the H-5 proton resonated at 2.12 ppm (s, 1H) and that 
for the H-9 proton resonated at 2.20 ppm (d, 1H).  The signal for H-14 resonated at 
3.00 ppm (s, 1H) and that for H-2β (1H) was observed a little downfield as a broad 
singlet at 5.21 ppm due to the presence of the adjacent α-acetyl group.  
The DEPT spectra revealed sixteen protonated carbons: six methylene (-CH2 × 6, 
including the exomethylene group), seven methine (-CH × 7), and three methyl groups 
(CH3 × 3). In this case the structure has gained one methine and lost one methylene 
carbon compared to 2-O-acetylorochrine. The complete carbon-proton correlations for 
these protons and carbons were established by analysing the gHSQC, gCOSY and 
TOCSY (long range couplings) spectra, as tabulated in Table-15. 
From the gHMBC correlation (Table 16), proton-carbon connectivities were 
established and the cross peaks observed were assigned on the scaffold of the hetisane 
type alkaloids. Cross peak assignment established C-4, C-6, C-8, C-10, C-13 and C-16 
as quaternary carbons. The peaks at 35.9 ppm, 47.7 ppm and 55.8 ppm in the 13C-NMR 
were assigned to C-4, C-10 and C-5 respectively as the chemical shifts were within the 
normal range noted for these carbon signals in the related alkaloids122.  
The C-7 (71.7 ppm) carbon was substituted by a hydroxyl group and its proton H-7 was 
ascribed to the 1H-NMR signal at 4.35 ppm. It was reported in the literature that, as a 
rule in these alkaloids this C-7 hydroxyl group has the α-orientation and the signal for 
H-7β should be within the chemical shift range of 3.87-4.50 ppm122. Although the 
chemical shifts for C-7 and its proton (s, 1H, H-7) were within the range noted in the 
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literature, the gNOESY correlation (Table 16) supported a β-orientation of the C-7 
hydroxyl group in lingshinaline. From the 3D model (Figure 8) of lingshinaline 
(enantiomeric form shown apart from C-2, C-7 configuration), the C-7 hydroxyl group 
was found to be protruding to the front and the hydrogen atom going backward thereby 
correlating with the H-5, H-9 and H-15 protons which also had α-orientations. The 
gNOESY correlation is diagrammatically represented in Figure 9. 
 
Table 15.    gHSQC,  gCOSY and TOCSY NMR data (500 MHz, CDCl3) of lingshinaline 26. 
 
Carbon                                                    
                                     gHSQC (δC to δH) 
δC (ppm) Assignment  δH (ppm) Multiplicity Integration   J (Hz)  
gCOSY 
Correlation 
     TOCSY 
Correlation    
C-1 31.2 -CH2 1.65 
1.74 
d 
d 
1H 
1H 
16.5 
15.5 
  
C-2 66.9 -CH 5.21 s 1H  H-1, H-3 H-3  
C-3 37.9 -CH2 1.65 
1.93 
d 
d 
1H 
1H 
17 
16.5 
H-1  
C-4 35.9 Q       
C-5 55.8 -CH 2.12 s 1H    
C-6 105.7 Q        
C-7 71.7 -CH  4.35 s 1H    
C-8 45.3 Q       
C-9 46.7 -CH 2.20 d 1H 7.5 H-11 H-11 
C-10 47.7 Q       
C-11 22.1 -CH2 1.86 d 2H 6.5   
C-12 51.6 -CH 2.95 s 1H  H-11 H-9, H-11 
C-13 206.7 Q, C=O       
C-14 52.5 -CH 3.00 s 1H  H-9 H-11, H-9 
C-15 28.2 -CH2 2.48 
2.96 
d 
d 
1H 
1H 
17.5 
17.5 
  
C-16 139.1 Q       
C-17 113.1 -CH2 4.92 
5.00 
bs 
bs 
1H 
1H 
 H-12, H-15 H-15 
C-18 29.7 -CH3 1.52 s 3H    
C-19 70.4 -CH2 3.42 
3.61 
d 
d 
1H 
1H 
11.5 
10.0 
 H-14, H-21 
C-20 73.5 -CH 3.63 s 1H  H-14  
C-21 (N-Me) 40.4 -CH3 3.12 s 3H   H-14 
C-22 (CH3*COO) 
C-23 (*CH3COO) 
169.1        
21.4 -CH3 2.01 s 3H    
  Note: Q = quaternary carbon, *carbon represented in numbering. 
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Table 16.    gHMBC and g NOESY NMR data (500 MHz, CDCl3)  of  lingshinaline 26. 
                             
Carbon                    δC  (ppm)   δH (ppm)            
                                gHMBC Correlation  
   δC  to δH                                        δH  to   δC                       
gNOESY 
Correlation 
C-1 31.2 1.65 and 1.74 H-20, H-3 C-2, C-5, C-8 (w), C-3 
(w), C-4 
H-3 
C-2 66.9 5.21 H-3, H-1, H-18 (w),  
H-23 (vw) 
 H-1, H-3 
C-3 37.9 1.65 and 1.93 H-1 (w), H-18, H-19 C-2, C-5, C-4 (w), C-1 H-18 
C-4 35.9  H-19, H-3, H-18   
C-5 55.8 2.12 H-3, H-1, H-18 C-20, C-7, C-19, C-9, C-18 H-3, H-18 
C-6 105.7  H-20, H-21   
C-7 71.7 4.35 H-21 (w), H-5 (w) C-14, C-10 H-5, H-9 
C-8 45.3  H-14, H-11, H-1 (w)   
C-9 46.7 2.20 H-14, H-15, H-5, H-11,  
H-12 
 H-5, H-11  
C-10 47.7  H-7, H-20   
C-11 22.1 1.86  C-13, C-16, C-8, C-12 (w), 
C-9 (w) 
H-1 
C-12 51.6 2.95 H-17, H-15 (w), H-11 C-16,C-17,C-9 H-11 
C-13 206.7  H-20, H-14, H-12, H-11   
C-14 52.54 3.00 H-7, H-15 C-13, C-20, C-9, C-8  
C-15 28.2 2.48 and 2.96 H-17, H-7 (w) C-16, C-17, C-9, C-14  
C-16 139.1  H-15, H-12, H-11   
C-17 113.1 4.92 and 5.00 H-15, H-12 C-12, C-15 H-12, H-15 
C-18 29.7 1.52 H-19, H-5 C-19, C-2, C-5, C-3, C-4  
C-19 70.4 3.42 and 3.61 H-20, H-21, H-5, H-18 C-20, C-3, C-4, C-18, C-5, 
C-21 (w) 
H18,  H-21 
C-20 73.5 3.63 H-19, H-21, H-14, H-5 C-13, C-6, C-10, C-1,  
C-19 (w) 
H-1, H-14, 
H-21, H-23 
C-21 (N-Me) 40.4 3.12 H-19 (w) C-6, C-20, C-7, C-19 H-14 
C-22 (CH3*COO) 
C-23 (CH3COO) 
169.1  H-23   
21.4 2.01  C-22, C-2 (w)  
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                   Figure 9. gNOESY correlation of lingshinaline 26. 
 
To confirm the structure, the NMR data for lingshinaline was compared with that of 2-
O-acetylorochrine 25 (Table 17) and the general range of chemical shifts for the 
 
 
55 
respective carbons and protons reported in the literature on hetisine type C20-
diterpenoid alkaloids122,140. Except for C-7 (as expected), the 13C-NMR chemical shift 
values of lingshinaline were found to match closely with those for 25, and all the 
chemical shifts were found consistent with the ranges of chemical shifts provided in the 
literature above.  
Slight differences observed were very negligible and could have been caused by either 
differences in the NMR solvents used or the variations in oxygen containing 
substituents at C-2 and C-7 positions. Thus the structure of lingshinaline was 
established and confirmed as 26. 
 
Table 17.  Comparison of NMR data of the 2-O-acetylorochrine (500 MHZ, CD3OD) with NMR data of lingshinaline (500 
MHz, CDCL3).   
 
 
Carbon 
Compound 
2-O-acetylorochrine 25 
δC (ppm)                 δH (ppm, J=Hz) 
Lingshinaline 26 
  δC (ppm)                 δH (ppm, J=Hz) 
C-1 31.6 1.65 (d, 2H, J=17.5) 31.2 1.65 (d, 1H, J=16.5) 
1.74 (d, 1H, J=15.5) 
C-2 69.0 5.11(d, 1H-2β, J=3) 66.9 5.21 ( s, 1H) 
C-3 38.5 1.66 (d, 1H, J=15.5) 
1.92 (d,1H, J=16 
37.9 1.65 (d, 1H, J=17.0) 
1.93 (d, 1H, J=16.5) 
C-4 36.5  35.9  
C-5 58.5 2.17 (s, 1H) 55.8 2.12 (s, 1H) 
C-6 106.6  105.7  
C-7 38.0 2.23 (d, 1H, J=14.5) 
2.27 (d, 1H, J=14.5) 
71.7 4.35 (s, 1H) 
C-8 44.2  45.3  
C-9 49.3 2.17 (s, 1H) 46.7 2.20 (d, 1H, J=7.5) 
C-10 47.4  47.7  
C-11 23.3 1.84 (m, 2H, Half width = 3.5) 22.1 1.86 (s, 1H, J= 6.5) 
1.87 (s, 1H) 
C-12 53.3 2.89 (d, 1H, J=3.5) 51.6 2.95 (s, 1H) 
C-13 208.7 Ketone group 206.7 Ketone group 
C-14 56.2 2.97 (d, 1H, J=2) 52.5 3.00 (s, 1H) 
C-15 32.4 2.47 (d, 1H, J=17) 
2.62 (d, 1H, J=17.5) 
28.2 2.48 (d, 1H, J=17.5) 
2.96,(d, 1H, J= 17.5) 
C-16 142.3  139.1  
C-17 112.4 4.86, (bs, 1H) 
4.95  (bs, 1H) 
113.1 4.92 (bs, 1H) 
5.00 (bs, 1H) 
C-18 30.1 1.43 (s, 3H) 29.7 1.52 (s, 3H) 
C-19 70.5 3.37 (d, 1H, J=12) 
3.79,(d, 1H, J=12) 
70.4 3.42 (d, 1H, J=11.5) 
3.61 (d, 1H, J=10.0) 
C-20 75.1 3.76 (s, 1H) 73.5 3.63 (s, 1H) 
C-21 (N-Me) 37.3 2.90 (s, 3H)  40.4 3.12 (s, 3H) 
C-22 (COOCH3) 
C-23 (CH3COO) 
171.3  169.1  
21.3 2.06 (s, 3h) 21.4 2.01 (s, 3H) 
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3.4.4    Virescenine  
a.  Physico-chemical properties 
This alkaloid was obtained as an amorphous solid from which a crystalline 
hydrochloride salt was derived. The alkaloid had a low optical rotation ([α]D26  = + 
14.07) and a low melting point (76.7-79.8oC) compared with the alkaloids 22, 25, 26 
isolated from the same plant. Unfortunately the crystals of the hydrochloride were not 
suitable for a single crystal X-ray structure determination. 
 
b. Spectral analysis 
The LRCIMS of this alkaloid showed a peak at m/z 424 (MH+ peak). The HREIMS 
indicated the molecular formula as C23H37NO6 and hence an index of hydrogen 
deficiency of 20. Its mass was 24 amu more than that of lingshinaline 26. The LREIMS 
spectrum (Appendix 28) gave molecular and fragment ions at m/z 423 (M+), 408, 405, 
406, 390, 374, 365, 352, 336, 178, 164, 148, 122, 108, 98, 85, 71, 58 and 45. The 
molecular formula of this alkaloid was the same as that of senbusine A153 and 
virescenine 27154. Furthermore the optical rotation, melting point, and ion 
fragmentation pattern were very similar to those for virescenine ([α]D24 = +16.9 in 95% 
EtOH where c =1.0; m.p. = 68-70oC, Et2O-C6H14)47.  
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Virescenine 27 was previously isolated from Aconitum yesoense var. macroyesoense 
Tamura155, Aconitum delphinifolium DC156, Aconitum nagarum var.lasiandrum 
W.T.Wang157, Delphinium virescens Nutt154 and Aconitum napellus ssp.vulgare (DC.) 
Rouy et Fouc158. So the alkaloid isolated in this study was thought to be virescenine 27. 
To substantiate this deduction, the structure of the alkaloid was elucidated by 1H-NMR 
(Appendix 29), 13C-NMR (Appendix 30), DEPT (Appendix 31), gCOSY (Appendix 
32), gNOESY (Appendix 33), gHSQC (Appendix 34), TOCSY (Appendix 35) and 
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gHMBC (Appendix 36) spectral analysis. The 1H-NMR showed that the alkaloid had 
no aromatic protons as well as no H-17 exomethylene and H-18 methyl groups. Instead 
this alkaloid had two methoxyl signals that resonated at 3.29 ppm (s, 3H) and 3.31 ppm 
(s, 3H) and an N-ethyl signal whose methyl protons (N-CH2CH3) resonated at 1.08 ppm 
(t, 3H) and the methylene protons (H-18) at 2.95 ppm (q, 1H) and 3.06 ppm (q, 1H). 
This was the only alkaloid isolated from Aconitum orochryseum with an N-ethyl group. 
The H-19 protons (2H) that were present in orochrine, 2-O-acetylorochrine, 
lingshinaline and atisinium chloride were also present in this alkaloid and their signals 
resonated at 2.50 ppm (d, 1H, J=11 Hz) and 2.76 ppm (d, 1H, J=11 Hz).  
From the 13C-NMR spectrum, it was found that the alkaloid contained no ester or other 
carbonyl groups. The DEPT spectrum showed the presence of 19 protonated carbons: 
eight methylene, eight methine and three methyl groups. Based on the DEPT, gHSQC, 
gCOSY and TOCSY spectra, the assignment of the groups and carbon-proton 
connectivities was achieved (Table 18) and the complete structure was established 
using the gHMBC spectrum and gNOESY correlations (Table 19). 
 
Table 18. Proton-carbon correlation (from DEPT and gHSQC spectrum) and proton-proton correlation (from gCOSY and 
long range TOCSY spectrum) of the isolated alkaloid virescenine 27. 
 
Carbon 
δC (ppm) Assignment 
(From DEPT) 
δH (ppm, J=Hz) 
(From gHSQC) 
 
gCOSY 
 
TOCSY 
1 72.0 -CH  3.67 (s, H-1β) H-2, H-3, H-12  H-2, H-18 
2 28.7 -CH2 1.45 (q), 1.57 (d, J= 18.5)    
3 26.6 -CH2 1.63 (dd, J=5), 1.82 (dd, J=6) H-2 H-6 
4 37.6 Q    
5 41.7 -CH 1.71 (t, J=7)   
6 33.3 -CH2 1.54 (d), 2.26 (d) H-5, H-10 H-5, H-6 
7 85.7 Q    
8 76.0 Q    
9 47.7 -CH 2.15 (t, J=5.5) H-10 H-10 
10 43.3 -CH 1.76 (q)   
11 49.3 Q    
12 28.2 -CH2 1.55 (t), 1.97 (t) H-10 H-15 
13 39.4 -CH 2.27 (m) H-10, H-12 H-9 
14 75.3 -CH 4.17 (t, J=4.5, H-14β) H-9, H-13 H-9, H-13 
15 35.8 -CH2 1.73 (dd, J=9.5), 2.89 (m)  H-6 
16 81.5 -CH 3.37 (q, H-16α) H-10, H-15 H-15 
17 65.2 -CH 2.83 (s) H-12  
18 78.4 -CH2 3.01 (d, J=9), 3.16 (d, J=9)  H-5 
19 55.7 -CH2 2.49 (d, J=11), 2.72 (d, J=11)   
20 50.7 -CH2 (NCH2CH3) 2.95 (q), 3.06 (q) H-21 H-21 
21 13.4 -CH3 (NCH2CH3) 1.08 (t, J=7.5)   
22 59.3  -OCH3 (C-18-OCH3) 3.28 (s)   
23 56.3 -OCH3 (C-16-OCH3) 3.31 (s)  H-17 
Note: Q = Quaternary carbon. 
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Table 19.  gHMBC spectrum and the gNOESY correlation of  the isolated alkaloid virescenine 27. 
 
Carbon 
δC 
(ppm) 
δH 
(ppm) 
                       gHMBC 
δC to δH                                              δH to δC 
gNOESY 
Correlation 
1 72.0 3.67 H-3, H-5 C-3, C-5 H-2, H-10, H-12,  
H-15, H-17 
2 28.7 1.45, 1.57  H-3 (w) C-4, C-5, C-11 H-9 
3 26.6 1.63, 1.82 H-1, H-18, H-19 C-1, C-4, C-18, C-19 H-2 
4 37.6  H-3, H-5, H-6, H-18, H-19    
5 41.7 1.71 H-6, H-10, H-17, H-18, H-19  C-4, C-7, C-10, C-11, C-17, 
C-18, C-19 
H-2, H-12  
6 33.3 2.26, 1.54  H-17 C-4, C-5, C-7, C-11, C-17  H-5, H-9 
7 85.7  H-5, H-6, H-15   
8 76.0  H-5, H-6, H-9, H-10, H-14, 
H-15, H-17 
  
9 47.7 2.15 H-10, H-13, H-15 C-8, C-10, C-12, C-13, C-15 H-10 
10 43.3 1.76 H-1, H-2, H-5, H-9, H-13, H-
12, H-15, H-17 
C-1 (w), C-2, C-8, C-5, C-9, 
C-11, C-12, C-17 
 
11 49.3  H-12, H-10, H-17   
12 28.2 1.55, 1.97 H-9, H-10, H-16 (w) C-5, C-10, C-11, C-13, C-14, 
C-16 
H-15 
13 39.4 2.27 H-9, H-12, H-15 C-9, C-10, C-15, C-16 H-12 
14 75.3 4.17 H-12, H-16 C-8, C-16 H-6, H-9, H-13, 
15 35.8 1.73, 2.89 H-9, H-13 C-6, C-7, C-8, C-9, C-13,  
C-16 
 
16 81.5 3.37 H-12, H-14, H-15, H-23 C-12 (w), C-14, C-23 H-2, H-3, H-6, H-12 
17 65.2 2.83 H-5, H-6, H-10, H-19,  
H-20 (w) 
C-5, C-6, C-8, C-10 (w),  
C-11, C-19, C-20 
H-6, H-21 
18 78.4 3.01, 3.16 H-3, H-5, H-19, H-22 C-3, C-4, C-5, C-19, C-22 H-3, H-5, H-17 
19 55.7 2.49, 2.72 H-3, H-5, H-17, H-18, H-20  C-3, C-4, C-5, C-17, C-18,  
C-20 
H-3, H-6, H-21 
20 50.7 2.95, 3.06 H-17 (w), H-19, H-21 C-17, C-19, C-21 H-19, H-21 
21 13.4 1.08 H-20 C-20  
22 59.3  3.28  H-18 C-18 H-18 
23 56.3 3.31 H-16 C-16 H-3, H-6, H-15 
 
Considering the biogenetic relationship in these alkaloids, oxygenation occurs at C-1, 
C-3, C-4, C-6, C-13, C-16 and C-18. In fact almost all the C19 diterpenoid alkaloids 
bear a hydroxyl or methoxyl group on C-1, C-8, C-14 and C-16159,160. Using gCOSY, 
gNOESY and gHMBC correlations, the three hydroxyl groups of the isolated alkaloid 
were assigned to the C-1, C-8 and C-14 positions. The hydroxyl groups at C-1 and C-
14 had the α-orientation140,154,159. The last hydroxyl group was assigned to C-7. The C-
7 hydroxyl group is characteristic of the lycoctonine-type 7 C19 diterpenoid alkaloids 
and this hydroxyl group, as well as the hydroxyl group at C-8, has the β-
orientation47,158. The C-16 methoxyl group was assigned to the β-position while the 
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adjacent C-16 proton was assigned as α in almost every report of the aconitane-type 
diterpenoid alkaloids126.  
The NMR spectroscopic data for the isolated alkaloid was then compared with the data 
for virescenine 27 (Table 20). The NMR spectra were all obtained in CDCl3; very close 
chemical shift matches were noted apart from the chemical shifts of C-10 and C-13. 
The literature on virescenine140,154 has reported the chemical shift of C-10 as 39.9 ppm 
and that of C-13 as 43.6 ppm. In contrast, with the alkaloid isolated in this study, the C-
10 signal resonated at 43.3 ppm and for C-13 at 39.4 ppm. The assignment of these C-
10 and C-13 signals for the alkaloid was supported by the gCOSY and the gHMBC 
correlations.  
From the gCOSY spectrum, the protons of C-6 (1.54 ppm, d and 2.26 ppm, d), C-9 
(2.15 ppm, t), C-12 (1.55 ppm and 1.97 ppm, t), C-13 (2.27 ppm, m) and C-16 (3.37 
ppm, q) were coupled to the proton (1.76 ppm, q) of the carbon that resonated at 43.3 
ppm. This suggested that the carbon at 43.3 ppm was C-10. From the gHMBC 
correlation, C-10 was connected to the neighbouring carbons C-11 (quaternary), C-9 (-
CH) and C-12 (-CH2) rendering it a quartet. 
  
Table 20. Comparison of  1H-NMR and 13C-NMR data of the isolated alkaloid (500 MHz, CDCl3) with that of virescenine154. 
 
Carbon 
Virescenine Virescenine (Isolated) 
δC (ppm) δH (ppm) J=Hz δC (ppm) δH (ppm) J=Hz 
1 72.4  72.0 3.67 (s) 
2 28.8  28.7 1.45 (q), 1.57 (d, J= 18.5)  
3 29.3  26.6 1.63 (dd, J=5), 1.82 (dd, J=6) 
4 37.7  37.6  
5 42.0  41.7 1.71 (t, J=7) 
6 33.6  33.3 2.26 (d), 1.54 (d) 
7 86.1  85.7  
8 76.3  76.0  
9 47.9  47.7 2.15 (t, J=5.5) 
10 39.9  43.3 1.76 (q) 
11 49.5  49.3  
12 26.9  28.2 1.55 (t), 1.97 (t) 
13 43.6  39.4 2.27 (t) 
14 75.5 4.23 (1H, t, J=5, H-14β) 75.3 4.17 (t, J=4.5, H-14β) 
15 35.9  35.8 1.73 (dd, J=9.5), 2.89 (m) 
16 82.2  81.5 3.37 (q) 
17 64.9  65.2 2.83 (s) 
18 78.7  78.4 3.01 (d, J=9), 3.16 (d, J=9) 
19 55.9  55.7 2.49 (d, J=11), 2.72 (d, J=11) 
-CH2 (NCH2CH3) 50.5  50.7 2.95 (q), 3.06 (q) 
-CH3 (NCH2CH3) 13.9 1.10 (3H, t, J=7.0) 13.4 1.08 (3H, t, J=7.5) 
-OCH3 (C-18-OCH3) 59.4 3.33 (3H, s) 59.3  3.28 (3H, s) 
-OCH3 (C-16-OCH3) 56.4 3.35 (3H, s) 56.3 3.31 (3H, s) 
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The long range gHMBC correlation also found that C-5, C-8, C-11, C-13 and C-17 
correlated with the protons (1.76 ppm, q) attached to the carbon that resonated at 43.3 
ppm (assigned as C-10, Table 20) and this carbon peak (43.3 ppm, δC to δH) 
correlated with the protons H-1, H-2, H-5, H-9, H-12, H-13, H-15 and H-17. If the 
carbon peak at 43.3 ppm is assigned to C-13, these correlations would not be possible. 
Similarly, from the gHMBC correlation, C-13 (39.4 ppm) for the alkaloid isolated was 
connected to C-12 (-CH2), C-14 (-CH) and C-16 (-CH). From the 1H-NMR spectrum, 
the chemical shift of the signal ascribed to the C-13 proton resonated well downfield at 
2.27 ppm compared to the C-10 protons that resonated at 1.76 ppm. This was plausible 
because the C-13 protons were close to the carbons that are substituted with hydroxyl 
(C-14) and methoxyl (C-16) groups.  
There has been little discussion in the literature on the proton-carbon correlations in 
this alkaloid. It is possible that the original spectra were incorrectly assigned. Since all 
the 13C-NMR data, other than C-10 and C-13, were in agreement with each other, it 
was concluded that the alkaloid (27) isolated was virescenine. 
 
3.4.5     Atisinium chloride  
a.  Physico-chemical properties 
This alkaloid was the major alkaloid of the plant and had been reported before from 
many Delphinium and Aconitum species47,124,161. The needle-like crystals were obtained 
from methanol/diethyl ether. The alkaloid had an optical rotation of [α]D25 = + 31.27 (c, 
0.94 in MeOH) and a melting point of 305.7-308.6oC (decomposition) which was 
slightly different from the corresponding values noted in the literature {optical rotation 
varies from [α]D23 = + 22.6 (c, 4.9 in 95% EtOH)162 to [α]D25 = + 28 (c,1.10 in H2O)47 and 
the melting point from 311-312oC47 to 325-326oC162}. The alkaloid was the most polar 
compound of the other alkaloids isolated from the same plant. 
 
b. Spectral analysis   
The LRCIMS indicated the MH+ peak at m/z 344. From the HRESMS, the molecular 
formula was found to be C22H33NO2 (M+) for this alkaloid. The LREIMS spectrum 
(Appendix 37) had ion peaks at m/z 343 (M+), 342, 328, 314, 300, 284, 257, 241, 186, 
171, 159, 143, 131, 105, 91, 79, 72, 55 and 44. 
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Figure 10.   The X-ray structure of Atisinium chloride. 
 
The crystal structure (Figure 10) was determined by single crystal X-ray 
crystallography (by Professor A.H.White, University of Western Australia; Appendix 
38) and was identified as atisinium chloride 28. An earlier crystal structure of atisinium 
chloride (with 4S, 5S, 8R, 12S, and 15S absolute configuration) had been reported in 
1976162.  
The torsion angles (deg) (Appendix 38), crystal data, data collection parameters, and 
refinement results (Table 21) were compared with the old data reported in the 
literature162. All this data including dihedral angles, fractional atomic position 
parameters, individual atom parameters, input atom coordinates, bond angles and 
contact distances were found in agreement to the previous crystal data on atisinium 
chloride. 
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Table 21. Crystal data and refinement results of a atisinium chloride. 
Description Atisinium chloride (1976) Atisinium chloride (2004) 
Cell dimensions 
a 
b 
c 
V 
 
14.340 
18.180 
7.709 
2009.7 
 
7.670 
14.246 
17.919 
1958.1 
Space group 
Z 
Mol wt 
P212121 
4 
379.972 
P212121 
4 
379.97 
Density, g cm-3 
                  Observed 
Calculated 
 
1.256 
1.256 
 
1.289 
1.289 
2θmax 150.20
o 65o 
Reflections 
                   Measured 
Observed 
        Non-observed 
 
2377 
2007 
370 
 
3372 
3408 
485 
Final agreement 
             R 
             Rw 
Average  shift/estimated 
Max in final difference electron 
density map, eÅ-3 
 
0.038 
0.037 
0.33 
 
0.20 
 
0.042 
0.045 
0.64 
 
0.36 
 
3.4.6     AO-358 
This alkaloid was isolated as a milky white solid. It had a high melting point (122.6-
124.2oC) and a large optical rotation ([α]D27 = +86.6). The LRCIMS indicated a peak at 
m/z 358. From the HRCIMS, the molecular formula was found out to be C22H32NO3. In 
the HREIMS, ion fragments were observed at m/z 357 (M+), 344, 342, 329, 328 
(100%), 327, 326, 312, 300, 286, 284, 250, 234, 148, 122, 105, 91, 77, 71, and 60. 
When the mass spectral library (available on the Department of Chemistry mass 
spectrometer) was searched for a match, none of the spectra matched the HREIMS 
spectrum of this alkaloid isolated here.  
The 1H-NMR spectrum (nanoprobe) was not clear enough to assign the structure and 
the sample was insufficient to obtain the 13C-NMR spectrum and 2D spectra. However, 
the presence of three methoxy groups, a C-methyl group and N-ethyl signals were clear 
in the 1H-NMR spectrum. The three methoxyl protons resonated at 3.23 ppm (s, 3H), 
3.38 ppm (s, 3H) and 3.43 ppm (s, 3H). The C-methyl protons (probably C-18) 
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resonated at 1.10 ppm (s, 3H) and the N-CH2CH3 protons at 0.90 ppm (t, 3H) with the 
methylene (-CH2) protons resonating at 3.12 ppm (q, 2H). Since the alkaloid didn’t 
have signals for an exomethylene group it probably belongs to the C19-diterpenoid type 
of alkaloid whose structure could be related to virescenine 27. Nevertheless, the 
structure was not established due to the lack of spectroscopic data.    
Interestingly, another alkaloid fraction was also isolated with the same molecular 
weight but different molecular formula, and different polarity (on TLC). This 
compound had a lower Rf value compared to the above compound. Its molecular 
formula was determined by HRCIMS to be C15H5NO10 .  
 
3.4.7  AO-340 
This alkaloid was isolated as a milky white solid. The LRCIMS indicated the presence 
of a peak at m/z 340 (MH+). The HRCIMS supported the molecular formula of 
C21H26NO3. In the LREIMS, the molecular ion and ion fragments were observed at m/z 
339 (M+), 322, 310, 297, 283, 245, 179, 159, 128, 124 (100%), 108, 94, 79, 65, 55, and 
42.  
 
3.4.8  AO-330 
This alkaloid was isolated as a milky white solid. LRCIMS indicated the MH+ peak at 
m/z 330. The HRCIMS supported the molecular formula of C20H28NO3. Due to small 
quantities of sample, it was not possible to obtain adequate NMR data. The mass 
spectral library was searched for compound matches and none of the spectra in the 
mass spectrometer library was found to match the mass spectrum of AO-330. Judging 
by the molecular formula and ion fragmentation pattern, it appears to be a new alkaloid. 
 
3.4.9  AO-372 
This alkaloid was isolated as a pale brown solid. The LRCIMS indicated the presence 
of an MH+ peak at m/z 372. The HRCIMS indicated a molecular formula of 
C21H26NO5. In the LREIMS, ions were observed at m/z 371 (M+, 100%), 355, 343, 327, 
299, 296, 238, 210, 192, 162, 134, 122 and 105. 
 
3.4.10     AO-414 
This alkaloid was obtained as a pale green solid. The LRCIMS gave a peak at m/z 414 
(MH+) and the HREIMS supported a molecular formula of C23H27NO6. In the LREIMS, 
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ion fragments were observed at m/z 413 (M+), 385, 369, 354, 342, 310, 280, 252, 220, 
212, 148, 134, 122, 105, 91, 79, 67, 57, 55, 44 (100%), 43 and 42.  
 
3.4.11    O-466 
This alkaloid was isolated as a pale green solid. The LRCIMS indicated a peak at m/z 
466 for MH+. The HRCIMS supported a molecular formula of C25H40NO7. In the 
LREIMS, ions were observed at m/z 465 (M+), 450, 448, 432, 422, 403, 402 (100%), 
390, 374, 358, 342, 329, 300, 284, 194, 164, 148, 122, 98 and 91. 
No structures could be assigned for these minor alkaloids (AO-340, 330, 372, 414 or 
466) due to the very small quantities available. 
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Chapter 4 
Alkaloids from Corydalis gerdae Fedde 
 
 
 
 
 
 
4.1  Botanical Description and Ethno-medical use 
Corydalis gerdae Fedde is an annual flowering herb that grows to about 7-20 cm in 
height with a long scaly rhizome and stems surrounded by persistent petiole bases of 
the bipinnatisect (2-4 x 1.5-2 cm) basal leaves that have broadly ovated leaflets77,111. 
The umbellate inflorescence has 3-6 horizontal flowers supported by 10-15 mm 
pedicels exserting above the bracts (6-12 mm) and the petals are purple or mauve and 
white with an outer pair broadly crested and lower deflexed lip petal111. 
This species of Corydalis is used in Bhutanese traditional medicine in treating 
malaria105, coughs and colds, and bile inflammation77. Other Corydalis species have 
also been used by many cultures in folklore medicines worldwide163. The genus 
Corydalis contains more than 300 species, with a vast variety of isoquinoline alkaloids 
being isolated from these plants4,47,163.   
 
4.2      Isoquinoline Alkaloids: Biosynthesis and Classifications 
The isoquinoline type alkaloids are the most widely distributed alkaloids and are found 
in plants of thirty two botanical families44,164. Morphine was the first isoquinoline 
alkaloid to be isolated from Papaver somniferum (Papaveraceae) in 1805165. To date 
about 1,200 isoquinoline alkaloids have been isolated from plants belonging to these 
different types of families mentioned above44. 
The classification of isoquinoline alkaloids is not clearly defined. However, based on 
their structural types and biogenesis, they are commonly divided into twenty categories, 
each of which is further branched into different sub-classes47. Each group presents 
striking and enormously varying structural types basically derived from tyrosine, and 
these types are briefly described below. 
1. Simple isoquinoline derivatives, e.g Corydaldine 29. 
2. Emetine group (derivatives with a monoterpenoid unit) e.g. Emetine 30. 
3. Benzylisoquinolines (derived from two molecules of tyrosine), e.g. Cularine 31. 
Family:    Fumariaceae 
Genus:    Corydalis 
Species:   gerdae 
gSo-ba rig-pa name:  sTong-ril-zilpa, 
Distribution:   Endemic to Himalayas 
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4. Proaporphines, e.g. Orientalinone 32. 
5. Aporphines (formed by phenol oxidative coupling of a benzylisoquinoline 
precursor), e.g.  Liriodenine  33. 
6. Protoberberines (derived from benzylisoquinolines by condensation with a one-
carbon unit), e.g. Ophiocarpine 34. 
7. Benzophenanthridines (derived from tetrahydro-protoberberine precursors), eg. 
Chelidonine 35. 
8. Dibenzopyrrocoline alkaloids (derived by oxidation of a benzylisoquinoline 
precursor), e.g Cryptaustoline 36. 
9. Protopines (formed by oxidative ring fission of protoberberine N-metho salts), 
e.g Protopine 37. 
10.  Rhoeadine alkaloids (derived from two tyrosine units via tetrahydroberberine 
and protopine intermediates), e.g Rhoeadine 38. 
11. Other categories includes Narceine and Phthalideisoquinoline alkaloids, the 
Pavine/isopavine group, Spirobenzylisoquinolines166, the Protostephanine and 
Hasubanonine groups, Bis-benzylisoquinoline alkaloids,  the Morphine group, 
and the Phenethylisoquinoline group. 
Although these alkaloids are quite often typical and restricted to certain genera of the 
family as in the case of rhoeadine alkaloids, which are encountered only in the Papaver 
genus, more than one class of alkaloids have been observed commonly even within a 
genus. The protoberberine alkaloids are distributed among the plant families 
Alangiaceae, Berberidaceae, Fumariaceae, Hydrastidaceae, Lauraceae, Leguminosae, 
Menispermaceae, Papaveraceae, Ranunculaceae, Rutaceae and Annonaceae44. 
However, these families also host large reservoirs of other classes of alkaloids. The 
investigation of the Annona squamosa L. of the Annonaceae family resulted in the 
isolation of ten alkaloids (corydine, annonaine, roemerine, norcorydine, norisocorydine, 
isocorydine, glaucine, dienone, aporphine and norlaureline) belonging to 
protoberberine as well as aporphine alkaloids167.  
The protopine group of alkaloids is distributed in a variety of genera in the 
Fumariaceae (Corydalis, Dactylicapnos, Dcentra, Fumaria), Papaveraceae (Argemone, 
Bocconia, Chelidonium, Eschscholtzia,  Glaucium, Hunnemannia, Hylomecon, 
Macleaya,  Meconella, Meconopsis, Papaver, Roemeria, Romeya, Sanguinaria, 
Stylomecon), Hypecoaceae, Berberidaceae (Berberis), Sapindaceae (Pterodophyllum), 
Nandinaceae, and the Pteridophyllaceae plant families. Protopine is the principal 
alkaloid of this group of families. Other groups like protoberberines and 
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benzophenanthridines were also reported from the same family along with protopine as 
illustrated by the analysis of Bocconia cordata Wild.168 and Chelidonium majus 
L.(Papaveraceae)169.  
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Scheme 2    The biosynthetic pathway of the protopine-type and the benzo[c]phenanthridine-type 
      alkaloids. 
 
Recently, two new protopine-type alkaloids, argemexicaines-A and B along with 
thirteen known alkaloids including its related alkaloid, benzo[c]phenanthridine-6-
acetonyldihydro-chelerythrine were isolated from the methanol extracts of Formosan 
Argemone mexicana L (Papaveraceae)170. Benzo[c]phenanthridine-6-acetonyl-dihydro-
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chelerythrine exhibited a significant anti-HIV activity in lymphocytes with EC50 and TI 
(Therapeutic Index) values of 1.77 µg/ml and 14.6 µg/ml respectively170. About 20 
alkaloids including protopine, cryptopine, stylopine, scoulerine and sinactine171, and 
minor alkaloids like fumarofine, fumaricine, fumaritine, and fumariline172, were 
isolated and identified from the plant Fumaria officinalis (Fumariaceae).   
These alkaloids are related biosynthetically and many biosynthetic correlations have 
been studied for the isoquinolines. The biosynthetic pathways for protopine-type (e.g. 
protopine) and benzo[c]phenanthridine-type (e.g. chelidonine) alkaloids from Corydalis 
incisa PERS. and Chelidonium majus L. are presented. The plants are related to each 
other and their biosyntheses are relevant to the alkaloids currently isolated from 
Corydalis gerdae Fedde by the author.  
It was suggested that the protopine-type and benzo[c]phenanthridine type alkaloids 
were related biosynthetically as both were derived from the tetrahydroprotoberberine 
alkaloids. Battersby et al.173 studied the biosynthetic pathway for these alkaloids using 
Corydalis incisa PERS and Chelidonium majus L and established (by tracer 
experiments174) the biosynthetic pathway as illustrated in Scheme 2. This pathway 
showed that chelidonine and protopine were biosynthesised in plants from tyrosine 39 
via (S)-reticuline 40, (S)-scoulerine 41 and (S)-stylopine 42175.  
The same experiment confirmed that (S)-cheilanthifoline 47 isolated from Corydalis 
incisa plants was biosynthetically converted to corynoline and protopine and was a 
probable true intermediate  between scoulerine and stylopine174. It has also been shown 
that the protopine-type alkaloids occupy a central position biosynthetically between the 
tetrahydroprotoberberine-N-metho salts and the benzophenanthridines and between the 
N-quaternary tetrahydroberberines and the rhoedines168. 
   
N
O
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H
MeO
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4.3      Phytochemical and Pharmacological Investigation of Isoquinoline Alkaloids 
from the genus Corydalis 
Many bioactive alkaloids belonging to different classes of isoquinoline alkaloids (as 
described earlier in this chapter) have been isolated from Corydalis species 
(Fumariaceae). Sibiricine176 and ochrobirine177 were first isolated  from Corydalis 
siberica by Manske et al. in 1936. The Dictionary of Alkaloids47 has listed 58 species 
of Corydalis (including unknown species) and 119 different types of alkaloids were 
reported to have been isolated from these plants. Cheilanthifoline was isolated from 
Corydalis cheilanthifolia, Corydalis scouleri, Corydalis siberica and the Corydalis 
gigantea178. Scoulerine and many other alkaloids were reported from Corydalis 
tuberosa, Corydalis cava, and Corydalis pallida179. Examination of Corydalis 
koidzumiana resulted in the isolation of protopine, α-allocryptopine, (±)-
tetrahydropalmatine, (+)-corydaline, (+)-stylopine, (−)-scoulerine, (−)-capaurine, (−)-
isocorypalmine, (−)-cheilanthifoline, (+)-corybulbine, sanguinarine, oxysanguinarine, 
dihydrosanguinarine, (+)-reticuline, sinoacutine and pallidine180.  
Protopine was isolated from Corydalis ternata and Corydalis caseana A.Gray181.  
Stylopine was also reported from a Corydalis spp47. Varieties of alkaloids were also 
isolated from Corydalis bungeana Turez182 and Corydalis decumbens183 and the 
isolation work is still ongoing. 
Amongst different classes of alkaloids isolated from the plants, protoberberine and 
protopine groups have shown a wide range of pharmacological activities. Berberine 
was found to be therapeutically useful in the treatment of malaria (Plasmodium 
falciparum)184. Seventeen quaternary protoberberine alkaloids related to berberine were 
tested for antimalarial activity and six of them displayed more potent activity than 
berberine itself185.  
Protopine exhibited both anti-acetylcholinesterase and anti-amnesic properties186.  
Protopine was also found to have phospholipase and thromboxane synthetase inhibitory 
activity187, weak spasmolytic, weak anti-tumour activity, smooth muscle stimulant, 
bactericidal activity and sedative property47. When 18 protopine derivatives were tested 
for antimalarial activity, the derivatives A65, A74, A77 and A20 in which the 
methylenedioxy moiety was modified by replacing a H atom with Br, NH2, I and SbCl2 
respectively exhibited promising antimalarial activity188. Stylopine showed 
antipsychotic and neuroleptic activity in mice and rats. Dehydrocorydaline, (+)-
corydaline and (±)-tetrahydropalmatine isolated from the Chinese Corydalis tubers 
were claimed to be good pain killers and anti-ulcer medicines189.  With the hope of 
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finding a novel pharmacophore, we have studied one of the Corydalis plant endemic to 
Himalayas. 
 
4.4      Isolation and Identification of Alkaloids from Corydalis gerdae Fedde 
The methanol extract of the air dried plant material was subjected to routine procedures 
of extraction, fractionation, separation and purification (Chapter 9). Out of many 
fractions, only four known alkaloids were isolated and identified by matching their 
LREIMS spectra with the spectra in the Mass Spectrometer Database. NMR spectra 
and physico-chemical properties of the isolated compounds were also compared to 
further confirm their identification. From these analyses, it was confirmed that the 
alkaloids were protopine, scoulerine, stylopine and cheilanthifoline. Other amide and 
acid like compounds were also obtained in the process of alkaloid extraction. 
 
4.4.1  Protopine 
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a.  Physico-chemical properties 
This alkaloid, which belongs to the protopine-type isoquinoline alkaloids, was obtained 
as a white amorphous solid. It was the major alkaloid of the plant and had been isolated 
before from many plants as described in the earlier part of this chapter. The alkaloid 
was optically inactive and had a high melting point (203.7-207.8oC, decomposition). 
An earlier literature has reported the melting point of protopine as 210-211oC190 and 
207o C47.  
b.  Spectral Analysis 
The LRCIMS indicated an MH+ peak at m/z 354. The HRCIMS and the HREIMS 
supported the molecular formula as C20H19NO5 and hence a hydrogen deficiency of 12. 
From the same HREIMS, the molecular ion and ion fragments were observed at m/z 
353 (M+), 338, 309, 295, 281, 267, 252, 237, 224, 210, 190, 163, 149, 148 (100%), 134 
and 89.  
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     Figure 11.   HREI MS library matching of an unknown alkaloid (top) with protopine (below).    
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Figure 12.  1H-NMR spectrum (top) and 13C-NMR spectrum (bottom) of the major alkaloid (500 MHz, 
DMSO-d6) from Corydalis gerdae.  
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The molecular formula and the ion fragmentation pattern corresponded with that of 
protopine. From the mass spectrometer library (in the Shimadzu QP-5000 mass 
spectrometer) matching analogy, the HREIMS spectrum of the isolated alkaloid was 
found to match that of protopine (Figure 11). Thus, this alkaloid was identified as 
protopine.  
The identification was further confirmed by comparing the 1H-NMR and 13C-NMR 
spectral values of the alkaloid with that of the 1H-NMR and 13C-NMR spectral values 
(Figure 12) reported in an earlier literature for protopine190. The 1H-NMR spectrum 
(300 MHz, CDCl3) of protopine indicated the 2,3-OCH2O proton at 5.93 ppm (s), the 
9,10-OCH2O at 5.91 ppm (s) and the N-CH3 protons at 1.93 ppm (s)190. These protons 
were clearly observed in the 1H-NMR spectrum (500 MHz, DMSO-d6) of the unknown 
major alkaloid under investigation in which the signal for the 2,3-OCH2O resonated at 
5.96 ppm (s), for the 9,10-OCH2O at 5.93 ppm (s), and for the N-CH3 at 1.79 ppm (s). 
The chemical shifts of the other proton signals as well as the 13C-NMR shift values of 
the alkaloid corresponded to the chemical shifts of the proton and carbon signals of 
protopine (Table 22) further confirming that the alkaloid was protopine.  
 
Table 22. Comparison of 1H-NMR spectrum (500 MHz, DMSO-d6) and 13C-NMR spectrum (500 MHz, DMSO-d6) of the 
major alkaloid with 1H-NMR spectrum (300 MHz, CDCl3) and 13C-NMR spectrum (75.4 MHz, CDCl3) of protopine190. 
 
Carbon 
Protopine (Literature) Alkaloid (Isolated) 
δC (ppm) δH (ppm) J (Hz) δC (ppm) δH (ppm) J (Hz) 
1 108.0 6.89 (s)  107.4 6.92 (s)  
2 145.7   145.3   
3 147.8   147.3   
4 110.3 6.63 (s)  110.4 6.77 (s)  
4a 132.6   132.7   
5 31.7 2.89 (s) WH 18 30.5 3.15 (s)  
6 57.7 2.52 (t) 5 57.4 2.38 (bs)  
8 50.6 3.57 (d) 1.5 50.7 3.47 (bs)  
8a 117.7   118.3   
9 146.2   145.8   
10 145.8   145.4   
11 106.6 6.67 (d) 8.5 106.3 6.74 (d) 7.5 
12 124.9 6.65 (dd) 8.5, 1.5 125.1 6.66 (d) 8.0 
12a 128.8   129.6   
13 46.3 3.79 (s)  46.1   
14 194.8   194.8   
14a 136.0   136.0   
2,3-OCH2O 101.1 5.93 (s)  101.1 5.96 (s)  
7-CH3 41.3 1.93 (s)  41.1 1.79 (s)  
9,10-OCH2O 100.7 5.91 (s)  100.7 5.93 (s)  
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4.4.2     Scoulerine  
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a.  Physico-chemical properties 
This alkaloid was isolated as a dark brown solid compound. The alkaloid was optically 
active ([α]D24 = −282, c = 0.74 in MeOH) and had a high melting point (153-157o C, 
decomposition). This compound was isolated previously from many other plants as 
described earlier in this chapter and had a reported melting point of 155oC and an 
optical rotation of [α]D28 = −289 (c, 0.62 in MeOH)47. Thus the optical rotation and 
melting point of the alkaloid closely resembled that of scoulerine.  
 
b.  Spectral analysis of Scoulerine 
The LRCIMS gave an MH+ peak at m/z 328 and the HREIMS indicated the molecular 
formula as C19H21NO4 which suggested an index of hydrogen deficiency of 10. In the 
HREIMS, the molecular ion and ion fragments were observed at m/z 327 (100%, M+), 
326, 312, 310, 207, 179, 178 (100%), 176, 162, 150, 149 and 135. The MS-library was 
searched for a match and it was found that the alkaloid matched the MS spectrum of 
scoulerine (Figure 13). Major fragments appeared at m/z 135, 150, 176, 178 and 326, 
corresponding to the favoured cleavage of tetrahydroberberines191,192. Thus, from this 
spectral matching and the close proximities of its physico-chemical properties to that of 
scoulerine, the alkaloid was identified as scoulerine 41. It is also biosynthetically 
plausible.  Slight variations in melting point, optical rotation and peak fragments were 
observed because of experimental variation and some very minor impurities. 
The literature on the 1H-NMR of scoulerine191 reported the presence of two O-methyl 
groups (s, τ 6.18), four aromatic protons (τ 3.1-3.5) and the absence of the N-methyl 
group in the spectrum. Another publication on scoulerine193 reported the presence of 
signals ascribed to the 2-OH at 5.26 ppm (2H, bs), the 2-OMe group at 3.85 ppm (6H, 
s), and an AB-quartet at 3.48 ppm and 4.21 ppm with a coupling constant of 16 Hz. 
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When the 1H-NMR spectrum of the isolated alkaloid was compared with the above data 
reported in the literature, they corresponded well.  
 
          m/z 
         Figure 13.  HREIMS spectrum of the alkaloid (top) and that of scoulerine (bottom). 
 
 
Figure 14. 1H-NMR spectrum (300 MHz, CD3OD, TMS) of the alkaloid (identified as scoulerine) 
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In the 1H-NMR spectrum (Figure 14) of the isolated alkaloid, the signal assigned to the 
2-OMe group resonated at 3.24 ppm (s) and 3.21 ppm (s), the 2-OH group resonated at 
5.38 ppm (s), and the ABX system resonated at 3.52 ppm (q) and 4.14 ppm (d) with a 
coupling constant of 15.9 Hz. Signals for the four aromatic protons were observed 
between 6.54-6.72 ppm. The slight differences observed could be due to the different 
NMR solvents used in the experiments. Therefore, this comparative study further 
confirmed that the alkaloid was scoulerine. 
 
4.4.3  Cheilanthifoline  
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a.  Physico-chemical properties 
This UV active alkaloid was obtained as a pale green solid and was recrystallised from 
MeOH/diethyl ether. This alkaloid was also a known alkaloid. Its optical rotation 
([α]D20= −262 , c = 0.60 in CDCl3) and the melting point (168-170.4oC, decomposition) 
corresponded broadly to that of cheilanthifoline whose melting point was reported as 
184oC and its optical rotation as [α]D20   = −311 (MeOH)47. In another report, its melting 
point was reported to be 170o C (decomposition) and the optical rotation of [α]D20 = 
−315193. The difference in optical rotation observed may be due to the different solvent 
used.  
 
b.  Spectral analysis 
In the LRCIMS, an MH+ peak was observed at m/z 326 for the alkaloid. The HREIMS 
indicated its molecular formula as C19H19NO4 and hence an index of hydrogen 
deficiency of 11. In the LREIMS spectrum of the alkaloid, the main ion fragments were 
observed at m/z 325 (M+), 177 and 148 (100%) suggesting that the alkaloid was a 
protoberberine base194. When this LREIMS spectrum of the alkaloid was searched in 
the mass spectrometer library, it was found to correspond with that of 
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cheilanthifoline193 (Figure 15). Based on this comparative analogy, the alkaloid was 
identified as cheilanthifoline. 
To further confirm the identification, the 1H-NMR spectrum (Figure 16) of the alkaloid 
was obtained and its chemical shifts were compared with the 1H-NMR data of 
cheilanthifoline reported in the literature193. In the 1H-NMR spectrum of the alkaloid 
isolated here the methoxy group signal resonated at 3.87 ppm (s, 3H, OMe), the 
methylenedioxy resonated at 5.93 ppm (d, 2H,-CH2-) and the C-8 methylene protons 
resonated at 3.53 (q) and 4.09 ppm (d, J=15 Hz).  
 
m/z 
    Figure 15.  LREIMS of the unknown alkaloid (top) and that of cheilanthifoline (bottom) 
   
Solvent peak
Four aromatic protons
Methylenedioxy protons
OMe
C-8 methylene protons
OH
 
     Figure 16.  1H-NMR (500 MHz, CDCl3, TMS) of the alkaloid (cheilanthifoline). 
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These chemical shifts were in agreement with the 1H-NMR values of cheilanthifoline 
reported in the literature193 in which the methoxy group (s, 3H, OMe) signal resonated 
at 3.85 ppm, the methylenedioxy resonated at 5.90 ppm (d, 2H, -CH2-) and the C-8 
methylene resonated at 3.48 ppm (q) and 4.21 ppm (1H, d, J = 16 Hz). The 1H-NMR 
spectrum of the alkaloid also indicated the presence of the hydroxy group at 1.25 ppm 
and the four aromatic protons (m) between 6.59 ppm to 6.81 ppm. The DEPT 
experiment of the isolated alkaloid, though not clear, distinctly showed the presence of 
four methylene groups in the structure. This comparative analysis of the data on 1H-
NMR further confirmed that the alkaloid was cheilanthifoline 47. 
 
4.4.4     Stylopine  
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a.  Physico-chemical properties 
This known alkaloid was isolated as a brown solid. It had a melting point of 163-165o C 
(decomposition) and was optically active with [α]D24 = −304 (c, 0.56 in MeOH). The 
literature47 has reported the melting point of stylopine as 2040C and an optical rotation 
of [α]D23 −310. In other literature on stylopine, its melting point was reported as 220-
221°C175 and 194-195°C195 and no consistency was observed in the melting points of 
this alkaloid. The differences in these physicochemical properties could be due to 
instrumentation error. However, spectral analysis confirmed that the alkaloid was 
stylopine 42. 
 
b. Spectral analysis 
The LRCIMS gave a MH+ peak at m/z 324. The HREIMS indicated a molecular 
formula of C19H17NO4 for the alkaloid and hence an index of hydrogen deficiency of 
12. In the LREIMS of the alkaloid, the major ion fragment peaks were observed at m/z 
323 (M+), 322, 174 and 148 (100%) and this corresponded to the ion fragmentation 
pattern of stylopine195. When the mass spectrometer library was searched for its match, 
it was confirmed that the alkaloid was stylopine (Figure 17). 
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        Figure 17.   LREIMS of the alkaloid (top) and that of stylopine (bottom). 
 
4.4.5  CG-337 
This UV absorbing compound was a minor alkaloid. The HREIMS indicated a 
molecular formula as C19H15NO5 and hence an index of hydrogen deficiency of 13. 
Since the amount of the alkaloid was very small, not enough data was obtained for 
identifying the alkaloid. 
 
4.4.6   9-Octadecenamide  
            
NH2
O
48  9-octadecenamide  
This non-alkaloid compound was isolated as white solid. The LRCIMS gave an MH+ 
peak at m/z 338 and HREIMS confirmed its molecular formula as C22H43NO. In the 
HREIMS, ion fragments were observed at m/z 337 (M+), 319, 277, 136, 122, 97, 83, 72, 
69, 59 (100%), 43, and 41. 
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      Figure 18.   HREIMS of compound (top)and that of  9-octadecenamide (from library, bottom). 
 
The compound was identified as 9-octadecenamide based by the MS library matching 
(Figure 18). This fatty acid amide occurs naturally in plants and has been isolated 
before from Vetiveria zizanioides196 and Clausena lansium197 (collected in Hainan 
Island, China). 9-octadecenamide was also isolated from the freshwater green algae 
Rhizoclonium hieroglyphicum growing in the Ural Mountains198 as its major 
component (2.26%). 
Another two non-alkaloid compounds with molecular mass 337 and 335 were also 
isolated as white solids (Chapter 9).  
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Chapter 5 
Alkaloids from Tribulus terrestris Linn. 
 
 
 
 
 
 
 
 
5.1     Botanical Description and Ethno-medical use 
Tribulus terrestris is a prostrate annual herb. It is known as goathead in the USA, 
“Ying-jili” in China and dZe-ma ra-go-ma in Bhutan. The genus Tribulus comprises of 
approximately 20 species which grow as shrubs about 10-60 cm high199,200. It is 
considered a noxious weed and is found abundantly on roadsides and vacant lots with 
many reddish branches spreading radially from a central point. It has small oppositely 
arranged pinnate leaves with three to seven branching green oblong leaflets (3-7 cm 
long)201. It gives yellow flowers202. The fruits are light brown when mature and 
measure about a centimeter in diameter. It has sharp spines (2 spines measuring 2-3 
cm) accompanied by several spikes around it201. The fruits and seeds are of great 
importance to traditional or natural medicines practiced worldwide (Table 23). 
 
Table 23.  Traditional medicines using Tribulus terrestris Linn 
Traditional 
Medicines 
 
Ethno-medical use 
Bhutanese Kidney and its related disorders, impotence and as diuretics. 
Bulgarian           Libido enhancer and treating infertility203. 
Chinese   
 
Calm liver, dizziness, headache, premature  ejaculation, cardio-vascular 
diseases204, acute conjunctivitis and vertigo205. 
Greeks  As a diuretic, mood enhancer, headache, constipation, sexual dysfunction, 
hypertension and hypercholesterolemia206,207. 
Indians     As a diuretic, antiseptic and  anti-inflammatory203. 
Pakistanis    As a tonic and aphrodisiac. 
Turkish   As a diuretic, for colic pain and  hypercholesterolemia207. 
 
However, the plant had been found to have adverse toxic effects on livestock, 
especially on sheep. The ingestion of its leaf and foliage in large quantities caused the 
Family:    Zygophyllaceae 
Genus:   Tribulus 
Species:   terrestris 
Common name:  Puncture vine or Caltrop fruit 
gSo-ba Rig-pa name:   dZe-ma-ra-go-ma 
Distribution:  Cosmopolitan 
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hepatogenous photosensitization, known as geeldikkop, tribulosis ovis or yellow 
bighead in sheep and goats208,209. The outbreak of this disease has been reported in 
South Africa208, Australia108,109,210, United States211, Argentina and Iran ever since 
1932209.  
 
5.2     Chemical and Pharmacological Studies of Tribulus species 
Owing to ethno-medical claims and also after the tragedy of photosensitization 
outbreak in sheep, the plant has been extensively investigated by a number of workers 
in those countries. The presence of steroidal glycosides, steroidal saponins, flavonoids 
and alkaloids in the plant have been reported107. Saponins such as glucopyranosyl, 
galactopyrans, ruscogenin, hecogenin, gitogenin, titogenin, protodioscin, diosgenin and 
yamogenin212,213; sterols such as sitosterol, and campesterol; flavonoids such as 
kaemferol, kaempferol-3-glucoside, tribuloside and quercetin214,215; and other 
constituents like fatty acids, polysaccharides, tannins,  amino acids and potassium salts 
have been isolated from this plant.  
Alkaloids like norharman 49, harman 50, harmol 51, harmine 52, 3-hydroxymethyl-
norharman 53, harmalol 54, harmaline 55, tetrahydronorharman 56, tetrahydroharman 
57, 2-ethyltetrahydro-norharman 58, tribulusterine 59, and amides such as 
terrestriamide, terrestribisamide, N-p-coumaroyltryamine and cinnamic amide110,205,216 
were also isolated from the plant. At least five such alkaloids were isolated from the 
Australian Tribulus terrestris and harman and norharman were found out to be the main 
alkaloids of this plant107,217. Recently, the structure of tribulusterine 59 has been revised 
to that of perlolyrine with a 5-hydroxymethyl substituent in the furan ring218. 
The saponins and the β-carboline alkaloids in Tribulus terrestris have been reported to 
have shown a wide range of pharmacological activity219. It was suggested that steroidal 
saponins, diosgenin and yamogenin caused the geeldikkop diseases220. When the 
synthetic harman and norharman were administered subcutaneously to sheep at a dose 
rate of 54mg/kg, it was found that both of them caused similar nervous system effects 
(mainly limb paresis)110. This result suggested that the β-carboline alkaloids were 
responsible for causing staggers in sheep. Tribulus terrestris also treats impotence, 
increases sperm count (50%) and serves as a natural testosterone enhancer that 
invigorates and boost strength, stamina, muscles growth, fat loss and libido. 
Protodioscin was reported to be the main active steroidal saponin exhibiting 
aphrodisiac properties221,222.  
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A cream made from an extract of this plant showed very strong antibacterial, anti-
inflammation, anti-virus, anti-herpes effects and in some cases was found to block the 
growth of cancer cells223. It was suggested that the activity of the Tribulus terrestris 
extracts could be due to unknown steroidal saponins224. Tribulosin and β-sitosterol-D-
glucoside from Tribulus terrestris showed anthelmintic activity with ED50 values of 
76.25 and 82.50 μg/ml respectively225. Tribusponin was found to be a useful as an 
antisclerotic agent226. Some β-carboline alkaloids, flavonoids, kaemferol and quercetin 
are known to have antimicrobial effects227,228.  
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56   Tetrahydronorharman:           R2 = H, R2 = H
57   Tetrahydroharman:                R1 = CH3,   R2 = H
58   2-Ethyltetrahydronorharman: R1 = H, R2 = CH2CH3
 
54   Harmalol:                               R = OH
55   Harmaline:                             R = OCH3
49   Norharman:                           R1 = H, R2 =H, R3 =H
 
50   Harman:                                R1 = CH3, R2 = H, R3 = H
51   Harmol:                                 R1= CH3, R2 =OH, R3= H
52   Harmine:                               R1 = CH3, R2 = OCH3, R3 = H
53   3-Hydroxymethylnorharman: R1 = H, R2 =H, R3 = CH2OH
                     
  
N
H
N
O
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59  Tribulusterine  
 
The search for new such bioactive saponins and β-carboline alkaloids is still 
proceeding. This study is directed towards the Australian sourced Tribulus terrestris 
species and aimed to isolate new minor alkaloids (if any) present in the plant. 
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5.3 β-Carboline Alkaloids and Classification 
β-Carboline alkaloids are defined as heterocyclic amines with a 9H-pyrido[3,4-b] 
indole structure and they are found in various plants including edible plants229. These 
alkaloids are biosynthetically derived from the amino acid L-tryptophan. They were 
first isolated from the plant Peganum harmala L and based on this, the β-carbolines are 
also known as harmala alkaloids107. Since then, they have been reported in a variety of 
plant families including the Leguminoseae, Malpighiaceae, Rubiaciae, Rutaceae, 
Graminae, Simaroubaceae and Zygophyllaceae.  
The β-carboline derivatives include C-1 unsubstituted β-carbolines (e.g 1, 2, 3, 4-
tetrahydro-6-methoxy-2-methyl-β-carboline), the C-1 methyl substituted harman group, 
the C-1 vinyl, acyl or carboxyl substituted group, and the C-3 substituted group47. 
Many groups of β-carboline alkaloids have also been isolated from marine sources. 
Only recently two new β-carbolines, eudistomin-W 60 and eudistomin X 61 which 
exhibited antibiotic activity toward Bacillus subtilis, Staphyloccocus aureus and 
Escherichia coli and fungicidal activity against Candida albicans, were discovered in a 
Micronesian ascidian Eudistoma species230. 
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60  Eudistomin W 61 Eudistomin X  
 
It was suggested that the pathway for the biosynthesis of these β-carboline alkaloids 
involves tryptophan, tryptamine and then 1-methyl-1,2,3,4-β-carboline-1-carboxylic 
acid107. Stolle and GrÖger proposed that condensation of tryptamine with pyruvic acid 
formed the β-carboline ring of harman with 1,2,3,4-tetrhydro-β-carboline-1-carboxylic 
acid as an intermediate product 231. 
 
5.4 Attempted Isolation of β-Carboline Alkaloids from Tribulus terrestris Linn. 
Aerial parts of Tribulus terrestris Linn were collected in New South Wales by Dr. C. 
Bourke (NSW Agriculture, Orange) and the plant material was dried before processing. 
The regular process of solvent extraction, fractionation, separation (PTLC) and 
purification of the plant’s crude extract unfortunately gave no alkaloid fractions. The 
 
 
85 
extraction procedure was kept specific for alkaloids, but the major component isolated 
gave an MH+ peak at m/z 209 (LRCIMS) and absorbed the UV light but didn’t give a 
positive alkaloid test with Dragendorff’s reagent. HRCIMS indicated a molecular 
formula of C11H13O4. The compound was identified as 3,4-Dimethoxycinnamic acid 62 
based on the comparative analysis and the 1H-NMR spectral peaks of the compound 
with those reported in the literature47. Extra peaks observed in the 1H-NMR of the 
compound were from small impurities.  
 
                 
MeO
MeO
H
H
COOH
62  3,4-Dimethoxycinnamic acid                                                    
 
3,4-Dimethoxycinnamic acid occurs naturally and has been isolated before from plants, 
Zanthoxylum acutifolium (leaf)232 and Milletia ovalifolia (seed)233, and also from 
beeswax234. 
Although some crude fractions also showed CI peaks at m/z 213, m/z 183 and m/z 265 
corresponding to those expected for harmine, harman and perlolyrine, none of these 
could be isolated for structural confirmation. TLC analysis revealed that these 
compounds had similar retention factors as those of the standards: harmine, harman and 
perlolyrine. Extractions of the plant material with different solvents were also 
conducted but no substantial amount of crude alkaloid could be recovered. It should be 
noted that the dried plant material gave only a very faintly positive Culvenor Fitzgerald 
test106 for the presence of alkaloids. This confirmed that the alkaloid content of the 
plant was extremely low which could have been caused by either inappropriate drying 
of the plant material or its time of collection. Extreme drying and exposure to light can 
cause some alkaloids to degrade. As discussed in Chapter 1, alkaloid content may also 
vary from season to season and with geographical location. Alkaloid yields may be thus 
improved by collecting the plant at an appropriate time. Further collections of the plant 
were not conducted due to time constraints. 
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Chapter 6 
Investigation of Ranunculus brotherusi Freyn for alkaloids 
 
    
 
  
 
 
6.1     General Introduction 
Ranunculus brotherusi is an erect plant with yellow flowers. This plant is used in the 
traditional medicine of Bhutan as an antipyretic and for treating infections and wounds. 
The genus is found in aquatic and terrestrial habitats. Some Ranunculus species have 
been found to cause diarrhoea, drooling, licking air, teeth grinding, excessive chewing, 
paddling and death in cattle235. Other studies have shown that Ranunculus species 
(Ranunculus acer) contain a vesicant toxin called ranunculin that is released upon 
mastication236,237.   
 
6.2     Phytochemical and Pharmacological Studies of the genus Ranunculus 
Many saponins, flavonoids and glycosides have been isolated from this plant. 
Stigmasterol, hexadecanoic acid, eicosanoic acid, nonacosanol, ternatolide A and 5-
hydroxy-benzaldehyde were isolated from Ranunculus ternatus238. Coumarins like 
aesculetin (6,7-dimethoxycoumarin) and scopoletin 63, which showed potent antiviral 
and cytotoxic activity, were isolated from the Egyptian species Ranunculus asiaticus 
L239. Four major quercetin triglycosides, namely quercetin 3-sophoroside-7-glucoside, 
quercetin 3-sambubioside-7-glucoside and quercetin 3-diglucoside were isolated along 
with other components from an Antarctic Ranunculus species240. 
Alkaloids have also been found in Ranunculus species. For example, protoberberine-
type quaternary alkaloids like palmatine 64, berberine 65 and columbamine 66, and the 
benzylisoquinoline-type magnoflorine 67, were isolated from the rhizomes of 
Ranunculus serbicus241. The leaf extract of Ranunculus sceleratus L. showed a rapid 
fungicidal action, tolerance against heavy fungal inoculum, activity on a broad pH 
range, broad fungicidal spectrum, and no phytotoxicity with a lethal dose of 1:40 
dilution242. Phytochemical investigation of this plant species led to the isolation of the 
glycoside ranunculin, its aglycone protoanemonin 68, and anemonin 69243. 
  
Family:   Ranunculaceae 
Genus:   Ranunculus 
Species:   brotherusi  
gSo-ba Rig-pa name:  lche-tsa 
Distribution:   Himalayas 
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Protoanemonin was also isolated from Ranunculus oxyspermus M.B. and Ranunculus 
acer244. It was suggested that protoanemonin has hepatotoxic activity245. It showed 
bacteriostatic and bactericidal activity against a large number of Gram-positive and 
Gram-negative bacteria as well as fungistatic activity against Saccharomyces cerevisiae 
and Candida albicans246. An extract of Ranunculus japonicus showed analgesic and 
anti-inflammatory effects when determined in several animal models (mice and rats)247. 
 
6.3     Investigation of Ranunculus brotherusi Freyn for Alkaloids 
The methanol extract of Ranunculus brotherusi only afforded a very small quantity of 
crude alkaloid material after an acid/base separation. This separation gave many UV-
active fractions, but none of them gave any positive results when tested for alkaloids 
with Dragendorff’s reagent. The sequential extraction was repeated by increasing the 
pH from 9 to 11 and then to 13 using aqueous sodium hydroxide. A liquid-liquid 
extraction was then performed using different solvents like chloroform, 
dichloromethane and ethyl acetate but still no alkaloids were obtained. The Culvenor-
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Fitzgerald test was performed for this plant before the methanol extraction was 
conducted and it gave a faint positive test. No further work was done on this plant due 
to time constraints.  
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Chapter 7 
Microbiological Bioassay  
7.1 General Introduction 
As discussed in Chapter one, medicinal plants offer a vast resource of interesting 
bioactive lead compounds. Studies of the Structure-Activity Relationships of the leads 
combined with computer-aided modelling should then result in molecules with optimal 
activity, better bioavailability, fewer side effects and an acceptable therapeutic index 
and consequently, good candidates for the development to new drugs248.  Thus, one of 
the key steps in the methodology of drug development is the bioassaying or the testing 
of activities of the plant isolates. To conduct the bioassays, efficient collaborations with 
pharmacologists, medical doctors, plant pathologists and biologists may sometimes be 
crucial, and there are relatively few simple laboratory-based in vitro methods which 
could be performed by chemists alone249. 
Bioassays involve quantitation of the response which follows the application of a 
stimulus to a biological system250. The bioassays are performed on crude extracts 
especially in bioactivity-guided screening or on blindly purified compounds249. The 
bioassays can be best divided into general screening bioassays and the specialized 
screening bioassays. Antimalarial testing is one example of a specialised screening 
bioassay. The general screening bioassays can be further classified to broad screening 
bioassays and primary screening bioassays. Primary screening bioassays include the in 
vivo animal assays (even involving human volunteers) and the in vitro microbiological 
assays248.   
The microbiological bioassays involve the detection of antibacterial and antifungal 
activities and potencies (Minimum Inhibitory Concentration; MIC) of compounds using 
different end point methods like plate assays (agar diffusion assay) and tube assays 
(agar dilution streak assays and broth dilution MIC assays)250,251. Due to the 
requirement of a long incubation time, the agar diffusion assay (plate assay) cannot be 
used for volatile and unstable compounds and therefore, agar-overlay methods (agar 
dilution methods or liquid media methods) have normally been followed.  
In the agar-overlay methods, the degree of antimicrobial activity and the MIC of a 
compound are greatly influenced by factors like “compound concentration, carbon 
dioxide and oxygen concentration, media compatibility with the test compound, 
solubility and stability of the test compound, pH of the medium, types nutrient of 
media, temperature, the duration of the exposure to the compound and the types of 
strains (bacterial, fungal or viral) used in the testing”54,58. For these reasons, growth 
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promoting or inhibiting potencies of test samples have to be standardised and compared 
with standard preparations of the test compound250. Thus, the choice of antimicrobial 
bioassay method has to be selectively adapted taking the above factors into 
consideration. Such methods should be sensitive enough to detect active principles, the 
minimum inhibitory concentrations, and the dose response of the microorganisms 
(bacteria and fungi). A comparison of the disk diffusion method, the hole-plate 
diffusion method and the bioautographic TLC assay showed that the nature and amount 
of substance influence to a great extent the selection of the test method252.  
A number of alkaloids (about 300) have been shown to possess antimicrobial 
activity253. Screening of medicinal plants used in traditional medicines has shown that 
the incidence of antimicrobial activity found is much higher than for random 
screening253. In conjunction with this, alkaloids isolated from some of the traditional 
medicinal plants of Bhutan were analysed here for their antibacterial and antimalarial 
activities. 
 
7.2     Assays for Detecting Antibacterial Activity 
To test if a sample can exert antibacterial activity, it should preferably be made up into 
an aqueous solution by dissolving in water254. If it is insoluble in water, 
ultrasonification should be first tried and if that too fails, water miscible organic 
solvents like methanol, acetone or the use of emulsifying agents, are other 
options254,255. In such cases, however, care must be taken to avoid false test positives 
due to lethality of the uncontrolled final concentration of the solvent or emulsifying 
agents.  
The antibacterial activity assay is distinguishable into bacteriostatic activity and 
bactericidal activity. Bacteriostatic activity of the compounds refers to stopping or 
inhibiting bacterial growth and multiplication. Bactericidal activity is the property of an 
antibacterial agent responsible for killing bacteria. Both disk diffusion assay and broth 
methods can be used to examine bacteriostatic activities but the bactericidal activities 
can be detected only by microscopic analysis or by the assessment of bacterial cell 
recovery in fresh media58 .   
Susceptibility of Mycobacterium tuberculosis to antimicrobial agents has been tested 
by the bioluminescent assay (ATP) method, the Mycobacteria Growth Indicator Tube 
(MGIT) method, the MIC method and the M24-T agar proportion method. It was found 
that the ATP method was the most rapid and reliable method for the assessment of drug 
(antibacterial) susceptibility testing256. The Fluorescein Diacetate (FDA) Assay, based 
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on the enzymatic hydrolysis of fluorescein diacetate to fluorescein, is suitable for use 
with a wide range of different microorganisms and was recommended for determining 
the MIC of crude extracts and purified compounds257. This method is commonly used 
in antibacterial testing, although problems can arise with fluorescent components in the 
growth media or fluorescence of the test compound. Kamia et al. also has reported that 
the turbidometric assay was rapid, reproducible and a very useful method for 
quantitative estimation of antibacterial activity258.  
 
7.2.1  Results of the Antibacterial Testing 
The crude methanol extracts (AO-ME and CG-ME), crude alkaloids (AO-CEA and 
CG-CEA), atisinium chloride, orochrine and protopine (CG-354) obtained from 
Aconitum orochryseum Stapf. and Corydalis gerdae Fedde were sent for antibacterial 
assay at the Amrad Corporation Laboratories, Melbourne using the antibacterial 
screening methodology described in Chapter 9. All the samples were prepared in 
DMSO (2.5%) solution. The crude plant extracts and the alkaloids were tested against 
Staphylococcus aureus and all these samples showed very weak activity against this 
bacterium with MIC values greater than 125 µg/ml. Atisinium chloride and orochrine 
were tested against vancomycin-resistant and vancomycin sensitive Enterococcus 
faecium. These alkaloids were also found to be essentially inactive against this 
bacterium with similar MIC values (>125 µg/ml). 
Antibacterial tests could not be conducted on the other alkaloids isolated in this project 
since they were available in very small quantities. However, from the results obtained, 
antibacterially active components did not appear to be present in Aconitum 
orochryseum or Corydalis gerdae, at least for Gram-positive bacteria. 
  
7.3  Assays for Detecting Antimalarial Activity 
Different types of antimalarial test methods like biochemical and molecular techniques, 
colorimetric enzyme assays, flow cytometry, and micro-dilution assays, have been 
developed over the past years259. The colorimetric enzyme assay which was described 
by Basco et al. is based on the measurement (using spectrophotometry)260 of the 
activity of the enzyme lactate dehydrogenase in living Plasmodium falciparum and 
Plasmodium ovale. A semi-automated micro-dilution assay261 involves the inhibition of 
uptake of a nucleic acid precursor, 3[H]-hypoxanthine, in to the malarial protozoa. A 
modified form of this method was used in this study.  
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A simple and reproducible method has also been described by Pandey et al and 
modified micro-dilution assay methods has been routinely used in the identification of 
potential antimalarial compounds54.   
 
7.3.1  Results of Antimalarial Testing  
The pharmacopeia of Bhutanese Traditional Medicine (gSo-ba rig-pa) had indicated 
Corydalis gerdae for the treatment of malaria and Aconitum orochryseum for treating 
infections, snake bites and high fever arising from blood poisoning, cold and flu, bile 
inflammation and malaria105. Based on this ethno-medical information, in vitro 
antimalarial activity testing against Plasmodium falciparum, for both an antifolate 
sensitive strain (TM4) and an antifolate resistant strain (K1) was performed on the 
crude methanol plant extracts, crude alkaloids and the major alkaloids of these two 
plants.  
The methanol extracts, crude alkaloids and the major alkaloids (protopine and atisinium 
chloride) of these two plants were found to be active against both strains of 
Plasmodium falciparum. Comparably, Corydalis gerdae was found to possess active 
antimalarial compounds. The methanol extract (CG-ME) of this plant (Corydalis 
gerdae) inhibited the TM4 strain with an IC50 value of 1.00 µg/ml and the K1 strain 
with an IC50 value of 2.56 µg/ml. The inhibitory activity of the crude alkaloid (CG-
CEA) of the same plant increased significantly with IC50 values of 0.33 µg/ml for the 
TM4 strain and 0.63 µg/ml for the K1 strain. However, decreased antimalarial activities 
of the alkaloids, protopine and cheilanthifoline, were observed. Protopine inhibited the 
TM4 strain with an IC50 value of 4.25 µM (1.50 µg/ml) and the K1 strain with an IC50 
value of 4.29 µM (1.51 µg/ml). Cheilanthifoline inhibited the TM4 strain and the K1 
strain with IC50 values of 2.78 µM (0.90 µg/ml) and 3.76 µM (1.22 µg/ml) respectively. 
This suggested perhaps that a minor alkaloid was responsible for the high activity 
exhibited by the crude alkaloid extract. The high activity of this extract could also be 
due to the synergistic effects of the total range of alkaloids present. 
The methanol extract of Aconitum orochryseum inhibited the TM4 strain with an IC50 
value of >10 µg/ml and the K1 strain with an IC50 value of >10 µg/ml. The crude 
alkaloid extract showed increased antimalarial levels and inhibited the TM4 strain with 
an IC50 value of 20.4 µg/ml and the K1 strain with an IC50 value of 19.2 µg/ml. The 
antimalarial activity very significantly increased for the pure alkaloid atisinium 
chloride (the major alkaloid of the plant). This alkaloid inhibited the K1 Strain with an 
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IC50 value of 3.59 µM (1.35 µg/ml) and the TM4 Strain with an IC50 value of 4.02 µM 
(1.51 µg/ml). Though atisinium chloride was reported previously, no antimalarial 
testing has been done before on this alkaloid. Thus, from the above antimalarial assay 
results, it was evident that these two plants, Aconitum orochryseum and Corydalis 
gerdae contain bioactive alkaloids which are potential antimalarial drug leads.  
The antimalarial assay was not done for the rest of the alkaloids isolated from these two 
plants since their quantities were too small. It would be worthwhile to synthesise the 
new alkaloids and test them for malaria along with the known alkaloids isolated from 
Corydalis gerdae. The high activity of the crude alkaloid of Corydalis gerdae could be 
either due to scoulerine or stylopine, which was not tested. It was also possible that 
some minor alkaloids were responsible for the high activity of this crude alkaloid 
mixture or all the alkaloids present in the mixture might have acted synergistically to 
bring in that high activity against K1 and TM4 strains. Alkaloids from Aconitum 
orochryseum could also possibly have antiviral activities since the plant was indicated 
ethno-medically for treating cold and flu. 
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Chapter 8 
Conclusions and Future Directions 
8.1     Conclusions 
Infectious diseases like HIV-AIDS, tuberculosis, malaria and other viral and bacterial 
infections are claiming millions of lives every year. These diseases will continue to be 
leading causes of death unless researchers find a concrete arsenal of drugs to combat 
them. One approach is to search for such new drugs from natural sources. Bhutan is one 
of the countries that is rich in biodiversity as well as being rich in traditional medical 
knowledge. It thus has the potential to contribute towards discovering natural product-
based drugs.  
Systematic natural product screening should be based on appropriate search strategies 
for efficient drug discovery. Since Bhutan has a reservoir of ethno-medical knowledge, 
the “ethno-directed biorational approach” provided such a strategy in combination with 
a chemo-directed approach based on alkaloids. The author has successfully engaged 
this joint strategy for this study in which plant selection was directed by the traditional 
medicine of Bhutan used for antibacterial or antimalarial treatments (ethno-directed 
biorational approach) and the presence of alkaloids in these plants (chemo-directed 
approach).  
The alkaloids from six selected plants were investigated. From Aconitum orochryseum 
Stapf., eleven alkaloids were isolated. Three of these were identified as new diterpenoid 
alkaloids and were named as orochrine, 2-O-acetylorochrine and lingshinaline. The 
crude methanol extract (AO-ME), crude alkaloid mixture (AO-CA), and the alkaloids 
atisinium chloride (AO-344, major alkaloid) and orochrine (AO-342) were inactive 
against the Gram-positive human pathogenic bacteria Staphylococcus aureus and 
Enterococcus faecium. However, in vitro activity was seen against the malarial 
protozoan Plasmodium falciparum (strains TM4 and K1, see Table 24 for the 
summarized results). Atisinium chloride gave the highest antimalarial activity among 
the analytes obtained from this plant. Although this alkaloid had been isolated 
previously from other species in the genus Aconitum, it had not been tested against 
malaria. Atisinium chloride thus provides a new anti-malarial drug lead. The other 
alkaloids (orochrine, 2-O-acetylorochrine, lingshinaline, virescenine and unidentified 
alkaloids) isolated from Aconitum orochryseum could also have similar activity, but 
due to the small quantities obtained, it was not possible to conduct an antibacterial 
assay and antimalarial assay on these alkaloids.  
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Table 24.  The summary of the results of alkaloid investigation of the plants 
 
Plants 
 
Alkaloids 
Antibacterial activity 
(IC50 in µM) 
     Staph.            VRE 
Antimalarial activity  
(IC50 in µM or µg/ml) 
TM4 strain     K1 strain 
Aconitum 
orochryseum 
Stapf. 
Methanol extract (AO-ME) >125 N/T >10 µg/ml >10 µg/ml 
Crude alkaloid (AO-CA) >125 N/T 20.4 µg/ml 19.2 µg/ml 
Atisinium chloride >125 >125 4.02 µM 
1.51 µg/ml 
3.59 µM 
1.35 µg/ml 
Orochrine >125 >125 N/T N/T 
2-O-acetylorochrine N/T N/T N/T N/T 
Lingshinaline N/T N/T N/T N/T 
Virescenine N/T N/T N/T N/T 
AO-330 N/T N/T N/T N/T 
AO-340 N/T N/T N/T N/T 
AO-358 N/T N/T N/T N/T 
AO-372 N/T N/T N/T N/T 
AO-414 N/T N/T N/T N/T 
AO-465 N/T N/T N/T N/T 
Corydalis 
gerdae 
Fedde.  
 
Methanol extract (CG-ME) >125 N/T 1.00 µg/ml 2.56 µg/ml 
Crude alkaloid (CG-CA) >125 N/T 0.33 µg/ml 0.63 µg/ml 
Protopine >125 >125 4.25 µM 
1.50 µg/ml 
4.29 µM 
1.51 µg/ml 
Cheilanthifoline N/T N/T 2.78 µM 
0.90 µg/ml 
3.76 µM 
1.22 µg/ml 
Scoulerine N/T N/T N/T N/T 
Stylopine  N/T N/T N/T N/T 
CG-337 N/T N/T N/T N/T 
Staph. = Staphylococcus aureus, VRE = Vancomycin Resistant Enterococcus faecium, Red = new 
alkaloid, Green = known alkaloids, Blue = unidentified, N/T = not tested 
 
From the plant Corydalis gerdae Fedde four known alkaloids, namely protopine (major 
alkaloid), scoulerine, cheilanthifoline and stylopine were obtained, together with one 
unidentified alkaloid. The crude methanol extract (CG-ME), crude alkaloid mixture 
(CG-CA) and the alkaloids protopine and cheilanthifoline were analysed for in vitro 
antimalarial activity. These analytes gave interesting and promising antimalarial 
activity results as summarised in Table 24. The inhibitory activity was highest in the 
case of the crude alkaloid mixture (CG-CA), possibly due to a highly active minor 
alkaloid. It could be also due to synergistic effects amongst the alkaloids present in the 
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mixture. The protopine (major alkaloid) and cheilanthifoline also showed significant 
activity in this assay. 
The extracts and isolates of Corydalis gerdae showed better antimalarial activity than 
those of Aconitum orochryseum. These results substantiated for the first time at the 
molecular level the ethno-medical use of these plants in anti-malarial treatment. 
Ranunculus brotherusi failed to yield any alkaloids although a preliminary test on the 
plant gave a positive test for alkaloids. Similarly, Tribulus terrestris also failed to yield 
any alkaloids. Ranunculus brotherusi had not been studied previously. Many β-
carboline alkaloids like harman, harmine, norharman and harmaline had been isolated 
from Tribulus terrestris in past work. Thus, it was concluded that these plant materials 
were either collected at the wrong time or their alkaloids could have been lost on 
drying. 
 
8.2     Future directions 
Since the extracts and the alkaloids of Aconitum orochryseum and Corydalis gerdae 
were found potentially active against Plasmodium falciparum strains, the immediate 
follow up work should be focused on doing antimicrobial assays with the other minor 
alkaloids present in these plants. In doing so, large scale extraction would be needed to 
get a reasonable amount of the minor alkaloids, especially from Corydalis gerdae 
because the crude alkaloid of this plant showed highest inhibitory activity (Table 24). 
Since the high activity of this crude alkaloid (Corydalis gerdae) could also be due to 
synergistic effects of total alkaloids (protopine, scoulerine, cheilanthifoline and 
stylopine) present in the crude extract, the antimalarial testing should be done on 
various mixtures of commercially available alkaloids (protopine, scoulerine, 
cheilanthifoline and stylopine) so as to find out if the activity of the crude alkaloid was 
because of synergistic effects.  
The six unidentified alkaloids of Aconitum orochryseum require further study and 
further bulk extraction of the plant material will be needed in order to obtain sufficient 
quantities for their structure elucidation and the evaluation of antimicrobial activities. 
Modifying the structures of the new alkaloids as well as of the known alkaloids 
(atisinium chloride, virescenine, protopine, scoulerine, cheilanthifoline and stylopine) 
which were active against Plasmodium falciparum could improve their antimalarial 
activities. This could lead ultimately to the development of candidates for new 
antimalarial drugs.   
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Since Aconitum orochryseum is traditionally used against colds, influenza and other 
microbial infections, it would also be worthwhile undertaking antifungal and antiviral 
(like SARS and HIV) testing on the alkaloids from this plant. The non-alkaloidal 
components of the plants studied here may be bioactive or at least could also be acting 
synergistically with the alkaloids. They should thus also be purified, identified and 
tested for bioactivity in the future. 
The results obtained in this study indicate that the combined ethno-medical-alkaloid 
search strategy is an efficient and direct one for locating potential new drug leads. The 
application of the strategy to other medicinal plants in Bhutan should thus be 
investigated. The chemical and pharmacological investigation of traditional Bhutanese 
drugs should be pursued in the long term. Such steps would mean a way forward in 
meeting the WHO standards for such drugs and, most significantly, in providing 
patients with better herbal medicines. 
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Chapter 9 
Experimental Section 
9.1     Equipment and Chemical Specifications 
9.1.1.    Equipment 
Preparative thin layer chromatography plates were made using Merck Kieselgel 60 
PF254 on glass plates (0.3 mm thickness, 20 × 20 cm). Pre-made silica plates with 
aluminium backing (0.2 mm thickness) supplied by Merck were used for separating 
smaller quantities of isolates. Visualization of the separated bands on preparative TLC 
plates was done using short and long wave UV light. Normal pH paper was used for 
determining the pH of the extracts and the solutions. Extracting funnels were used for 
the liquid-liquid separations and sintered glass funnels were used for filtration. A Büchi 
Rotary Evaporator with a high vacuum pump was used for evaporation of solvents 
under reduced pressure at 40oC. Nitrogen gas was used for evaporation of smaller 
quantities of solvents. 
Chemical ionisation mass spectra (LRCIMS) were obtained on a Shimadzu QP-5000 
(isobutane as the carrier gas) spectrometer by the direct insertion technique. Electron 
impact mass spectra (at 70 eV) were also obtained on a Shimadzu QP-5000 
spectrometer. HRCIMS were run on a Fison/VG Autospec oa-TOF Mass Spectrometer 
(methane as the carrier gas). Electrospray (ES) mass spectroscopy was performed on a 
Micro-mass Q-Tof-2TM with acetonitrile as solvent. Gas Chromatographic Mass 
Spectrometric (GCMS) analysis was conducted using a QP-5000 Shimadzu 
Spectrometer and VG Autospec (Fisons Instrument) Spectrometer. For the NMR 
spectra, one dimensional experiments like 1H-NMR, gCOSY, 13C-NMR (at 75.42 
MHz), DEPT and NOESY and two dimensional experiments like gHSQC, gHMBC and 
TOCSY were obtained using a Nanoprobe on a Varian Unity Inova-500 MHz NMR 
Spectrometer unless otherwise stated.  
The melting points were determined using a Reichert hot stage apparatus and were 
corrected. Melting points were corrected using the 2-benzoylbenzoic acid (m.p.126-
129oC) as a standard. The Optical Rotations were measured with a Jasco Dip-370 
Digital Polarimeter with a sodium lamp. The specific rotation was calculated by using 
the equation: [α]tD = α/l.c. where, α = observed rotation at temperature to Celsius, l = 
length of polarimeter cell (dm), and c = concentration of sample (g/100ml). An average 
of ten optical rotation readings was taken for the rotation α-value. 
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9.1.2.     Chemicals and solvents 
All the solvents were AR (analytical reagent) grade or distilled. DCM, chloroform and 
methanol were the main solvents used in carrying out the experiments. Deuterated 
chloroform, methanol, acetone, and acetonitrile were used as NMR solvents. Ethanol, 
diethyl ether, ethyl acetate, acetone and butanol were used for crystallizations unless 
otherwise stated. Methanol (10% v/v) in dichloromethane was used as the solvent for 
dissolving, loading and recovering extracts or compounds from the silica on preparative 
TLC plates. Sodium sulfate was used for drying traces of water in the separated organic 
solvents. Sodium carbonate (20% w/v) and potassium hydroxide (10% w/v) were used 
for the basification of the aqueous plant extracts to a pH of 8-11. Sulfuric acid (0.1 M 
to 1 M) was used for acidification. To improve separation and overcome tailing of 
alkaloids on TLC, concentrated aqueous ammonia (28%, 6 drops and 1 ml) was added 
in the TLC solvent system.  
 
9.2      Detection Methods and Spray Reagent 
Dragendorff’s reagent and Mayer’s reagent were used for the detection of alkaloids in 
the plant extracts. Mayer’s reagent was prepared by dissolving mercuric chloride (1.4 
g) and potassium iodide (5 g) in water (100 ml). 
Dragendorff’s reagent (Munier and Mache-boeuf)262 was prepared as follows: 
a. Bismuth subnitrate (2.5 g) was dissolved in a solution of  
     water (20 ml) and glacial acetic acid (5 ml). 
b.  Potassium iodide (4 g) was dissolved in water (10 ml). 
Solution a and b were then mixed together and stored as the stock solution. The spray 
reagent was prepared by mixing the stock solution (5 ml) with glacial acetic acid 
(10ml) and water (85 ml). On TLC plates, alkaloids gave an orange-red colouration 
with this spray reagent. 
 
9.3  Collection of Plant Material 
Six medicinal plants: Aconitum orochryseum (Ranunculaceae), Aletris pauciflora 
(Liliaceae), Codonopsis bhutanica (Campanulaceae), Corydalis gerdae (Fumariaceae), 
Ranunculus brotherusi (Ranunculaceae) and Tribulus terrestris (Zygophyllaceae) were 
selected for the study. The first five medicinal plants were collected from Lingshi 
Dungkhag (Bhutan) in June and August 2002 (see Chapter 2, Table 8). They were air-
dried at room temperature in the drying unit at Lingshi and were then transported to the 
Pharmaceutical and Research Unit (Bhutan). The herbarium was maintained and stored 
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in the Research Unit with appropriate labelling including herbarium numbers (see 
Chapter 2, Table 8). 
The preliminary test for alkaloids was done in the Pharmaceutical and Research 
laboratory in Bhutan following the Culvenor and Fitzgerald method106. A mortar and 
pestle was used for grounding plant material (10 g) with acid-washed sand. 
Dichloromethane (15 ml) and concentrated aqueous ammonia (5 drops) was then added 
to the ground material and stirred for 5 minutes. The mixture was filtered. The filtrate 
was acidified with 1 Molar H2SO4 (1 ml), shaken thoroughly and then allowed to stand 
for 30 minutes to effect good phase separation. A portion of the aqueous layer (5 drops) 
was transferred into a small petri dish. When the Mayer’s reagent (K2HgI4) was added, 
the solution turned milky with the alkaloid salt precipitate. The turbidity varied from 
plant to plant depending on the percentage of alkaloid content in that plant.  
Since two of the plant extracts from Codonopsis bhutanica and Aletris pauciflora were 
damaged on transportation to Australia and a Ranunculus brotherusi didn’t give any 
alkaloids, a locally available plant Tribulus terrestris, which caused neurotoxicity in 
sheep, was selected for the study. This plant is also used in Bhutanese traditional 
medicine. The air-dried (room temperature) plant material (stem, leaves, flowers and 
fruits, approx. 8 kg) which has been coarse chopped following drying using a petrol 
driven plant mulching machine, was supplied by Dr. C.Bourke, NSW Agriculture, 
Orange, NSW. It was collected near Wellington (Central West, NSW) in February 2002 
(Chapter 2, Table 8). 
 
9.4     General Procedure for Extraction and Isolation of Alkaloids. 
The alcoholic extraction method was applied to all the selected plants. The plant 
material (1 kg) was chopped into small pieces. The material was then soaked overnight 
in methanol (Analytical Grade). The methanol extract was filtered and the process was 
repeated four times (over 4 days) to ensure no alkaloids were remained in the residues. 
All the extracts obtained in each set were combined. The methanol was then removed 
by rotary evaporation. The dried methanol extracts obtained from each plant were then 
packed in glass bottles (250 ml) and then brought to Australia. The residues from the 
methanol extracts were air dried and stored with proper labelling for future reference. 
The extracts were kept refrigerated and away from light (wrapping with aluminium 
foil) prior to further processing. 
Sequential extractions and isolations were done following the schematic procedures 
outlined in Scheme 3. The solvents in the filtrates were evaporated under reduced 
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pressure and the crude alkaloids were obtained. The crude alkaloids were then 
separated using Preparative Thin Layer Chromatography on silica gel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.  Outline of the alkaloid separation procedure carried out for the selected medicinal 
plants of Bhutan and the sources of materials used in the antimicrobial assays. 
Filtrate (MeOH extract) 
 Evaporated MeOH at 40o C 
Residues 
 Dried and stored 
 Soaked in Methanol (4× 17 hrs) 
 Filtered 
 Acidified with 0.1M H2SO4 
 Extracted with CHCl3 (3 × 60 ml) 
Organic phase I 
 Neutral and acidic 
materials (stored) 
Aqueous phase I 
 Basified with 20% Na2CO3 to pH 9/10 
 Extracted with CHCl3 (3 × 60ml)  
 
Organic phase II 
 Washed with H2O 
 Dried with Na2SO4 
 CHCl3  evaporated at 40o C 
Aqueous phase II 
 Water soluble 
materials 
Crude alkaloids 
Chopped plant material (1 kg) 
 Separated and purified using PTLC 
 NMR and identification of alkaloids 
Pure alkaloids 
Tested for 
alkaloids with 
Mayer’s reagent 
Antimicrobial assays (Antibacterial and Antimalarial testing) 
 Tested for alkaloids with 
Dragendorff’s reagent 
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The alkaloids were recovered from the silica gel as soon as the preparative plate TLC 
separation was complete to prevent decomposition. The alkaloids were also kept for 
minimal time in solution in order to avoid reaction and formation of artefacts. The 
appropriate developing solvent system was determined by manipulating the ratios of 
the mixture of different solvents, mainly dichloromethane, chloroform and methanol. 
The TLC separation yielded different fractions of compounds with different polarities. 
Each fraction was tested for purity using TLC, MS and 1H-NMR analysis. The process 
of TLC separation and purification was repeated for each fraction till pure compounds 
were isolated. Concentrated aqueous ammonia solution (28%, 6 drops to 1 ml) was 
used to prevent tailing in the TLC separation. However, the merging of bands on silica 
plates occurred when compounds with closer Rf values were present together. 
 
9.5     Purification and Structure Elucidation of Alkaloids from Aconitum 
orochryseum Stapf. 
A methanol extract (101.65 g) was obtained from the dried plant material (1 kg) and a 
reference sample (26.21 g of this extract) was kept refrigerated. A portion of this 
reference material (20 mg) was used for antimicrobial testing (Scheme 3). The 
remaining crude methanol extract was extracted for alkaloids using the general 
schematic isolation and extraction procedure (Scheme 3). Crude alkaloid (0.561 g) was 
obtained. Again this crude alkaloid (51 mg) was tested for antimicrobial activity. The 
LRCIMS of the crude alkaloid revealed ion peaks at m/z 344, 342, 384, 400, 358, 424, 
440, 406, 314, 448/466 and 298. The ion peak at m/z 344 was the major component. 
Focussing on these individual peaks, preparative plate separations were conducted. 
All the crude alkaloid (494.0 mg) was dissolved in MeOH (10%): DCM (90%) solvent 
and was loaded on PTLC plates (65 g × 8 plates). An appropriate mobile phase was 
developed using DCM (89%): MeOH (10%): Ammonia solution (28%, 1 ml). Eleven 
fractions/bands were obtained and each band was monitored using the LRCIMS peaks 
(Table 25). Each band contained a mixture of compounds. All the fractions/bands 
containing similar mass peaks and with the same Rf values were grouped together as in 
Table 25 and were further purified by development in an appropriate solvent system 
and the process was repeated until pure compounds were obtained. 
Group 1 was purified by PTLC on silica gel in DCM (85%): MeOH (14%) : Ammonia 
solution (28%, 1 ml). This gave two fractions. Fraction one (AO-gr-1-1) contained a 
LRCIMS peak at m/z 344 (MH+), and gave crystals when it was recovered from the 
silica. It was recrystallized from methanol/diethyl ether and fine needle-like crystals 
 
 
103 
(16.9 mg) were obtained. A crystal was sent for X-ray crystallography and was 
identified as atisinium chloride. 
 
Table 25.   Bands separated from the crude alkaloid of Aconitum orochryseum 
Bands Net wt. 
(in mg) 
Peaks present (LRMS-CI, m/z) 
 
Major peaks in 
the fractions (m/z) 
Inferences 
1 61.7 326, 344, 342, 424, 358, 400 326, 344, 342 Band 1, 2, 3 and 4 
formed group 1  2 24.1 400, 342, 456, 384 400, 342 
3 20.2 384, 342, 400, 440 384, 342 
4 16.3 400, 406, 424, 342, 456, 384 400, 424 
5 21.8 384, 406, 424, 358, 448, 466, 390 384 Band 5 and 6 
formed  group 2 6 20.3 384, 448, 466, 358 384 
7 31.9 358, 374, 448, 466, 179 358 Band 7, 8, 9, 10 
and 11 formed  
group 3 
 
8 26.7 432, 358, 450, 374 432, 358 
9 38.1 358 358 
10 18.6 358, 303 358 
11 16.9 358, 257, 303 358, 257, 303 
 
The second fraction (Ao-gr-1-2) still contained a mixture of compounds. Further 
separation by PTLC on silica gel using DCM (89%): MeOH (10%): Ammonia solution 
(28%, 1 ml) resulted in the isolation of three compounds: orochrine (LRCIMS peak at 
m/z 342), Ao-372 (LRCIMS peak at m/z 372), 2-O-acetylorochrine (LRCIMS peak at 
m/z 384) and lingshinaline (LRCIMS peak at m/z 400). Recrystallization from several 
solvents was attempted on each of these fractions. However, only orochrine gave fine 
small crystals (14.9 mg) from acetone/diethyl ether but the crystals were not big 
enough to determine the structure by X-ray crystallography. This was then sent for 
synchrotron X-ray crystallography in the USA. Unfortunately, no results were available 
at the time of completing this thesis. Crystallization was also attempted on the Group 2 
and Group 3 fractions using acetone/diethyl ether but they failed to crystallise.  
Group 2 was then purified by PTLC on silica gel with MeOH (8%): CHCl3 (91%): 
Ammonia solution (28%, 1 ml) as the developing solvent. This resulted in the isolation 
of another alkaloid, virescenine (LRCIMS peak at m/z 424). 
Group 3 was also subjected to PTLC on silica gel in DCM (95%): MeOH (5%): 
Ammonia solution (28%, 10 drops). This group yielded the minor alkaloids designated 
as AO-358, AO-414, AO-372, AO-466, AO-340, and AO-330 (Table 26). The final 
NMR spectra were obtained using a Nanoprobe for all of the five major alkaloids. Due 
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to very small quantities of sample, it was impossible to obtain useful NMR data for the 
minor alkaloids like AO-330, AO-358, AO-372, AO-372, AO-414 and AO-466.  
 
Table 26.  Alkaloids isolated from each fractions using discrete solvent system. 
No. Alkaloid MW Molecular 
formula 
Wt.  
(mg) 
PTLC solvent system 
1 Orochrine 341 C21H27NO3 14.9 10% MeOH:89% DCM:1% NH3 
2 Atisinium chloride 343 C22H33NO2 16.9 85% DCM:14% MeOH:1% NH3 
3 2-O-acetylorochrine 383 C23H29NO4 5.2 8% MeOH: 91% CHCl3:1% NH3 
4 Lingshinaline 399 C 23H29NO5 8.1 10% MeOH: 89%DCM: 1%NH3 
5 Virescenine 423 C23H37NO6 4.6 6% MeOH: 93% DCM:1% NH3 
6 AO-330 329 C20H27NO3 1.8 10% MeOH:89% DCM:1% NH3 
7 AO-340 339 C21H25NO3 1.9 10% MeOH:89% DCM:1% NH3 
8 AO-358 357 C22H31NO3 2.9 97% DCM:2% MeOH:1% NH3 
9 AO-372 371 C21H25NO5 2.1 10% MeOH:89% DCM:1% NH3 
10 AO-414 413 C23H27NO6 2.2 6% MeOH:93% DCM:1% NH3 
11 AO-466 465 C25H39NO7 3.6 10% MeOH:89% DCM:1% NH3 
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Orochrine 22: Colourless crystals (needles); m.p. 210.1-213.6oC; [α]D23 = ─ 65 (c, 0.62 
in MeOH); 1H-NMR (CD3OD, 500 MHz, Nanoprobe), δ 2.90 (s, 3H, N-Me), δ 5.04 
and δ 4.94 (bs, 1H each, H-17 exocyclic methylene), δ 4.14 (bs, 1H,  H-2β), δ 1.48 (s, 
3H, H-18 methyl), δ 1.59 (d, 1H, H-1, J = 15 Hz), δ 1.75 (d, 1H, H-1, J =15 Hz), δ 1.60 
(d, 1H, H-3, J =15 Hz), δ 1.93 (t, 1H, H-3, J =15 Hz), δ 2.15 (s, 1H, H-5), δ 2.23 (d, 
1H, H-7, J =12.5 Hz), δ 2.31 (d, 1H, H-7, J =15 Hz), δ 2.20 (s, 1H, H-9), δ 1.86 (d, 1H, 
H-11, J =14 Hz), δ 2.03 (d, 1H, H-11, J =14.5 Hz), δ 2.97 (bs, 1H, H-12), δ 2.98 (bs, 
1H, H-14), δ 2.52 (d, 1H, H-15, J =17.5 Hz), δ 2.69 (d, 1H, H-15, J =17 Hz), δ 3.35 (d, 
1H, H-19,  J =11.5 Hz),  δ 4.30 (d, 1H, H-19, J =11.5 Hz)  and δ 4.27 (s, 1H, H-20). 
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13C-NMR (CD3OD, 500 MHz, Nanoprobe), δ 34.5 (C-1), δ 65.5 (α-OH, C-2), δ 41.4 
(C-3), δ 36.6 (C-4), δ 59.1 (C-5), δ 106.2 (C-6), δ 38.2 (C-7), δ 43.9 (C-8), δ 49.4 (C-
9), δ 47.4 (C-10), δ 23.3 (C-11), δ 53.5 (C-12), δ 208.7 (C-13), δ 56.3 (C-14), δ 32.6 
(C-15), δ 142.6 (C-16), δ 112.3 (Exocyclic methylene, C-17), δ 30.3 (Me, C-18), δ 70.5 
(C-19), δ 75.1 (C-20), δ 37.3 (N-Me, C-21). 
gHSQC (CD3OD, 500 MHz, Nanoprobe), δ 1.59 (d) & δ 1.75 (d)/ δ 34.5 (C-1), δ 4.14 
(bs, H-2β)/δ 65.5 (C-2), δ 1.60 (d) & δ 1.93 (t)/ δ 41.4 (C-3), δ 2.15 (s)/ δ 59.1 (C-5), δ 
2.23 (d) & δ 2.31 (d)/ δ 38.2 (C-7),  δ 2.20 (s)/ δ 49.4 (C-9), δ 1.86 (d) & δ 2.03 (d)/ δ 
23.3 (C-11), δ 2.97 (bs)/ δ 53.5 (C-12), δ 2.98 (bs)/ δ 56.3 (C-14), δ 2.52 (d) & δ 2.69 
(d)/ δ 32.6 (C-15), δ 5.04 (bs) & δ 4.94 (bs)/ δ 112.3 (C-17), δ 1.43 (s)/ δ 30.3 (C-18),  
δ 3.35 (d) & δ 4.30 (d)/ δ 70.5 (C-19), δ 4.27 (s)/ δ 75.1 (C-20), δ 2.90 (s)/ δ 37.3 (C-
21). 
gHMBC (CD3OD, 500MHz, Nanoprobe), δC to δH, C-1/H-20; C-2/H-1, H-3; C-3/H-
1, H-18, H19; C-4/H-3, H-18, H-19; C-5/H-1, H-3, H-7, H-15, H-20; C-6/H-7, H-9, H-
19, H-20, H-21; C-8/H-7, H-11, H-15, H-20; C-9/H-5, H-7, H-15, H-20; C-10/ H-1, H-
3, H-11, H-12, H-14, H-20; C-12/H-9, H-11, H-15, H-17; C-13/H-11, H-12, H-14, H-
20; C-14/H-7, H-12, H-15, H-19, H-20; C-15/H-12, H-14, H-17; C-16/H-11, H-12, H-
14, H-15; C-17/H-12, H-15; C-18/H-3, H-5, H-19; C-19/H-3, H-5, H-18, H-20, H-21; 
C-20/H-1, H-2, H-5, H-9, H-12, H-14, H-19, H-21; C-21 (N-Me)/H-19.   
δH to δC, H-1/C-2, C-3, C-4, C-5, C-10, C-20; H-2/C-20; H-3/C-1, C-2, C-4, C-5, C-
10, C-18; H-5/C-9, C-18, C-19, C-20; H-7/C-5, C-6, C-8, C-9, C-11, C-14, C-15, C-20; 
H-9/C-5, C-6, C-8, C-10, C-11, C-12, C-14, C-20; H-11/C-8, C-9, C-10, C-12, C-13, 
C-16; H-12/C-13, C-14, C-15, C-16, C-17; H-14/C-9, C-13, C-15, C-16,  C-20; H-
15/C-7, C-8, C-9, C-12, C-14, C-16, C-17; H-17/C-12, C-15, C-16 (w); H-18/C-3, C-4, 
C-5, C-19; H-19/C-3, C-4 (w), C-5 (w), C-6, C-14, C-18, C-20, C-21; H-20/C-1, C-4 
(w), C-6, C-8, C-9, C-10 (w), C-13, C-14, C-19;  H-21/C-6, C-19, C-20. 
LRCIMS, m/z 342 (MH+); LREIMS, m/z 341 (M+), 326, 313, 298, 282, 254, 192, 173, 
157, 136, 122, 105, 91, 84, 55 and 44 (100%); HREIMS, C21H27NO3 (M+, measured 
341.1974, calc.341.1990).  
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2-O-Acetylorochrine 25:  Amorphous solid; m.p. 148.3-150.1o C; [α]D22 = ─82.47 (c, 
0.82 in CHCl3). 1H-NMR (CD3OD, 500 MHz, Nanoprobe), δ 2.91 (s, 3H, N-Me), δ 
4.86 and δ 4.95 (bs, 1H each, H-17 exocyclic methylene), δ 5.11 (bs, 1H, H-2β), δ 1.43 
(s, 3H, H-18 methyl), δ 1.65 (d, 2H, H-1, J =17.5 Hz), δ 1.66 (d, 1H, H-3, J =15.5 Hz), 
δ 1.92 (d, 1H, H-3, J =16 Hz), δ 2.17 (s, 1H, H-5), δ 2.23 (d, 1H, H-7, J =14.5 Hz), δ 
2.27 (d, 1H, H-7, J =14.5 Hz), δ 2.17 (s, 1H, H-9), δ 1.84 (m, 2H, H-11, J =3.5 Hz), δ 
2.89 (d, 1H, H-12, J = 3.5 Hz), δ 2.97 (d, 1H, H-14, J = 2Hz), δ 2.47 (d, 1H, H-15, J 
=17 Hz), δ 2.62 (d, 1H, H-15, J =17.5 Hz), δ 3.37 (d, 1H, H-19,  J = 12 Hz),  δ 3.79 (d, 
1H, H-19, J =12 Hz), δ 3.76 (s, 1H, H-20), δ 2.06 (s, 3H, H-23/CH3COO). 
13C-NMR (CD3OD, 500MHz, Nanoprobe), δ 31.6 (C-1), δ 69.0 (α-acetyl, C-2), δ 38.5 
(C-3), δ 36.5 (C-4), δ 58.5 (C-5), δ 106.6 (C-6), δ 38.0 (C-7), δ 44.2 (C-8), δ 49.3 (C-
9), δ 47.4 (C-10), δ 23.3 (C-11), δ 53.3 (C-12), δ 208.7 (C-13), δ 56.2 (C-14), δ 32.4 
(C-15), δ 142.3 (C-16), δ 112.4 (Exocyclic methylene, C-17), δ 30.1 (Me, C-18), δ 70.5 
(C-19), δ 75.1 (C-20), δ 37.3 (N-Me, C-21), δ 171.3 (C-22, COOCH3), δ 21.3 (C-23, 
COOCH3). 
gHSQC (CD3OD, 500 MHz, Nanoprobe), δ 1.65 (d)/ δ 31.6 (C-1), δ 5.11 (bs, H-2β)/δ 
69.0 (C-2), δ 1.66 (d) & δ 1.92 (d)/ δ 38.5 (C-3), δ 2.17 (s)/ δ 58.5 (C-5), δ 2.23 (d) & δ 
2.27 (d)/ δ 38.0 (C-7), δ 2.17 (s)/ δ 49.3 (C-9), δ 1.84 (m)/ δ 23.3 (C-11), δ 2.89 (d)/ δ 
53.3 (C-12), δ 2.97 (d)/ δ 56.2 (C-14), δ 2.47 (d) & δ 2.62 (d)/ δ 32.4 (C-15), δ 4.86 
(bs) & δ 4.95 (bs)/ δ 112.4 (C-17), δ 1.43 (s)/ δ 30.1 (C-18),  δ 3.37 (d) & δ 3.79 (d)/ δ 
70.5 (C-19), δ 3.76(s)/ δ 75.1 (C-20), δ 2.90 (s)/ δ 37.3 (C-21), δ 2.06(s)/ δ 21.3 (C-23, 
CH3COO). 
gHMBC (CD3OD, 500 MHz, Nanoprobe), δC to δH, C-1/H-3, H-11(w), H-20; C-2/H-
1, H-3, H-18(w); C-3/H-1, H-19; C-4/H-1, H-3, H-18, H-19; C-5/H-1, H-3, H-7, H-9, 
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H-18; C-6/H-5, H-7, H-19, H-20, H-21; C-7/H-9(w), H-15; C-8/H-7, H-9, H-11, H-15; 
C-9/H-5, H-7, H-11, H-12, H-14, H-15, H-20; C-10/H-1, H-3, H-9 (w), H-11, H-14; C-
12/H-9, H-11, H-15, H-17; C-13/H-11, H-12, H-14, H-20; C-14/H-7, H-9, H-15, H-19 
(w), H-20, H-21(w); C-15/H-7, H-12, H-17; C-16/H-11, H-15; C-17/H-12 (w), H-15; 
C-18/H-1, H-3, H-5, H-19; C-19/H-3, H-5, H-18, H-20, H-21; C-20/H-1, H-5, H-14, 
H-19, H-21; C-22/H-2, H-23 (CH3COO).   
δH to δC, H-1/C-2, C-3, C-4, C-5, C-10, C-20; H-2/C-22; H-3/C-1, C-2, C-4, C-5, C-
10, C-18, C-19; H-5/C-7 (w), C-9 (w), C-14, C-18, C-19, C-20; H-7/C-5, C-6, C-8, C-9 
(w), C-14, C-15 (w); H-9/C-5 (w), C-7 (w), C-12, C-14, C-20; H-11/C-1 (w), C-8(w), 
C-9, C-10, C-12, C-13, C-16; H-12/C-9, C-13, C-14, C-15; H-14/C-9, C-10, C-13, C-
20; H-15/C-7 (w), C-8, C-9, C-12, C-14, C-16, C-17; H-17/C-12, C-15; H-18/C-3, C-4, 
C-5, C-19; H-19/C-4, C-5, C-14(w), C-18, C-20; H-20/C-1, C-6, C-8, C-9 (w), C-13, 
C-14 (w), C-19;  H-21/C-6, C-19, C-20, H-23(CH3COO)/C-22. 
LRCIMS, 384 (MH+); LREIMS, m/z 383 (M+), 368, 355, 340, 324, 296, 282, 268, 
254, 226, 176, 174, 173, 148, 134, 122, 105, 91, 84, 70, 55, 44, 43; HREIMS, 
C23H29NO4 (M+, measured 383.2085, calc.383.2096). 
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26 Lingshinaline  
Lingshinaline 26: Pale green solid; m.p. 110-112o C; [α]D25 = ─31.76 (c, 0.34 in 
MeOH); 1H-NMR (500 MHz, Nanoprobe, CD3OD), δ 3.12 (s, 3H, N-Me), δ 4.92 and δ 
5.00 (bs, 1H each, H-17 exocyclic methylene), δ 5.21 (s, 1H,  H-2β), δ 1.52 (s, 3H, H-
18 methyl), δ 1.65 (d, 1H, H-1, J = 16.5 Hz), δ 1.74 (d, 1H, H-1, J =15.5 Hz), δ 1.65 (d, 
1H, H-3, J =17 Hz), δ 1.93 (d, 1H, H-3, J =16.5 Hz), δ 2.15 (s, 1H, H-5), δ 4.35 (s, 1H, 
H-7β), δ 2.20 (d, 1H, H-9, J = 7.5 Hz), δ 1.86 (d, 2H, H-11, J =6.5 Hz), δ 2.95 (d, 1H, 
H-12), δ 3.00 (d, 1H, H-14), δ 2.48 (d, 1H, H-15, J =17.5 Hz), δ 2.96 (d, 1H, H-15, J 
=17.5 Hz), δ 3.42 (d, 1H, H-19,  J = 11.5 Hz),  δ 3.61 (d, 1H, H-19, J =10 Hz), δ 3.63 
(s, 1H, H-20), δ 2.01 (s, 3H, H-23, CH3COO). 
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13C-NMR (CD3OD, 500 MHz, Nanoprobe), δ 31.2 (C-1), δ 66.9 (α-acetyl, C-2), δ 37.9 
(C-3), δ 35.9 (C-4), δ 55.8 (C-5), δ 105.7 (C-6), δ 71.7 (C-7), δ 45.3 (C-8), δ 46.7 (C-
9), δ 47.7 (C-10), δ 22.1 (C-11), δ 51.6 (C-12), δ 206.7 (C-13), δ 52.5 (C-14), δ 28.2 
(C-15), δ 139.1 (C-16), δ 113.1 (exocyclic methylene, C-17), δ 29.7 (Me, C-18), δ 70.4 
(C-19), δ 73.5 (C-20), δ 40.4 (N-Me, C-21), δ 169.1 (C-22, COOCH3), δ 21.4 (C-23, 
CH3COO). 
gHSQC (CD3OD, 500 MHz, Nanoprobe), δ 1.65 (d) & δ 1.74 (d) /δ 31.6 (C-1), δ 5.21 
(s, H-2β)/δ 66.9 (C-2), δ 1.65 (d) & δ 1.93 (d)/ δ 37.9 (C-3), δ 2.12 (s)/ δ 55.8 (C-5), δ 
4.35(s)/ δ 71.7 (C-7), δ 2.20 (d)/ δ 46.7 (C-9), δ 1.86 (d)/ δ 22.1 (C-11), δ 2.95 (s)/ δ 
51.6 (C-12), δ 3.00 (s)/ δ 52.5 (C-14), δ 2.48 (d) & δ 2.96 (d)/ δ 28.2 (C-15), δ 4.92 
(bs) & δ 5 .00(bs)/ δ 113.1 (C-17), δ 1.52(s)/ δ 29.7 (C-18), δ 3.42 (d) & δ 3.61 (d)/ δ 
70.4 (C-19), δ 3.63(s)/ δ 73.5 (C-20), δ 3.12 (s)/ δ 40.4 (C-21), δ 2.01(s)/ δ 21.4 (C-23, 
CH3COO). 
gHMBC (CD3OD, 500 MHz, Nanoprobe), δC to δH, C-1/H-3, H-20; C-2/H-1, H-3, H-
18 (w), H-23 (-COOCH3, vw); C-3/H-1 (w), H-18, H-19; C-4/H-3, H-18, H-19; C-
5/H-1, H-3, H-18; C-6/H-20, H-21; C-7/H-21 (w), H-5 (w); C-8/H-1 (w), H-11, H-14; 
C-9/H-5, H-11, H-12, H-14, H-15; C-10/H-7, H-20; C-12/ H-11, H-15 (w), H-17; C-
13/H-11, H-12, H-14, H-20; C-14/H-7, H-15; C-15/ H-7 (w), H-17; C-16/H-11, H-12, 
H-15; C-17/H-12, H-15; C-18/H-5, H-19; C-19/H-5, H-18, H-20, H-21; C-20/H-5, H-
14, H-19, H-21, C-22(COOCH3)/H-23 (CH3COO).   
δH to δC, H-1/C-2, C-3 (w), C-4, C-5, C-8 (w); H-3/C-1, C-2, C-4 (w), C-5; H-5/C-7, 
C-9, C-18, C-19, C-20; H-7/C-10, C-14; H-11/C-8, C-9 (w), C-12 (w), C-13, C-16; H-
12/C-9, C-16, C-17; H-14/C-8, C-9, C-13, C-20; H-15/ C-9, C-14, C-16, C-17; H-
17/C-12, C-15; H-18/C-2, C-3, C-4, C-5, C-19 ; H-19/C-3, C-4, C-5, C-18, C-20, C-21 
(N-Me, w); H-20/C-1, C-6, C-10, C-13, C-19 (w); H-21/C-6, C-7, C-19, C-20, H-23 
(CH3COO)/C-22 (COOCH3), C-2(w). 
LRCIMS, m/z 400 (MH+); LREIMS: m/z 399 (M+), 382, 370, 356, 340, 315, 312, 270 
176, 174, 173, 148, 134, 122, 105, 91, 84, 55, 44, 43. HREIMS, C23H29NO5 (M+, 
measured 399.2155, calc.399.2045). 
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Virescenine 27: Colourless crystals (needles); m.p. 76.7-79.8oC; [α]D26  = + 14.07 (c, 
0.8 in MeOH); 1H-NMR (500 MHz, Nanoprobe, CDCl3), δ3.67 (s, 1H, H-1β), δ 1.45 
and δ1.57 (q, 1H each, H-2), δ1.63 and δ1.82 (dd, 1H each, J = 5Hz, 6Hz, H-3), δ1.71 
(t, 1H, J = 7 Hz, H-5), 1.54 and δ 2.26 (d, 1H each, H-6), δ2.15 (t, 1H, J=5.5, H-9), 
δ1.76 (q, 1H, H-10), δ1.55 and δ1.97 (t, 1H each, H-12), δ 2.27 (m, 1H, H-13),δ4.17 (t, 
1H, J=4.5 Hz, H-14β), δ1.73 and 2.89 (d, 2H, J=9.5Hz, H-15), δ3.37 (q, 1H, H-16), 
δ2.83 (s, 1H, H-17), δ3.01 and δ3.16 (d, 1H each, J=9 Hz, H-18), δ2.49 and δ2.72 (d, 
1H each, J=11Hz, H-19), δ2.95 and δ3.06 (q, 1H each, N-CH2-), δ1.08 (t, 3H, J=7.5 
Hz, N-CH2CH3), δ3.28 (s, 3H, C-18OCH3), δ3.31 (s, 3H, C-16OCH3). 
13C-NMR (500 MHz, Nanoprobe, CDCl3), δ72.0 (C-1), δ28.7 (C-2), δ26.6 (C-3), δ37.6 
(C-4), δ41.7 (C-5), δ33.3 (C-6), δ85.7 (C-7), δ76.0 (C-8), δ47.7 (C-9), δ43.3 (C-10)  , 
δ49.3 (C-11), δ28.2 (C-12), δ39.4 (C13), δ75.3 (C-14), δ35.8 (C-15), δ81.5 (C-16), 
δ65.2 (C-17), δ78.4 (C-18), δ55.7 (C-19), δ50.7 (NCH2-), δ13.4 (NCH2CH3), δ59.3 (C-
18OCH3), δ56.3 (C-16OCH3). 
gHSQC (500 MHz, Nanoprobe, CDCl3), δ3.67 (s, 1H, H-1β)/δ72.0 (C-1), δ 1.45 and 
δ1.57 (q, 1H each, H-2)/ δ28.7 (C-2), δ1.63 and δ1.82 (dd, 1H each, J = 5Hz, 6Hz, H-
3)/ δ26.6 (C-3), δ1.71 (t, 1H, J = 7 Hz, H-5)/ δ41.7 (C-5), δ1.54 and δ 2.26 (d, 1H each, 
H-6)/ δ33.3 (C-6), δ2.15 (t, 1H, J=5.5, H-9)/ δ47.7 (C-9), δ1.76 (q, 1H, H-10)/ δ43.3 
(C-10), δ1.55 and δ1.97 (t, 1H each, H-12)/δ28.2 (C-12), δ 2.27 (m, 1H, H-13)/ δ39.4 
(C-13), δ4.17 (t, 1H, J=4.5 Hz, H-14β)/δ75.3 (C-14), δ1.73 and 2.89 (d, 2H, J=9.5Hz, 
H-15)/ δ35.8 (C-15), δ3.37 (q, 1H, H-16)/ δ81.5 (C-16), δ2.83 (s, 1H, H-17)/ δ65.2 (C-
17), δ3.01 and δ3.16 (d, 1H each, J=9 Hz, H-18)/ δ78.4 (C-18), δ2.49 and δ2.72 (d, 1H 
each, J=11Hz, H-19)/ δ55.7 (C-19), δ2.95 and δ3.06 (q, 1H each, N-CH2-)/δ50.7 (C-
20), δ1.08 (t, 3H, J=7.5 Hz, N-CH2CH3)/ δ13.4 (C-21), δ3.28 (s, 3H, C-18OCH3)/ 
δ59.3 (C-22), δ3.31 (s, 3H, C-16OCH3)/ δ56.3 (C-23). 
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gHMBC (500 MHz, Nanoprobe, CDCl3), δC to δH, C1/H-3, H-5; C-2/H-3 (w); C-
3/H-1, H-18, H-19; C-4/H-3, H-5, H-6, H-18, H-19; C-5/H-6, H-10, H-17, H-18, H-19; 
C-6/H-17; C-7/H-5, H-6, H-15; C-8/H-5, H-6, H-9, H-10, H-14, H-15, H-17; C-9/H-
10, H-13, H-15; C-10/H-1, H-2, H-5, H-9, H-13, H-12, H-15, H-17; C-11/H-12, H-10, 
H-17; C-12/H-9, H-10, H-16 (w); C-13/H-9, H-12, H-15; C-14/H-12, H-16; C-15/H-9, 
H-13; C-16/H-12, H-14, H-15, H-23; C-17/H-5, H-6, H-10, H-19, H-20 (w); C-18/H-3, 
H-5, H-19, H-22; C-19/H-3, H-5, H-17, H-18, H-20; C-20/H-17 (w), H-19, H-21; C-
21/H-20; C-22/H-18; C-23/H-16. 
δH to δC, H-1/C-3, C-5; H-2/C-4,C-5,C-11; H-3/C-1,C-4, C-18, C-19; H-5/C-4, C-7, 
C-10, C-11, C-17, C-18, C-19; H-6/C-4,C-5,C-7,C-11,C-17; H-9/C-8,C-10,C-12,C-
13,C-15; H-10/C-1(w),C-2,C-8,C-5, C-9, C-11, C-12, C-17; H-12/C-5, C-10, C-11, C-
13, C-14, C-16; H-13/C-9, C-10, C-15, C-16; H-14/C-8, C-16; H-15/C-6, C-7, C-8, C-
9, C-13, C-16; H-16/C-12 (w), C-14, C-23; H-17/C-5, C-6, C-8, C-10, C-11, C-19, C-
20; H-18/C-3, C-4, C-5, C-19, C-22; H-19/C-3, C-4, C-5, C-17, C-18, C-20; H-20/C-
17, C-19, C-21; H-21/C-20; H-22/C18; H-23/C-16. 
 LRCIMS, m/z 424; HREIMS,  C23H37NO6 (M+, measured 423.2619, calc. 423.2620). 
LREIMS, m/z 423 (M+), 408, 407, 406, 390, 374, 365, 352, 336, 98, 85, 71, 58 
(100%).  
  
CH3
H
H H
CH2
N
+OH
OH
Cl
28 Atisinium chloride
20
6
R
R
S
S
S
S
R
   
Atisinium chloride 28: Crystals (needle shaped); [α]D25 = +31.27 (c, 0.94 in MeOH);  
m.p. 230.7-233.6oC (decomposition); LREIMS, m/z 343 (M+), 342, 328, 314, 300, 
284,  257, 241, 186, 171, 159, 143, 131, 105, 91, 79, 72, 55, 44.  HRESMS (electro-
spray), C23H33NO2 (measured 344.2572, calculated 344.2590). The structure was 
determined and confirmed by single crystal X-ray crystallography (Figure 10).     
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Figure 10.   The X-ray structure of Atisinium chloride. 
 
AO- 358: white solid; m.p. 122.6o-124.2oC, [α]D27 = +86.6 (c, 0.09 in MeOH); 
LRCIMS, m/z 358 (MH+); HREIMS, m/z 357 (M+), 344, 342, 329, 328 (100%), 327, 
326, 312, 300, 286,284,250, 234, 148,122, 105, 91, 77, 71, 60. HRCIMS, C22H32NO3 
(MH+, measured 358.2399, calculated 358.2382). Another alkaloid with same LRCIMS 
peak at m/z 358 (MH+) was obtained. It had a lower RF than the one described above. 
HRCIMS, C15H5NO10 (MH+, measured 358.9901, calculated 358.9913). 
 
AO-466: pale green solid, LRCIMS, m/z 466 (MH+); LREIMS, m/z 465 (M+), 450, 
448, 432, 422, 403, 402 (100%), 390, 374, 358, 342, 329, 300, 284, 194, 164, 148, 122, 
98, 91; HRCIMS, C25H40NO7 (MH+, measured 466.2785, calculated 466.2804).  
 
AO-340: white solid; LREIMS, m/z 339 (M+), 322, 310, 297, 283, 245, 179, 159, 128, 
124 (100%), 108, 94, 79, 65, 55 and 42. HRCIMS, C21H26NO3 (MH+, measured 
340.1912, calculated 340.1912).  
 
AO-372: pale brown solid; LREIMS, m/z 371 (M+, 100%), 355, 343, 327, 299, 296, 
238, 210, 192, 162, 134, 122 and 105; HRCIMS, C21H26NO5 (MH+, measured 
372.1816, calc. 372.1811).   
 
AO-414: pale green solid; LREIMS, m/z 413 (M+), 385, 369, 354, 342, 310, 280, 252, 
220, 212, 148, 134, 122, 105, 91, 79, 67, 57, 55, 44 (100%), 43, 42; HREIMS, 
C23H27NO6 (M+, measured 413.1822, calculated 413.1838).  
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AO-330: white solid; HRCIMS, C20H28NO3  (MH+, measured 330.2066, calculated 
330.2069). 
 
9.6     Purification and Structure Elucidation of Alkaloids from Corydalis gerdae 
Fedde. 
A methanol extract (58.22 g) was obtained from dried plant material (1 kg). Part of the 
methanol extract (15.22 g) was kept refrigerated as reference material. Antimicrobial 
testing was done on a portion of this reference material. The remaining MeOH extract 
(43 g) was extracted for alkaloids using the general schematic isolation and extraction 
procedure (Scheme 3). This yielded crude alkaloids (303.8 mg) and antimicrobial 
testing was conducted on a portion of this alkaloid mixture (40 mg). The mass spectral 
analyses (CIMS) on the crude alkaloids revealed ion peaks at m/z 354, 338, 326, 324, 
and 224. The ion peak at m/z 354 was the major component. Focussing on these ion 
peaks, the isolation and purification was conducted using preparative TLC. 
The crude alkaloids (about 260 mg) was dissolved in MeOH (10%):DCM (90%) 
solvent and then applied to PTLC silica gel plates (65 g × 4 plates). A mixture of DCM 
(95%): MeOH (4%): Concentrated aqueous NH3 solution (28%, 1 ml) was found to be 
the best solvent system for separating this crude extract. The solvent was allowed to 
saturate the tank for 1 hour and the PTLC separation was then performed. Ten bands 
were obtained and each of them contained different compounds with CIMS ion peaks 
(MH+) as tabulated below (Table 27).  
 
Table 27.   Bands separated from the crude alkaloid of Corydalis gerdae 
Bands Net wt. 
(mg) 
Peaks present 
LRCIMS (m/z) 
Suitable solvent system used for 
purifying respective bands (PTLC) 
Compound 
isolated 
(m/z) 
1+2 24.6 237, 257, 308,354 DCM (83ml):MeOH (17ml):NH3 (1ml) 354 
3+4 21.9 328,354,410 DCM (93ml):MeOH (7ml):NH3 (1ml) 328 
5 28.8 282, 312, 328, 354 DCM(94ml):MeOH (5ml):NH3 (1ml) 328 
6 66.5 354,410 DCM (94ml):MeOH (5ml):NH3 (1ml) 354 
7+8 57.8 257, 312, 326, 354 DCM (98.5 ml) : MeOH (1ml):NH3 (0.5ml) 326, 338 
9 28.0 257, 324   DCM (99ml): MeOH (0.5 ml):NH3 (0.5 ml) 324 
10 12.6 257, 338, 354,371 DCM (99ml): MeOH (0.5 ml):NH3 (0.5 ml) 282, 338 
 
The bands/fractions were initially not pure and contained mixtures of compounds. They 
were separated again by PTLC on silica gel by developing in different solvent systems 
and each of these first bands gave two or more bands with different mass peaks 
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(LRCIMS). The fractions with the same Rf values and same LRCIMS peaks were 
combined and were again purified by developing appropriate solvent system and the 
purification was repeated till pure compounds were obtained (Table 28). 
Crystallization was attempted for all fractions using single solvent and a two different 
solvents system. In a crystallization which involved two solvent systems 
(chloroform/ethanol, MeOH/acetone, ethanol/acetronitrile and MeOH/diethyl-ether), 
the compound was first dissolved in the more powerful solvent, and the second, more 
volatile and less powerful solvent allowed it to diffuse into it, which facilitated steady 
growth of large crystals. However, only cheilanthifoline gave small crystals from 
methanol/diethyl-ether. The crystals were washed with diethyl-ether and was collected 
and sent for synchrotron X-ray crystallography to USA. This result will further confirm 
its structure but its result was not available at the time of completion of this thesis. 
Finally four alkaloids were isolated from this plant.  
 
   Table 28.  Alkaloids isolated from Corydalis gerdae 
Alkaloids Mol.Wt. Molecular formula Wt. obtained 
Protopine 353 C20H19NO5 23.1 
Scoulerine 327 C19H21NO4 9.2 
Cheilanthifoline 325 C19H19NO4 6.5 
Stylopine 323 C19H17NO4 5.9 
Unidentified 337 C19H15NO5 1.6 
 
O
O N
O
O
Me
O
37 Protopine   
Protopine 37: white amorphous solid; m.p. 203.7-207.8oC (decomposition; optically 
inactive; LRCIMS, m/z 354 (MH+); HREIMS, C20H19NO5 (MH+, measured 354.1342, 
calc.354.1341); HREIMS m/z 353 (M+), 281, 267, 252, 190, 163, 149, 148 (100%)  
134 and 89.  1H-NMR (500 MHz, Nanoprobe, DMSO-d6), δ6.92 (s, H-1), δ6.77 (s, H-
3), δ3.15 (s, H-5), δ2.38 (bs, H-6), δ3.47 (bs, H-8), δ6.74 (d, J=7.5 Hz, H-11), δ6.66 (d, 
J=8.0 Hz, H-12), δ5.96 (s, 2,3-OCH2O), δ5.93 (s, 9,10-OCH2O), δ1.79 (s, 7-CH3). 13C-
NMR (500 MHz, Nanoprobe, DMSO-d6), δ107.4 (C-1), δ145.3 (C-2), δ147.3 (C-3), 
δ110.4 (C-4), δ132.7 (C-4a), δ30.5 (C-5), δ57.4 (C-6), δ50.7 (C-8), δ118.3 (C-8a), 
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δ145.8 (C-9), δ145.4 (C-10), δ106.3 (C-11), δ125.1 (C-12), δ129.6 (C-12a), δ46.1 (C-
13), δ194.8 (C-14), δ136.0 (C-14a), δ101.1 (2,3-OCH2O), δ41.1 (7-CH3), δ100.7 (9,10-
OCH2O). 
 
N
OH
MeO
OH
OMe
H
41  Scoulerine  
 
 Scoulerine 41: reddish brown solid; m.p. 153-157oC (decomposition); [α]D24 = ─282 
(c, 0.74 in MeOH); 1H-NMR (CD3OD, 300 MHz): δ 3.21 (s, OMe), δ 3.24 (s, OMe), δ 
5.38 (s, OH),  δ 3.52 and δ 4.14 (AB-quartet, J = 15.9 Hz). HREIMS, C19H21NO4 
(measured 327. 1461, calc.327.1471); HREIMS:  m/z 327 (100%, M+), 326, 312, 310, 
207, 179, 178 (100%), 176, 162, 150, 149 and 135. 
 
N
O
CH2
O
OH
H
MeO
47 (-)-(S)-cheilanthifoline  
 
Cheilanthifoline 47: pale green solid; m.p. 168-170.4oC (decomposition);   [α]D20 = 
─262 (c, 0.60 in CDCl3); LRCIMS, m/z 326 (MH+); LREIMS, m/z 325 (M+, 100%), 
310, 176, 162 and 148 (100%); HREIMS, C19H19NO4 (measured 325.1304,  
calc.325.1314); 1H-NMR (CDCl3, 500 MHz): δ 3.87 (s, 3H, OMe), δ 5.93 (d, 2H, 
methylenedioxy), δ 3.53(q) and δ 4.09(d) (C-8 methylene, J = 15 Hz), δ 1.25 (bs, -OH), 
δ 6.59 to δ 6.81 (4 H, aromatic). 
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N
O
O
O
O
H
42 Stylopine  
Stylopine 42: pale green solid; m.p. 163-165o C; [α]D24 = ─304 (c, 0.56 in MeOH);  
LRCIMS: m/z 324 (MH+); LREIMS: m/z 323 (M+),  207, 174, 148 (100%) and 89. 
HREIMS: C19H17NO4;   (measured 323.1145, calc.323.1157).  
 
                        
NH2
O
48  9-octadecenamide  
9-Octadecenamide 48: white solid; blue fluorescence under UV; LRCIMS, m/z 338 
(MH+); HREIMS, C22H43NO (measured 337.3382, calc.337.3344); HREIMS, m/z 337 
(M+), 277, 136, 122, 97, 83, 72, 69, 59 (100%), 43 and 41. 
 
CG-338: white solid; LRCIMS, m/z 338 (MH+); HREIMS, C19H15NO5 (measured 
337.0940, calc.337.0936). 
 
CG-336: white solid; LRCIMS, m/z 336 (MH+); LREIMS, m/z 335 (M+, 100%), 320, 
306, 292, 248, 190, 167, 153, 139, 124, 95, 82, 75 and 63. HREIMS, C15H29NO7 
(measured 335.1939, calc.335.1944). 
 
9.7      Attempted Extraction and Isolation of Alkaloids from Tribulus terrestris L 
9.7.1 Attempt-I. 
A methanol extract (127.74 g) was obtained from air dried plant material (1.2 kg). 
Antimicrobial testing was performed on a part (15 mg) of this extract. The remaining 
methanol extract was extracted for alkaloids using the general schematic isolation and 
extraction procedure (Scheme 3) and yielded a crude alkaloid fraction (540 mg). 
However, when the crude fraction was tested with Dragendorff’s reagent, it gave a 
negative test. A portion of this crude extract (25.6 mg) was kept as reference material. 
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The mass spectral analysis (LRCIMS) on this crude extract revealed ions at m/z 144, 
163, 175 (major component), 191, 193, 209, 225 and 265.   
The crude alkaloid extract was dissolved in MeOH (10%) /DCM (90%) solvent and 
was loaded on to silica PTLC plates (65 g × 8 plates). After trying different ratios, a 
mixture of DCM (94%): MeOH (6%): concentrated aqueous NH3 solution (28%, 3 
drops) was selected as the best solvent system for separating this crude extract. The 
solvent system was left to saturate the tank for 1 hour and the PTLC separation was 
then performed. Ten bands were separated and each band was tested for alkaloids. 
None gave a positive test with Dragendorff’s reagent. One band yielded 3,4-
dimethoxycinnamic acid, as the major component isolated. 
 
MeO
MeO
H
H
COOH
62  3,4-Dimethoxycinnamic acid 
 
3,4-Dimethoxycinnamic acid 62: pale green solid; absorbed UV light; 1H-NMR 
(CDCl3, 300 MHz), δ 7.70 (d, 1H, J = 15.9 Hz), δ 7.07 to δ 7.13 (3H, aromatic 
protons), δ 6.92 (d, 1 H, J = 8.4 Hz), δ 3.80 (s, 3H, OMe) and δ 3.93 (s,3H,OMe); 
LRCIMS,  m/z 209 (MH+); HRCIMS,  C11H13NO4 (MH+,  measured 209.0817, 
calc.209.0813). 
 
9.7.2    Attempt-II 
To recheck the result obtained in the first attempt to isolate alkaloids from Tribulus 
terrestris, the extraction and the isolation of alkaloids from this plant was attempted for 
a second time using a slightly modified procedure. In this method, the air dried plant 
material (1.5 kg) was ground using a Grinder (mixer) and was then extracted with 
analytical grade methanol for 5 days. The separated methanol extract was evaporated 
and the residue was acidified (to pH 1) with 1 M H2SO4 (15 ml). The acidic solution 
was washed with chloroform and petroleum ether (4 × 60 ml). The aqueous layer was 
then basified (to pH 10) with Na2CO3 solution (20% w/v) and then extracted with 
chloroform (4 × 60 ml). This chloroform extract was evaporated and the residue tested 
for alkaloids. The crude extract failed to give any test for alkaloids when tested with the 
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Dragendorff’s reagent and with Mayer’s reagent. This confirmed that this batch of 
Tribulus terrestris contained no alkaloids.  
 
9.8 Attempted Isolation of Alkaloid from Ranunculus brotherusi Freyn  
A methanol extract (85.01 g) was obtained from air dried plant material (1 kg) and a 
small portion of this extract (15.90 g) was kept as a reference sample. The remaining 
methanol extract was extracted for alkaloids using the general schematic isolation and 
extraction procedure (Scheme 3) and yielded a crude alkaloid fraction (72.8 mg). This 
crude extract gave a negative test for alkaloids with Dragendorff’s reagent. The 
LRCIMS of the crude alkaloid extract gave ions at m/z 225, 209, 207, 197, 195 (major 
peak), 193, 191, 175, 163, 145, 127 and 86.  
All the crude basic extract was separated using PTLC plates (36 g × 2 plates) and the 
solvent system: DCM (90%):MeOH (10%):Concentrated aqueous NH3 solutions(28%, 
1 ml). The solvent was allowed to saturate the tank for 1 hour and PTLC separation was 
then performed. Eleven bands were separated and each band contained a mixture of 
different compounds (on the basis of LRCIMS analyses). None of the fractions gave a 
positive test with Dragendorff’s reagent. No further work was done on this plant 
extract. 
 
9.9      Antibacterial assay 
9.9.1 Sample Preparation 
The methanol extract (AO-ME, 10 mg), crude alkaloid (AO-CEA, 10 mg) and 
atisinium chloride isolated from Aconitum orochryseum were packed in small vials. 
Similarly, the methanol extract (CG-ME, 10 mg), crude alkaloid (CG-CEA, 10 mg) and 
protopine isolated from Corydalis gerdae were packed in small vials. These samples 
were then sent for antibacterial assays to the Amrad Corporation, Melbourne. All 
assays used the Staphylococcus aureus strain ATCC 6538P, or VRE strains 243, 449, 
820 and 987. It should be noted however that two strains, VRE 243 and 987 were in 
fact sensitive to vancomycin.  
 
9.9.2  Antibacterial  Testing Methodology263 
The Mueller-Hinton Broth (MHB) Medium culture media was prepared with final 
concentrations of 1 µg/mL MgCl2 and 2 µg/mL CaCl2 and was pre-warmed for 2-3 
hour at 37oC before use. Mueller-Hinton Agar (MHA) Medium culture media was 
prepared with final concentrations of 1.5% Agar (Merck Agar 1.01614). S.aureus was 
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streaked onto MHA and the plate was incubated overnight at 37oC. From this plate, 10 
cryovial were prepared by looping several colonies into 0.5 mL of 20% glycerol 
solution and were immediately stored at −140oC. A cryovial was removed from −140oC 
storage and thawed at room temperature. The MHA plate was streaked with a loopful 
of bacterial suspension and incubated overnight at 37oC to create a parent plate (P1). 
The parent plate was stored at 4oC. A daughter plate (D1) was incubated overnight at 
37oC and its loop of colony was used to inoculate a 125 mL flask containing 20 mL of 
MHB containing 25 µg/mL CaCl2.2H2O) and 12. 5 µg/mL MgCl2.6H2O. The flask was 
shaken at 260 rpm for 18 hour at 37oC on an orbital incubator shaker. The parent plates 
1 and 2 were each used twice to generate two daughter plates (D1 and D2) before being 
discarded. 
The standardised inocula for assays was prepared as 1/10 dilution of seed cultures by 
adding 250 µL of the cultures to 2,250 µL of MHB in a disposable cuvette and the 
required dilution factor was calculated by dividing the observed OD650. Sufficient 
volumes of the final inoculum cultures were prepared in pre-warmed MHB (37oC) by 
diluting the standardised cultures to the required final concentration (108 dilution). 
 
9.9.3  Assay Procedure for 96-well Microtitre Plates 
To each well of the 96-well microtitre plate was added 50 µL of liquid medium and 50 
µL of peptoid test solution which was prepared by dissolving in 2.5 % DMSO was 
added in triplicate to the top of the microtitre plate. A vancomycin control set 
(triplicate) and a compound negative control set (triplicate) were also set up on each 
plate. The inoculated culture medium was incubated at 37oC for 30 min shaking it at 
130 rpm and using the multichannel pipette and multistepper pipette the adding, 
transferring and mixing of the inoculum were performed on the wells of the plates. The 
plates were incubated at 37oC for 18 hrs shaking at 100 rpm in an environment with 
90% relative humidity and the results were recorded as the highest dilution of test 
compound that prevented bacterial growth (MIC). The MIC was also determined for 
DMSO (2.5%) as a control measure. 
 
9.9.4  Results of Antibacterial Testing 
When the methanol extracts, crude alkaloids and the major alkaloids (protopine and 
atisinium chloride) of the plants were tested, the following results (Table 29) were 
obtained. 
 
 
 
119 
Table 29. Antibacterial activities of the plant extracts and alkaloids on Staphylococcus aureus and 
Vancomycin resistant Enterococcus faecium 
Compound Culture MIC (µg/ml) 
AO-ME Staph >125 
AO-CEA Staph >125 
Orochrine Staph 
VRE # 243, VRE # 449, 
VRE # 820 and VRE # 987 
>125 
 
>125  
Atisinium chloride Staph 
VRE # 243, VRE # 449, 
VRE # 820 and VRE # 987 
>125 
 
>125 
CG-ME Staph >125 
CG-CEA Staph >125 
Protopine Staph >125 
Vancomycin 
(Standard) 
Staph 
VRE # 243, VRE # 449, 
VRE # 820 and VRE # 987 
2.5 
1.95 (< 0.98), 62.5, 125 and 1.95 
respectively 
Note: VRE = Vancomycin resistant Enterococcus; Staph = Staphylococcus aureus; Vanc = Vancomycin, 
MIC = Minimum Inhibitory Concentration. 
 
9.10      Antimalarial assay 
9.10.1     Sample Preparation 
The methanol extract (AO-ME, 20 mg), crude alkaloid (AO-CEA, 20 mg) and 
atisinium chloride isolated from Aconitum orochryseum were packed in small vials. 
Similarly, the methanol extract (CG-ME, 20 mg), crude alkaloid (CG-CEA, 20 mg), 
protopine and cheilanthifoline, isolated from Corydalis gerdae, were packed in small 
vials. These samples were then sent for antimalarial testing at the Protein-Ligand 
Engineering and Antimalarial Screening Laboratories, National Centre for Genetic 
Engineering and Biotechnology, National Science and Technology Development 
Agency in Bangkok, Thailand. The tests were done by Dr. Sumalee 
Kamchonwongpaisan and by Miss Roonglawan Rattanajak using a Microdilution 
Radioisotopes Technique.  
 
9.10.2    Antimalarial Assay Method  
Samples were made up in DMSO solution. Using the Microdilution Radioisotope 
Technique, the in vitro antimalarial activity of the alkaloids was tested against 
Plasmodium falciparum, TM4 and K1 Strains. The first strain is an anti-folate sensitive 
one while the second is an antifolate resistant strain.  
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The sample (25 µl, in the culture medium) was placed in triplicate in a 96-well plate. 
Red blood cells (200 µl) infected with Plasmodium falciparum with a cell suspension 
(1.5%) of parasitemia (0.5-1%) were added to the wells. The range of the final 
concentrations of the samples varied from 1 x 10-5 to 1 x 10-8 g/ml with 0.1% of the 
organic solvent. The plates were cultured under standard conditions for 24 hours and 
the 3H-hyphoxanthine (25 µl, 0.5 mCi) was added. The culture was incubated for 18-20 
hours. The parasites’ DNA was then harvested from the culture onto glass fibre filters. 
A radiation counter determined the amount of 3H-hypoxanthine. The inhibitory 
concentration of the sample was determined from its dose-response curves or by 
calculation. 
The Trager and Jensen method264 was used to culture Plasmodium falciparum K1 
strain. The parasites were maintained in human red blood cells in a culture medium. 
RPMI 1640 was supplemented with 25 mM HEPES, 0.2% sodium bicarbonate, and 8% 
human serum, at 37oC in a CO2 incubator54.  
 
9.10.3     Results of the Antimalarial Assay 
The following in vitro antimalarial test results (Table 30) were obtained for the 
methanol extracts (AO-ME and CG-ME), crude alkaloid mixtures (AO-CEA and CG-
CEA), atisinium chloride, protopine and cheilanthifoline. 
 
Table 30. Antimalarial activities of extracts and alkaloids isolated from Aconitum orochryseum and 
Corydalis gerdae (IC50 value against Plasmodium falciparum; TM4 and K1 strains). 
 
Plants 
 
Sample 
                     IC50  
TM4 K1 
Aconitum orochryseum AO-ME >10 µg/ml >10 µg/ml 
 AO-CEA 20.4 ± 1.74 µg/ml 19.2 ± 3.84 µg/ml 
 Atisinium chloride 4.02 ± 0.69 µ M  
(1.51 µg/ml) 
3.59 ± 1.24 µ M  
(1.35 µg/ml) 
Corydalis gerdae CG-ME 1.00 ± 0.34 µg/ml 2.56±  0.46 µg/ml 
 CG-CEA 0.33 ± 0.03 µg/ml 0.63 ± 0.14 µg/ml 
 Protopine 4.25 ± 0.69 µ M  
(1.50 µg/ml) 
4.29 ± 1.24 µ M 
(1.51 µg/ml) 
 Cheilanthifoline 2.78  ± 0.39 µ M 
(0.90 µg/ml) 
3.76 ± 1.00 µ M 
(1.22 µg/ml) 
 
An antibacterial and antimalarial testing were not done for Ranunculus brotherusi and 
Tribulus terrestris extracts.  
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